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Function and Regulation of myc-family bHLHZip Transcription 
Factors during the Animal and Plant Cell Cycle  
Abstract 
The myc-family of proto-oncogenes (c-, N- and L-myc) encodes transcription factors 
of the basic region helix-loop-helix leucine zipper (bHLHZip) family and plays 
important roles in cell proliferation, metabolism, apoptosis and many other 
fundamental cellular processes. myc-family genes are frequently deregulated in 
cancer, often correlating with poor prognosis. c-Myc is estimated to regulate 15% of 
all genes. 
 
This thesis focuses firstly on the mechanisms behind posttranslational negative 
regulation of Myc activities induced by growth inhibitory signals, secondly on the 
regulation of transcription of genes involved in G1/S transition during cell cycle by 
Myc, and thirdly on characterization of myc-related bHLH genes in Arabidopsis. 
 
Our results show that the cytokine interferon (IFN)-γ induces ubiquitylation and 
degradation of Myc-family proteins in N-myc-amplified neuroblastoma cells and in 
Myc-transformed monocytic cells and induces expression of the Myc antagonist 
Mad1. IFN-γ-induced turnover of Myc involves reduced phosphorylation of Ser-62 
through inhibition of cyclin E/ cyclin-dependent kinase 2 (Cdk2), which was 
identified as a Ser-62 kinase. The mechanism behind this inhibition was shown to 
be IFN-γ-induced expression of the Cdk-inhibitor p27
Kip1. p27
Kip1 was further 
demonstrated to target the Myc/cyclin E/Cdk2-complex directly at Myc target 
promoters, resulting in transcriptional repression of Myc target genes. This study 
also shows that during cell cycle progression, Myc associates with S-phase genes 
already in early G1 but cannot activate those genes until in late G1/S. This 
correlated with binding of the E3 ubiquitin ligase and cofactor Skp2 to these 
promoters. We propose that Skp2 and cyclin E/Cdk2 cooperate in this regulation. 
Taken together, this thesis suggests that Myc intimately interact with cyclinE/Cdk2, 
p27
Kip1, and Skp2 in the control of the cell cycle genes, which might provide 
potential new strategies for cancer therapy. 
 
Our study in the plant Arabidopsis thaliana (At) characterized 84 myc-related At 
bHLH genes. Expression profiling of these genes in proliferative tissues showed that 
15 of the bHLH genes were expressed in a cell cycle regulated manner, suggesting 
that they may play a role in cell division in plants. 
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  101 Background 
1.1 Cancer 
Cancer is a complex disease involving dynamic changes in the genome (for 
reviews see (Hanahan and Weinberg, 2000)). Tumorigenesis is a multi-step 
procession during which the genome of the cancer cells suffers disruption 
from point mutation to changes in chromosome complement (for review see 
(Kinzler and Vogelstein, 1996)). Cells in the tumour proceed via a process 
similar to Darwinian evolution, that the cells with a serials of genetic change 
acquire one or another growth advantage, driving the formation of cancer 
(for reviews see (Hanahan and Weinberg, 2000)). 
 
There are three types of genes involved in tumorigenesis: oncogenes, 
tumour-suppressor genes, and stability genes (caretaker) (Vogelstein and 
Kinzler, 2004). Mutations on only one allele of oncogenes are able to 
promote the gene activity, and are sufficient for cells to gain growth 
advantage, but which is not enough to cause cancer. Tumor-suppressor 
genes and stability genes form strong barriers for malignant tumorigenesis in 
human cells. Unlike oncogenes, tumor-suppressor genes usually need to be 
mutated on both alleles for function lost. The deregulation of both 
oncogenes and tumour-suppressor genes works to promote cell proliferation, 
decrease cell apoptosis, and inhibition of cell arrest, hence increasing total 
number of tumour cells. Mutated stability genes don’t contribute to cancer 
cell number directly; instead, they decrease genome stability through the 
impaired function of DNA damage repair mechanisms, thereby creating 
opportunities for cell transformation. Two mutations are required for 
cultured rodent cells to acquire tumorigenic competence, while at least three 
are required for human cells (Hahn et al., 1999). Deregulation of cyclin E 
  11causes genetic instability in both rodent and human cells (Spruck et al., 
1999, Minella et al., 2002), which may due to impaired mini-chromosome 
maintenance proteins (MCM), a key component of the pre-replication 
complex (pre_RC) and may be involved in the formation of replication 
forks and in the recruitment of other DNA replication related proteins, 
loading on replication origins. In addition to gene mutation, apoptosis may 
also lead to genomic instability when DNA in dead cells being incorporated 
into neighboring cells by phagocytosis (Holmgren et al., 1999). 
 
An instable genome renders cell opportunities of going through the six 
alterations for tumorigenesis, which are self-sufficiency in growth signal, 
insensitivity to anti-growth signals and block of differentiation, evasion of 
apoptosis, limitless replicative potential, sustained angiogenesis, and tissue 
invasion and metastasis (Hanahan and Weinberg, 2000). 
 
 
Figure1: Outline of cellular processes affected by genetic alterations in cancer cells. 
Printed with permission of Natalie von der Lehr. 
1.1.1  Self-sufficiency in growth signals  
Normal cells need to receive mitogenic growth signals (GS) from their 
environment via trans-membrane receptors for proliferation. Oncogenes act 
by mimicking normal growth signals in one way or another so that the cells 
are able to proliferate independent of extra cellular stimuli.  
 
There are several ways to gain growth signal autonomy. One is the 
process called autocrine stimulation, through which the cancer cells 
  12synthesize GS of their own and then create a positive feedback signal loop. 
In some other cancer cells, surface receptors transducing GS are 
overexpressed so as to generate cells hyperresponsive to growth stimuli 
(Slamon et al. 1987). Another possible way is the capability of cancer cells to 
switch the types of extracellular matrix receptors (intergrins) they express, 
favouring those that transmit pro-growth signals (Lukashev and Werb, 1998; 
Giancotti and Ruoslahti, 1999). The most complex mechanisms of acquired 
GS autonomy derive from the mutation of genes encoding proteins that 
transduce and process signals emitted by ligand- activated GS receptors and 
intergrins in cytoplasm. One example is the Ras-proteins. Ras relies on its 
intrinsic GTPase activity to terminate signalling by hydrolizing GTP to 
GDP. This process is catalysed by GTPase-activating proteins (GAP). 
Mutations in ras are found in 30% of human cancers, resulting in impaired 
Ras GTPase activity and resistance to GAPs. The active Ras-GTP activates 
the Raf kinase and then induces mitogen-actived protein kinases (MAPKs). 
Downstream targets of Ras-MAPK pathway phosphorylate H3 at Ser 10 and 
Ser 28 as well as a variety of transcription factors, which leads to chromatin 
structure destabilization and promotes expression of genes such like c-myc, c-
jun, and c-fos (Dunn et al., 2005, Ito, 2007,Diaz-Flores and Shannon, 2007). 
1.1.2  Insensitivity to anti-growth signals 
In normal cells, anti-proliferative signals function to maintain cellular 
quiescence and tissue homeostasis. These signals drive cells out of active 
proliferating cycle into quiescence (G0) or into postmitotic states associated 
with differentiation straits. Insensitivity to anti-growth signals is an acquired 
genetic alteration of cancer cells.  
 
Much of the anti-proliferative signals circuitry is associated with the cell 
cycle, especially the components involved in G1 /S phase transition. Most, if 
not all, of the anti-proliferative signals are funnelled through the cell cycle 
regulator and tumour suppressor retinoblastoma protein (pRb). When in a 
hypophosphorylated state, pRb bocks proliferation by sequestering and 
altering the functions of E2F transcription factors that control the expression 
of genes essential for G1/S transition (Weinberg, 1995). This mechanism 
will be specified in the next chapter. pRb is mutated in many cancer cells, 
which causes continuously active of E2F, resulting in S phase entry even 
when in absence of mitogen stimuli. Loss of the tumour suppressor p53 is 
another common phenomenon in tumourgenesis that occurs in more than 
50% of human cancers (Hollstein et al., 1996; Vousden and Prives, 2005). 
p53 is well known as the “guardian of the genome”, which is activated by 
  13various types of cellular stress, including DNA damage and oncogenic stress. 
p53 stops the proliferation of precancerous cells by inducing cell cycle arrest 
or apoptosis, resulting from its integration of life or death signals such as 
oncogene activation, DNA damage, mitotic impairment or oxidative stress 
(Harris and Levine, 2005). Loss of p53 dramatically disrupts cells 
differentiation and promotes cancer formation in several oncogene-driven 
mouse tumour models. Even loss of one p53 allele will have similar effect in 
20% of all mice (for review see (Stiewe, 2007)). Moreover, the level of p53 
proteins has significant influence on cell fate. Low p53 level favours growth 
arrest whereas high p53 level triggers apoptosis (Laptenko and Prives, 2006) 
 
In addition to avoidance of anti-proliferative signals, lack or block cellular 
differentiation is another hallmark of cancer (for review see Tenen, 2003). 
This is particularly evident in hematopoitic tumours. Tumour cells use 
various strategies to avoid differentiation; one of them is deregulation and 
translocation of specific transcription factors that control the process of cells 
from self-renewing stage to mature differentiated stage. Beside, 
overexpression of oncogenes can also block differentiation, e.g c-myc. It is 
known that c-myc can induce a shift from differentiation to proliferation 
when overexpressed (for review see (Grandori et al., 2000)). Depletion of c-
myc inhibits cell proliferation, resulting in G0/G1 growth arrest in normal 
cells, while more variable arrest patterns (G0/G1, S, or G2/M) in different 
tumour cell lines (Wang et al., 2007). However, there is also evidence 
showing that Myc promotes differentiation in B lymphocyte (Habib et al., 
2008). This will be discussed in more details in the later chapter about Myc. 
1.1.3  Evasion of apoptosis 
The expansion of tumour cell population not only relies on the cell 
proliferation but also the cell death. Evasion of apoptosis, programmed cell 
death, is another important capability acquired by cancer cells. Apoptosis is 
an energy-dependent process characterized by several morphological features 
namely nuclear condensation and fragmentation, membrane blebbing and 
non-inflammatory phagocytosis of the cell fragments (Wyllie et al. 1980). 
There are two main pathways of apoptosis, the intrinsic and extrinsic 
pathway, although there is evidence for cross-talk between the two (for 
review see Meyer et al. 2006).  
 
Intrinsic pathway of apoptosis can be triggered by DNA damage, 
oncogene activation, hypoxia, or limited growth signal. Intrinsic pathway 
signals converge on the mitochondria where decision of survival or apoptosis 
  14of the cell will be made by balance between pro- and anti- apoptotic 
molecules. The BCL2 family of proteins is the main player of this process. 
This family can be divided into anti-apoptotic group (BCL2 and BCL-XL) 
and pro-apoptotic group (BAX, BAK, BID, PUMA, NOXA and BIM). 
Balance of the two groups will decide the fate of cells (Gross et al. 1999). 
When pro-apoptotic signals win, cytochrom C is released from 
mitochondria. It binds to Apaf-1 and activates caspase-9, which in turn 
cleaves and then activates downstream caspase-3 and caspase-7 (for review 
see Lavrik 2005). Caspases are a family of proteases that cleave substrates at 
those consensus sites containing asparagine residues. The caspase cascade can 
also be initiated by extrinsic pathway of apoptosis, also known as the death 
receptor pathway. The death receptors (CD95/Fas, TNFR and DR5) 
response to TFN-related apoptosis-inducing ligand (TRAIL). Upon death 
ligand simulation, the receptors oligomerise, bringing intracellular death 
domains (DD) together so they can interact with adaptor molecules such as 
FADD and TRADD (Danial 2004). Adaptor proteins contain both DD and 
death effector domain (DED), which in turn interacts with the DED 
domain of caspase-8, triggering its cleavage and activation. Activated 
caspase-8, like caspase-9, activats downstream caspases such as caspase-3 and 
caspase-7. 
 
Resistance to apoptosis can be achieved through various strategies in 
cancer cell. Enhancement of survival molecules is one of the possible 
mechanisms. Loss of the pro-apoptotic tumour suppressor p53 function is 
the most common way. It senses DNA damage signals and leads cells to 
growth arrest, where the damage can be repaired, or into apoptosis 
(Vousden, 2000). Apoptosis is mediated by p53 through both transcription-
dependant and –independent methods (Schuler and Green, 2005). p53 can 
not only activate transcription of apoptosis inducing genes like BAX and 
BIM, but also can be translocated from  nucleus to function at mitochondria 
through binding directly to BCL2/BCL-XL and BAK (for review see 
Meyer et al. 2006). P63 and p73, two relatives and evolutionary 
predecessors of p53, are thought to be required for p53 to transactivate pro-
apoptotic genes. (Flores et al., 2002, 2005).  
1.1.4  Limitless replicative potential 
The three acquired capabilities of cancer cells mentioned above all dedicate 
to uncouple the cell growth from its environment though disruption of cell-
to-cell signalling. However, they are not enough to generate the huge mass 
of cells required for malignant tumour constitution. All mammalian cells 
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that limits cell multi-replication. Break of the mortality barrier is necessary 
for cancer formation. 
 
Cells in culture have limited replicative potential (for review see hayflick, 
1997). Cells having gone through a certain amount of cell doublings (50 for 
human cell cultures) will stop growing. During each cell cycle, telomeres, 
which are composed of several thousand repeat of a short 6 bp element at 
the ends of chromosomes, will suffer a loss of 50 bp telomeric DNA. The 
continuous erosion of telomeres will eventually lead to complete loss of its 
ability to protect the ends of chromosomes, resulting in end-to-end fusion of 
chromosomes and massive cell death. 
 
Telomeres maintainment is the strategy used by almost all types of cancer 
cells to gain limitless prolicative potential. There are two methods of 
telomeres maintainment. One is upregulation of telomerase, an enzyme 
adding hexanuclotide repeats onto the telomeric DNA, which is used by 85 
–90% cancer cells (Bryan and Cech, 1999). The other method is called 
alternative lengthening of telomeres (ALT), where the maintainment is 
achieved through recombination based inter-chromosomal exchange of 
sequence information (Bryan et al., 1995; Ceth, 2004). 
1.1.5  Sustained angiogenesis, Tissue invasion and metastasis 
Nutrients and oxygen supplies are crucial for cell survival and functions. All 
cells in tissue can live only within a small distance (10µm) from capillary 
blood vessel. The rapid formation of blood vessel, a process named 
angiogenetic switch, is required for large size neoplasias. New blood vessels 
may either sprout from preexsiting mature ones or form freshly by recruiting 
bone-marrow-derived endothelia progenitor cells (for review see Bertolini 
et al., 2006; Rafii and Lyden, 2008). Further, evidence shows that 
endothelial progenitor cells control the angiogenic switch in mouse (Gao et 
al., 2008). Angiogenesis can be achieved through over-expression of 
angiogenesis inducers such as VEGF and suppression of angiogenesis 
inhibitors through transcription and proteases regulations (for review see 
(Hanahan and Weinberg, 2000)). 
 
Sooner or later the cancer development will achieve the stage known as 
metastasis, where the primary cancer cells invade adjacent tissues and made 
colonies at distant sites. Metastasis is responsible for 90% of human cancer 
death (Sporn, 1996). Metastasis initiates with dissemination, which is the 
  16process that invasive tumour cells enter the bloodstream through vasculature. 
Intravasation is also enhanced by an epithelial-to-mesenchymal transition 
that endows carcinoma cells with embryonic plasticity and added motility 
(Thiery, 2002, Huber et al., 2005). The efficiency of dissemination increases 
with tumour size. Intrinsic functions for evading of detachment-triggered 
cell death and extrinsic cooperation such as platelet aggregates are required 
for tumour cells to survive stresses during disseminating through 
bloodstream (Nierodzik and Karpatkin, 2006). Metastatic cells enter the 
parenchyma of a target organ by breaching the capillaries in which they are 
embedded. In the entry, they need cooperation of organic specific 
components of the tumour microenvironments for successful colonization 
(for review see (Nguyen and Massagué, 2007)). As each organ presents a 
highly specialized microenvironment, distinct sets of functions are required 
for colonizing different tissues (Gupta and Massagué, 2006). 
1.2  The eukaryotic cell cycle 
Cells reproduce through a serial of events known as the cell cycle, which 
includes duplication of the genome and cell division. The cell cycle is 
divided into four phases, G1 phase (G for gap), S phase (S for synthesis of 
DNA), M phase (M for mitosis), and G2 phase. In M phase, the replicated 
chromosomes are divided to form two new nuclei and the cell is then split 
in two by cytoplasmic division. Most cells require much more time for 
growth and organelle duplication, for this reason, two extra gap phases are 
inserted in cell cycles, the G1 and G2 phase. The two gaps also provide time 
for cells to monitor the internal and external environment signals to ensure 
that conditions are favourable and preparation are complete before the cells 
go into S phase and mitosis. Checkpoint in G1 phase is reported both in 
yeast and mammalian cells, where the cells decide to proceed or exit the cell 
cycle upon integration of anti- and pro-growth signals (for review see 
(Kastan and Bartek, 2004)). Once the cells pass the checkpoint, cell cycle 
will continue even if the signals that stimulate cell growth and division are 
removed. Checkpoint in G2 phase prevents cells from entering mitosis with 
damaged DNA, providing an opportunity for DNA repair and stopping the 
proliferation of damaged cells. The critical target of the G2 checkpoint is the 
mitosis-promoting activity of the cyclinB/Cdk1 kinase (Katsuhiro, 2004, 
Kastan and Bartek, 2004). Cells can also go into quiescence, the G0 phase, 
in either G1 or G2 phase, when internal and external signals are 
unfavourable, staying for days or even years before resuming proliferation. 
The G1, S, and G2 phase together are called interphase in which the cells 
  17spend the majority of its time and perform the majority of its cellular 
functions. Some human cells divide every 24 hours; in this case interphase 
takes about 22~23 hours, with 1or 2 hours for mitosis, which depends on 
the variety and size of the cells. 
 
 
Figure 2: A simplified overview of the mammalian cell cycle. Printed with permission of 
Anna Dimber.  
 
1.2.1  Cyclins, cyclin-dependent kinases and their inhibitors  
There are two types of proteins that constitute the major players in the 
regulation of the cell cycle, the cyclins and cyclin-dependent kinases (Cdks). 
There are 9 Cdks (referred as Cdk1-9) and at least 16 cyclins found in 
animal (Johnson and Walker, 1999) whereas there are 7 Cdks (CdkA-G) and 
7 cyclins (A, B, C, D, H, P and T) in plants (for review see (Francis, 2007)). 
Cyclins in different organisms might not be phylogenetically related, like in 
animal and yeast, but they still carry out similar functions, e.g. the activation 
of G1/S transcription by phosphorylating the transcription repressors Whi5 
(yeast) or Rb (animal and plant). 
 
  18Cdks are a group of serine/threonine kinases and each Cdk associates 
with a cyclin. The association is mediated via the cyclin box, a sequence of 
100 amino acids conserved in all cyclins. Cdk activities in eukaryotic cells 
are very low in G1, and rise progressively in mid-late G1, S, and peak and 
rapidly decrease during mitosis (Morgan, 1987). Full activation of the 
cyclin/Cdk complex occurs when a separate kinase, the Cdk-activating 
kinase (CAK), a complex of cyclin H and Cdk7, phosphorylates an amino 
acid near the entrance of he Cdk active site, then allows the complex to 
phosphorylate and activate certain set of substrate proteins. Different groups 
of cyclins and Cdks are linked to different cell cycle phase. Mammalian G1 
phase has three D type cyclins and two E type cyclins, which interact to 
Cdk4/6 or Cdk2 respectively. Various combinations of D type cyclins are 
expressed in different cell lines whereas cyclin E are expressed ubiquitously. 
The cyclins associated to S phase are A and E type, both binding with Cdk2. 
In G2/M phase, cyclin A and cyclin B, together with Cdk1, control cell 
cycle process (Arellano and Moreno, 1997, Nigg, 1995).  
 
The different cyclins and Cdks are biochemically similar. Their apparent 
differences in behaviour seem to reflect more of the spatial and temporal 
expression than of the specificity of substrates (for review see (Murray, 
2004)). For example, Cyclin B, which is normally excluded from the 
nucleus during interphase, can induce DNA replication when fused with 
nuclear localization sequence from cyclin E and thereby enter the nucleus 
(Strausfeld et al, 1996), suggesting that it can recognize the same substrates as 
cyclin E/Cdk2.  Further, evidences show that none of the G1 cyclin/Cdks 
is unique enough to impair cell cycle progress in mouse when being 
disrupted, and members in some classes, like D type cyclins, can compensate 
each other (for review see (Sherr and Roberts, 2004)). It is also possible that 
even though cyclin/Cdks are controlling cell cycle, there are still some other 
kinases that can be involved in this process (Murray, 2004). To sum up, the 
multiplicity of cyclins reflects redundancy and divergence that send different 
family members to different places at different time, which assures biological 
functions in different parts of the cells to be regulated separately. Although 
substrate specificity may not be the defining trait of different cyclin/Cdks, it 
does exist at certain level. The differences in substrate recognition between 
different cyclins associated to the same Cdk or between Cdk1 and Cdk2 is 
subtle (up to 5- fold), which is both small enough to help explain the 
survival capability of cells suffering multiple depletion of cyclins and Cdks 
and big enough to explain why such genetically disrupted cells often 
confront somewhat abnormalities during cell cycle. 
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The activity of a cyclin/Cdk complex can be inhibited by 
phosphorylation at two residues in the Cdk active site by the protein kinase 
Wee1, and the inhibitory process can be reversed by dephosphorylation of 
same sites by a phosphatase Cdc25. The other way of cyclin/Cdk complexes 
inactivation is through Cdk inhibitor proteins (CKIs), Ink4 and Kip/Cip 
families, p21
Cip1, p27
Kip1, and p57
Kip2. p27
Kip1  is a tumour suppressor that is 
highly expressed in quiescent cells and low in tumour cells. An important 
difference between p27
Kip1 and other tumour suppressor proteins, like p53 or 
p16, is that the down-regulation of p27
Kip1 in cancers is caused by accelerated 
degradation of the p27
Kip1 protein instead of mutations of the p27
Kip1 gene or 
epigenetic silencing  (Slingerland and Pagano, 2000). Regulation of p27
Kip1 is 
mediated by two independent phosphorylation sites on C-terminal of the 
protein. Phosphorylation on Thr187 by cyclinE/Cdk2 promotes its 
degradation whereas phosphorylation on Thr198 by AKT leads to its 
stabilization (Kossatz et al., 2006). In G0 phase, p27
Kip1 exists in monomeric 
form. Phosphorylation on Thr198 is needed to prevent proteolysis of the 
cyclin unbound p27
Kip1. When cells entering G1, Thr198-phosphorylated 
p27
Kip1  prefers to bind cyclinD/Cdk4/6 complex. Loss of Thr198-
phosphorylation shifts the binding preference from cyclinD/Cdk4/6 to 
cyclinE/Cdk2. p27
Kip1  is also known to help cyclinD/Cdk4/6 activation 
when binding to the complex.  
 
In plant, the two major cyclin-dependent kinases are CDKA and CDKB. 
CDKA regulates the transition from the G1 to S, which associates with 
cyclin D (CYCD) and cyclin A (CYCA) in G 1 and S phase, respectively. 
CDKB regulates G2 to M phases of the cell cycle. It associates with G2/M 
cyclins CYCA and cyclin B (CYCB). The CDK inhibitors (CKIs) are called 
Kip-related proteins, KRP (or ICK). They are related to animal p27
kip1 (for 
review see (De Veylder et al., 2007)).  
1.2.2  The ubiquitin and proteasome system (UPS) and degradation of G1 
phase cyclins 
Proteins are ubiquitylated through three enzymes, known respectively as E1, 
E2, and E3. Ubiquitin, a small 8kDa protein, is activated by the ubiquitin-
activating enzyme E1 in an ATP-dependent manner. The activated 
ubiquitin is transferred to ubiquitin-conjugating enzyme E2. Finally, the 
conjugated ubiquitin is covalently attached to a substrate protein by the 
ubiquitin ligase E3 to make a polyubiquitin chain via Ub
K48, leading to 
degradation of the substrate protein through proteasome. While there is only 
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members) E3 enzymes that determine the specificity of substrates 
recognition. The big E3 ligase family can be divided into four classes based 
on the structure specificity: HECT-type, RING-finger-type, U-box-type, 
and PHD-finger-type. The largest E3 ligases family Ring-finger family is 
composed of single and multisubunit E3 ligases. The single unit E3 ligases 
have substrate recognition element and Ring-finger in one single protein. 
For example, the p53 E3 ligase MDM2 belongs to this group. Multisubunit 
E3 ligases contain a ring-finger protein, a member of cullin family, an 
adaptor, and a substrate recognition protein. The subfamilies are SCF, VCB 
and APC complexes shown in Fig4. The 26S proteasome comprises a 20S 
core component and two 19S regulatory complexes. The 20S core is 
conserved from yeast to humans; it contains four α- and –β rings 
surrounding a barrel shaped cavity. The two inner β rings form a central 
chamber that carries out proteolytic function. The 19S complex contains 18 
distinct proteins; including six highly related ATPases of the AAA family. 
Ubiquitylated proteins are recognized by the ATPase subunit S6’ (spt6), 
unfolded and channelled via a central passage into the degradation chamber, 
cut into peptides, finally released through the entry channel (Lam et al, 
Finley, 2000, Hutschenreiter et al., 2004). 
 
Figure 3: The ubiquitin and proteasome system. 
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Figure 4: Components and architecture of multisubunit Ring-finger E3 ligases. Printed with 
permission of Natalie von der Lehr. 
 
The oscillation of cyclins during the cell cycle process is the result of 
orchestrated cyclin synthesis and proteolysis. Clearance of cyclins gives the 
cells enough time for growth and integration of intrinsic and extrinsic signals 
before there are enough cyclins accumulated to drive cells into another 
round of replication and division. All cyclins are destroyed through UPS 
pathway. Two types of E3 ligase are involved in cell cycle regulation, SCF 
complex and anaphase-promoting complex (APC). The name of SCF is 
derived from the three earliest identified components: Skp1 (adaptor 
protein), Cullin1 (scaffold protein), and F-box proteins (substrate 
recognition protein). The other components are the Ring-finger protein 
Rbx1 and Rub1/Nedd8. SCF complex functions from late G1 to early M 
phase, whereas APC actives from mid-mitosis to the end of G1 phase. Two 
F-box proteins, Skp2 and Fbw7, are thought to involve in G1/S phase 
regulation (for review see (Nakayama and Nakayama, 2005, 2006)). 
 
Skp2 was originally discovered as protein associated with the 
cyclinA/Cdk2 complex, and was named as p45. It is since then well 
established as a growth promoter and oncoprotein. Reported substrates of 
Skp2 include p27
Kip1, p21
Cip1, p53, p130, cyclin A, cyclin D1, free cyclin E, 
E2F1, ORC1, CDT1, CDK9, MYC, B-MYB, SMAD4, RAG2, UBP43, 
FOXO1 and papilloma virus E7 (for review see (Nakayama and Nakayama, 
2005)). Cyclin D is phosphorylated and exported from nucleus to cytoplasm 
through glycogen synthase kinase 3-β (GSK-3β), a kinase inhibited by 
Ras/PI3K/AKT pathway (Diehl et al. 1998, Alt et al. 2000), and recognized 
by F-box Skp2 in SCF complex, leading to its degradation. Skp2 also 
mediates degradation of free monomeric non-phosphorylated cyclin E 
(Clurman et al., 1996, Nakayama et al., 2000, Koepp et al., Strohmaier et 
al., 2001, Won et al., 1996). 
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tumour suppressor gene (Calhoun et al., 2003, Rajagopalan et al., 2004). In 
cell culture models, loss of Fbw7 leads to genomic instability (Rajagopalan et 
al., 2004). cyclin E is phosphorylated at multiple sites by GSK-3β (Thr380) 
and is autophosphorylated by Cdk2 (Thr380), producing the 
phosphodegron sequence recognized by Fbw7/hCdc4 (Clurman et al., 
1996; Welcker et al., 2003; Won and Reed, 1996). The involvement of 
GSK-3β in cyclin E stability suggests that cyclin E, just like cyclin D1, can 
be directly influenced by at least one mitogen-dependent kinase-signaling 
cascade (Ras/PI3K/AKT). A double phosphorylation at Thr380/Ser384 
creates high-affinity binding of cyclin E to Fbw7 whereas a single 
phosphorylation at Thr62 makes a low-affinity binding (Hao et al., 2007). 
Recent observations suggest that phosphorylated cyclin E, together with 
Pin1, binds to one of two isoforms of Fbw7, Fbw7α, potentiating prolyl 
isomerase activity of Pin1 to isomerize the trans bond between pralines 381 
and 382 of cyclin E. The isomerized cyclin E can be efficiently ubiquitylated 
by another Fbw7 isoform, Fbw7γ (van Drogen et al., 2006). In experiments 
performed by Tsunematsu and Mao, expression of cyclin E was unaffected 
in Fbw7–/– embryos (Tsunematsu et al., Mao et al., 2004), and 
concentration of cyclin E increased only in the placenta (Tetzlaff et al., 
2004), which suggested that Fbw7 regulates cyclin E degradation in a tissue 
specific manner. The other reported E3 ligase for cyclin E is Cul3-based E3 
ligase. Cul3 exclusively targets monomeric cyclin E (Clurman et al., 1996, 
Singer et al, 1999). The N terminus of Cul3 binds to one of many BTB 
domain-containing proteins, a family of proteins that have been shown to 
contain both the adaptor and substrate recognition moiety in a single 
polypeptide (Geyer et al., Xu et al., 2003). Mechanisms of Cul3 degradation 
pathway is still not very clear, but it is known that phosphorylation on 
Thr380 of cyclin E is not required here. Decreased levels of Cul3 increases 
both cyclin E protein levels and the number of cells in S phase. Cul3-based 
E3 ligase is essential to maintain quiescence in mammalian cells (McEvoy et 
al., 2007). 
1.2.3  G1/S transition regulation  
In early embryos, DNA synthesis starts directly after mitosis. In post-
embryonic cells, a gap G1 is inserted into the two phases. Yeast and animal 
have long G1 phase, where, as mentioned above, the cells decide to proceed 
into S phase or enter quiescent stage G0 depends on the availability of 
nutrients and growth factors. As a result, deregulation of G1/S transition is 
universal in cancers. Prohibition of fast entry into replication is achieved 
  23through Cdk inhibitors (CKIs) and S-phase negative regulator proteins (e.g. 
Rb family). A major role of G1 cyclins/Cdk complexes seems to be to 
disable cell cycle inhibitory proteins, after which the mitogenic signals can 
be delivered to the core cell cycle machinery to assure smooth process of cell 
proliferation and division (Sherr and Roberts 1995, 1999) 
1.2.4  The retinoblastoma protein pRb 
pRb family proteins play a crucial role in the cell cycle, especially DNA 
replication, by controlling the expression of E2F-dependent genes that are 
necessary for S phase entry, and important for CKI degradation, like cyclin E 
and  Skp2. Hypophosphorylated pRb binds promoters of such genes by 
forming a complex with E2F. It actively represses the activity of these 
promoters, at least in part by recruiting chromatin modulating factors such as 
histone deacetyltransferase 1 (HDAC1) (Luo et al., 1998), SWI/SNF type of 
chromatin remodeling factors (Harbour and Dean, 2000; De Luca et al., 
1997), polycomb group proteins (Dahiya et al., 2001) or histone 
methyltransferases (Nielsen et al., 2001) that act on the surrounding 
nucleosome structure to create functionally inactive chromatin. pRb 
proteins can also block G1/S transition though E2F- independent 
mechanisms. They inhibit cyclinE/Cdk2 kinase activity either by binding 
directly to this complex or by increasing p27
Kip1 expression and stabilizing 
p27
Kip1 proteins. The latter can be achieved through several mechanisms. 
First, pRb binds to Skp2, thus interfering with the Skp2-p27
Kip1 interaction 
and thereby preventing p27
Kip1 ubiquitylation (for review see (Giacinti and 
Giordano, 2006)). Second, pRb acts as a scaffold for Skp2 and its E3 ligase 
APC/C
cdh1, facilitating Skp2 degradation, resulting in stabilization of p27
Kip1 
(Binne et al. 2007). pRb phosphorylation is regulated by mitogenic signals 
and is exerted by the cyclinD/Cdk4/6 complex in the early and mid-G1, 
and cyclinE/Cdk2 in late G1. pRb can also be regulated at both the 
transcriptional and protein levels by the transcription factor ICBP90 
(inverted CCAAT box binding protein of 90 kDa), resulting in S phase 
entry (Hopnefer, 2000). 
 
The pRb/E2F pathway is also conserved in plants. The E2F transcription 
factor that controls expression of S-phase specific genes associates with the 
retinoblastoma protein-related corepressor RBR in G1 to keep these genes 
silenced. In late G1, CYCD/CDKA phosphorylates RBR, resulting in 
release of E2F and activation of S-phase genes (for review see (De Veylder 
et al., 2007)). 
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The D-type cyclins (D1, D2, and D3) activation is induced by mitogenic 
stimuli and is closely regulated at many levels, including gene transcription, 
cyclin D translation and stabilization, assembly of D cyclins with their Cdk 
partners (Cdk4 and Cdk6), and import of the holoenzymes into the nucleus, 
where they ultimately phosphorylate their substrates (Sherr and Roberts 
1999) through Ras/Raf/MAP kinase signal transduction cascade pathway 
(Diehl et al. 1998, Alt et al. 2000). Each type of cyclin D could receive 
different upstream signals. Cell proliferation, which controlled by different 
mitogens in various cell types, is regulated via expression of different D-type 
cyclin gene. cyclin D1 availability is controlled by a balance between the 
Ras/Raf/MAPK (cyclin D1 synthesis) and Ras/PI3K/AKT (cyclin D1 
stability) mitogenic pathways (for review see (Malumbres and Barbacid, 
2001, Massagué, 2004)). Once activated, cyclinD/Cdk4/6 complex can 
promote cell division through phosphorylation of substrate proteins such as 
pRb and Smad3. The main inhibitors of cyclinD/Cdk4/6 complexes are the 
Ink4 family (p16Ink4A, p15 Ink4B, p18Ink4C, and p19Ink4D) that can be 
induced by growth inhibitor such as TGF-β. They bind to the Cdk4/6 
kinases and prevent their association with cyclin Ds.  
 
The primary role of cyclin D is to activate cyclinE/Cdk2 in mid/late G1 
phase. In association with Cdk4/6, cyclin Ds initiate phosphorylation of 
pRb family protein (pRb, p107, and p130), thus helping to release 
transcriptional factor E2F from its suppression. The freed E2F will activate a 
group of genes required for S phase entry (Trimarchi and Lees 2002), among 
these are genes encoding cyclin Es. CyclinD/Cdk4/6 complexes can also 
activate cyclin E by sequestering Cip/Kip proteins, hence titrating these 
inhibitors away from cyclinE/Cdk2 complexes. Binding of Cip/Kip 
proteins to cyclinD1/Cdk4 stabilizes the complex and facilitates its nuclear 
import, without inhibiting cyclin D associated kinase activity (Blain et al., 
LaBaer et al., 1997, Cheng et al., 1999). Cyclin Es, acting with Cdk2s, 
target and hyperphosphorylate pRb family proteins that are already partially 
phosphorylated by CyclinD/Cdk4/6 complexes. Only after this latter 
modification pRb renders inactive and thus unable to occlude the 
transcription-activating domains on the E2F and to block cell cycle advance. 
Overexpression of cyclin E can greatly accelerate G1/S transition in cultured 
mammalian cells (Resnitzky et al. 1994). Ectopic cyclin E expression causes 
decreased mitogen requirement and increased cell size. All this data suggest 
that cyclinE/Cdk2 is crucial in G1/S transition. But reports from 2003 
challenged this concept when they showed that neither elimination of cyclin 
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vitally impaired continuous cell cycle in either embryonic or post-
embryonic cells (Geng et al., Ortega et al., 2003). Although these reports 
suggest that cyclin E is dispensable for cell division, and there is redundant 
activity that substitutes its loss, data accumulated during many years indicate 
that it plays a fundamental role in G1 in wild-type cells. cyclin E is regulated 
at both transcriptional and post-transcriptional levels. It forms a positive 
feedback loop with pRb and E2F, which makes the inactivation of pRb 
independent of mitogens once cyclinE/Cdk2 becomes active. cyclin E is 
regulated by other transcriptional factors in other circumstances, e.g. in 
pancreatic and hepatic cells it is target of LRH-1 (Bottrugno et al., 2004). 
The cyclin E mRNA is also regulated by alternative splicing, but the 
relevant functions of its different isoforms are not clear. cyclinE/Cdk2 
complex carries on most of its biological function through substrate 
phosphorylation. Its substrates include proteins involved in G1/S transition 
regulation (such as pRb and p27
Kip1), histone transcription (p220/NPAT) 
and acetylation (CBP/p300), and centrosome regulation (nucleophosmin 
B23 and CP110) (for review see (Möröy and Geisen, 2004, Hwang and 
Clurman, 2005)). cyclin E also plays an important role in DNA synthesis and 
functions synergistically with CDC6 to facilitate MCM (2-7) loading on 
replication origins (Coverly et al., 2002). Surprisingly, cyclin E mutant that 
fails to activate Cdk2 is able to interact with the critical replication licensing 
protein CDT1 and with MCM proteins, thus promoting the MCM loading, 
as good as wild type cyclin E (Geng et al., 2007). This result implies that the 
replication licensing function of cyclin E is independent of Cdk2. 
 
When cells enter S phase, cyclin E is degraded and Cdk2 then associates 
with cyclin A. In late S phase, CylinA/Cdk1 and CylinB/Cdk1 complexes 
are necessary for S phase completion and M phase entry. To exit mitosis, 
cyclin B destruction is required. 
1.2.6  The Skp2 autoinduction loop at the G1/S transition 
Ectopic expression of Skp2 allows cells to enter S phase in absence of 
mitogens (Sutterluty et al., 1999). The recent discovery that Skp2 is a 
transcriptional target of E2F (Zhang and Wang, 2006) gave rise to a positive 
feedback loop termed as the Skp2 autoinduction loop (Yung et al. 2007), 
which unifies many cell cycle regulators implicated in G1 restriction point 
control, such as Skp2, p27
Kip1, cyclinE/Cdk2 and pRb.  
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Kip1 deficiency almost completely rescues the aberrations obverted in 
Skp2-/- cells, suggesting that p27
Kip1 is the primary downstream effector of 
Skp2 (Nakayama et al., 2004). Direct physical contact between Cyclin E but 
not Cdk2 and p27
Kip1 is required for p27
Kip1 recruitment to SCF
Skp2. Arg306 of 
Skp2 is required for recognition and ubiquitylation of phosphorylated p27
Kip1 
(Ungermannova et al., 2005). p27
Kip1 requires the accessory protein Cks1 for 
its recognition and ubiquitylation by the SCF
Skp2 ligase (Ganoth et al., 2001; 
Spruck et al., 2001). Cks1 binds to the leucine-rich repeat (LRR) domain 
and C-terminal tail of Skp2. p27
Kip1 binds to the phosphate binding site on 
Cks1 though its phosphorylated Thr187 side chain, whereas binds to both 
Cks1 and Skp2 through another side chain of an invariant Glu185 (Hao et 
al., 2005). 
 
Skp2 triggers p27 degradation, which leads to activation of 
cyclinE/Cdk2, resulting in pRb phosphorylation, release of E2F, and further 
E2F-dependent Skp2 expression. While the overall flow through the loop is 
directional, two steps are bi-directional. One is that cyclinE/Cdk2 
inactivates pRb while pRb sequestration of E2F represses cyclin E 
transcription. The other is that p27
Kip1 inhibits cyclinE/Cdk2 activity while 
cyclinE/Cdk2 down-regulates p27
Kip1  level through phosphorylation of its 
T187A. The Skp2 autoinduction loop doesn’t have any intrinsic on/off 
mechanisms. Its regulation is dependent on external mitogens and anti-
mitogens. External mitogens turn on the loop through induction of cyclin 
D, but its turnoff is not restricted to decreased levels of cyclin D or 
inhibition of Cdk4/6. Knock-in of p27
T187A mutant that cannot be degraded 
by Skp2 is also able to block the loop (Yung et al., 2007). Blockade of the 
skp2 autoinduction loop strongly inhibits but not completely eliminates cells 
procession to S phase, which suggests that the loop may not be the only way 
for restriction point control. One possible option is that E2F can bind to 
cyclin D1 promoter and acts as another feedback loop which induces cyclin 
D1, finally resulting in pRb phosphorylation and further E2F release (for 
review see (Assioan and Yung, 2008)). Ubiquitylation and proteolysis of 
p27
Kip1 also occur at early G1 phase, a process independent of Skp2. p27
Kip1 
phosphorylated on Ser10 binds to CRM, a carrier protein for nuclear 
export, being translocated to the cytoplasm (Ishida et al., 2002) where it is 
degraded by Kip1 ubiquitylation-promoting complex (KPC). KPC2 
stabilizes KPC1, recruits polyubiquitylated p27
Kip1 and sends it to proteasome 
for degradation (Kamura et al., 2004, Kotoshiba et al., 2005, Hara et al., 
2005).  
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Figure 5: The Skp2 autoinduction loop. Figure is original from (Assioan and Yung, 2008). 
Published with permission from Cell Cycle (Journal). 
1.3  Overview of transcriptional regulation 
Transcription is the process where a DNA sequence is enzymatically copied 
by RNA polymerase to produce a complementary RNA nucleotide 
sequence. Proofreading mechanisms of transcription are fewer and less 
effective than that of DNA replication, therefore, transcription has a lower 
copying fidelity than DNA replication. The template strand of DNA is 
transcribed by RNA polymerase. The product, primary transcript RNA, has 
5'→ 3' direction and it is identical to the coding (non-template) strand of the 
DNA. After three main RNA processing steps, 5' capping, 3' 
polyadenylation, and RNA splicing, the mature mRNA is exported from 
nucleus to cytoplasm where the translation takes place. 
 
Gene expression is tightly controlled in cells, which is carried out 
through a serial of events by transcription activator and suppressor, 
polymerase I, II, and III, chromatin modifiers, and other general 
transcription factors (GTF). Polymerase I (Pol I) transcribes ribosomal RNA, 
while Polymerase III (Pol III) transcribes tRNA and various small RNA. 
Polymerase II (Pol II) transcribes protein-encoding genes. 
1.3.1  Initiation of transcription  
Transcription initiation is the first step of gene expression.  Formation of the 
preinitiation complex (PIC) at the right time and at the right promoter is a 
prerequisite of mRNA synthesis.  The process is governed through 
regulations affecting both the multi-subunit transcription factor complex and 
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polymerase (RNAP) and initiation specific subunit, σ factor, though it is 
much more complicating in eukaryotes. I will focus on transcription 
initiation by RNA polymerase II (Pol II) in eucaryotic cells in the following 
description. 
 
 
 
Figure 6: Overview of the transcription apparatus assembling on the promoter. Printed with 
permission from Robert Tjian. 
 
Transcription directed by RNA polymerase II needs several elements: cis-
acting elements, trans-acting elements, and the basal transcription machinery. 
The  cis-acting elements include the core promoter, proximal promoter 
elements/promoter-proximal basal level enhancers, and gene-specific signal-
responsive upstream promoters/distal enhancers. The core promoter often 
contains a TATA box (TATA), usually located 25 nucleotides upstream 
from the transcription start site, the initiator (Inr) and the downstream 
promoter element (DPE), which directs transcription by RNA polymerase 
II. Proximal enhancer elements, including BLE, GCbox, and CCAAT box, 
are usually bound by transcription factors such as Sp1 that enhance 
transcription. The gene-specific signal-responsive upstream promoters 
interact with different types of DNA-binding transcription factors that can 
be either activators or suppressors of transcription (for review see (Lemon 
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transcription activators and associated complexes that act in a gene-specific 
manner. Binding of transcription activators or activation of pre-bound 
activator usually is the initial step of RNA polymerase II directed 
transcription, followed by recruitment of the preinitiation complex (PIC) 
along with chromatin remodeling protein complexes. DNA-binding 
transcription activators contain at least two important domains, the DNA 
binding domain and the transactivation domain (TAD). They can be 
classified into different groups upon the DNA binding motif, such as helix-
turn-helix motif, zinc finger motif, leucine zipper motif, and helix-loop-
helix (HLH) motif. Many of the activators binding sites are located either in 
DNA regions not associated with histones such as linker regions or 
nucleosome-depleted regions (NDR), leading to direct access of the 
activators to the promoters, or in regions having lowest nucleosome 
occupancy, leading to outcompeting histones by the activators to create 
open chromatin and binding. Some genes are controlled by global 
suppressors that create a repressive chromatin environment. Transcription of 
these genes relies on release of the suppressor instead of binding of activator 
on promoters. There are also the third types of genes having “open” 
proximal promoter maintained by architectural factors or DNA sequence 
element, which makes them constitutively active, thus can be transcribed 
without activators (for review see (Morse, 2007)). This kind of activator- 
independent transcription is referred as basal transcription.  
 
The basal transcription machinery is the core player in transcription, 
which includes RNA polymerase II and the preinitiation complex (PIC) 
made of six general transcription factors referred as TFIIA, TFIIB, TFIID, 
TFIIE, TFIIF and TFIIH. Assembly of the basal transcription machinery to 
the promoters is a multi-step process. The first step is that TFIID recognizes 
and binds to promoter. TFIID is a multicomplex containing the TATA-
binding protein (TBP) and 12-15 TBP associated factors (TAFs), being 
responsible for core promoter recognition, coactivator function, catalysis of 
protein modification, and targeting to specially acetylated nucleosomes. 
TAFs recognize core promoter through binding to Inr (TAF2) and DPE 
(TAF6). They also provide coactivator interfaces for enhancer-binding 
transcription factors. TAFs show tissue specific promoter selection, for 
example, TAF4b is expressed in highly differentiated human B cell line and 
TAF1 and TAF10 are required for cell cycle progression (for review see 
(Hochheimer and Tjian, 2003)). TAF1 has intrinsic histone acetyltransferase 
(HAT) activity (Mizzen et al., 1996). Interestingly, TAF1 can recognize and 
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TFIID can initiate PIC biding even at nucleosome occupied promoters 
(Jacobson et al., 2000). Upon TFIID binding, the DNA is distorted and thus 
servers as a physical landmark for the location of an active promoter in the 
midst of a very large genome. It also brings together DNA sequences on 
both side of the binding to allow subsequent protein assembly steps, such as 
the adjacent binding of TFIIB. The N-terminal of TFIIB, named as the B 
finger, occupies almost the same location of the RNA/DNA hybrid in a 
transcribing complex. RNA/DNA hybrid containing more than 5 RNA 
residues has to compete with TFIIB for space in the Pol II saddle. Pol II 
escapes from promoter for elongation upon RNA victory, otherwise, the 
transcription initiation is aborted. After TFIIB brings the DNA to a point on 
polymerase surface then locates the transcription start point close to 
polymerase active center, TFIIE enters PIC and recruits TFIIH that uses 
ATP to spry apart the DNA double helix, resulting in formation of a 
transient bubble. TFIIF interacts with the nontemplate strand and upstream 
duplex DNA to trap the bubble, allowing the transcription initiation on 
template DNA (for review see (Kornberg, 2007)). TFIIH can also 
phosphorylate Pol II at the C-terminal domain (CTD), changing its 
conformation so that Pol II is released from the PIC to start transcription 
elongation. 
 
It has been suggested that transcription is a dynamic and stochastic 
process rather than static one. Highly mobile transcription factors and 
chromatin-associated proteins bind to and are released from promoters 
transiently through a stochastic mechanism known as “hit and run” without 
any productive result. Transcriptionally productive complexes, which have 
low mobility, are rarely formed on promoters. The transcription activity 
happens only when the specific required factors are recruited at appropriate 
time points (Métivier et al., 2006). 
1.3.2  Coactivators and cosuppressors  
Transcription activities need not only DNA-binding transcription factors but 
also additional proteins called co-regulators (coactivators and cosupressors).  
Animal cells utilize from 1000 to 10000 transcription regulators. Diverse 
combinational interaction between DNA-binding transcription factors and 
co-regulators gives high order complexity to the basal transcription apparatus 
with limited number of components. Further, cellular signal pathway 
control of transcription that assures right gene expression under certain 
cellular environment, is mediated through modification of co-regulators. 
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/cosupressors is essential to understand transcriptional regulation in 
eukaryotes. 
 
Coactivators can be divided into two groups: proteins that interact with 
or are components of the basal transcription machinery, and proteins that 
modify or remodel the chromatin structure (Näär et al., 2001, Featherstone, 
2002). The first group contains the TBP-associated factors (TAFs) and the 
mediator complex. Mediator, which is conserved in many organisms from 
yeast to humans, is a big protein complex with more than 20 subunits. It 
contacts both activators and Pol II to transduce transcriptional information 
from enhancers to core promoters (Kornberg, 2005, Malik and Roeder, 
2005). It is worth noting that mediator not only acts positively but also 
negatively for transcriptional regulation (Kornberg, 2007). Human mediator 
was first identified through a stable intracellular thyroid hormone-dependent 
association with thyroid hormone receptor (TR) (Fondell et al., 1996). 
Further, TRAP/mediator complex binding of TR through 
TRAP220/MED1 subunit is necessary for TR-dependent transcription by 
Pol II (Fondell et al., 1996, Zhu et al., 1997, Yuan et al., 1998). Different 
activators target specific mediator subunits, for example, Elk-1 and E1A 
interact with Sur2/MED23 subunit, whereas p53 interacts with 
TRAP80/MED17 subunits (for review see (Roeder, 2005)). The 
chromatin-remodeling or -modifying proteins contain two subgroups; one 
subgroup is involved in histone modification for facilitating the access of 
activators to DNA, such as Gcn5 (subunit of yeast SAGA complex), PCAF 
(the mammalian SAGA-like complex), CBP (CREB-binding protein), and 
p300. The other subgroup is ATP-dependent chromatin remodeling 
complexes, such as SWI/SNF complex in yeast or their mammalian 
counterpart BRG1 or BRM (Featherstone, 2002, Spiegelman and Heinrich, 
2004). Some of these proteins will be discussed later. 
 
Cosupressors behave opposite to coactivators. Unlike coactivators that 
recruit HAT activity, cosupressors often recruit HDACs (histone 
deacetyltransferase), resulting in a compacted chromatin that inhibits protein 
access to promoters; whereas coactivators stabilize PIC, cosupressors make 
inhibitory contacts to interfere transcription initiation. Examples of those 
cosupressors are the SMRT (silencing mediator of retinoid and thyroid 
hormone receptor) and N-CoR (nuclear hormone receptor-corepressor) 
(Privalsky, 2004). One should also bear in mind that since the same 
modification, e.g. H3K4 methylation, can cause either positive or negative 
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may change between cosupressor and coactivator under different 
circumstances. 
1.3.3 Chromatin  regulations 
Chromatin structure of packing DNA into nucleosomes is a significant 
barrier that has to be overcomed for transcription. The nucleosome core 
contains 147 bp of DNA wrapped 1.65 turns around the histone octamer 
made of two copies of each H2a, H2B, H3, and H4. The 14 contact points 
between histones and DNA make it one of the most stable protein-DNA 
complexes. The dynamics of chromatin structure are closely regulated 
through multiple mechanisms including histone modifications and 
chromatin remodelling. These histone modifications include methylation of 
arginine (R); acetylation, methylation, ubiquitylation, DP-ribosylation, and 
SUMOylation of lysines (K); and phosphorylation of serines and threonines. 
Modifications related to active transcription are referred as euchromatin 
modifications, whereas modifications associated with inactive regions are 
called heterochomatin modifications (for review see (Li et al., 2007)) 
Acetylation usually seems to be activating whereas SUMOylation is 
repressing. Methylation and ubiquitylation carry out variable functions 
according to sites and context. These modifications are not exclusive from 
each other; instead, crosstalks happen among them. One modification can 
sent completely different messages depending on the other histone 
modifications present. 
1.3.4 Histone  acyetylation 
Histone acetylation is traditionally seen as the mark of active transcription. 
Unlike other histone modifications, it can happen at multiple lysine sites. 
Histone acetyltransferases (HATs) catalyse the transfer of an acetyl group 
from acetyle-CoA to lysine residus on the N-terminal tails of the histones 
(Yang et al., 2004). Two main superfamilies of HAT have been 
characterized: the GNAT and the MYST families. In mammals, the most 
well known GNAT (Gcn-related N acetyltransferase) proteins are GCN5 
and PCAF (p300/CREB-binding protein-associated factor). GCN5 is 
involved in acetylation of histone H3 and, to lesser extent, H4. Its N-
terminal possesses chromatin substrates recognition function, whereas its C-
terminal interacts with the DNA-dependent kinase holoenzyme, which 
inhibits GCN5 HAT activity through phosphorylation. PCAF functions as 
HAT and as a coactivator in several processes: myogenesis, nuclear-reporter 
–mediated activation, and growth-factor-signalled activation. It can also 
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P300/CBP is another family of HATs, which acetylate the N-terminal tails 
of all four core histones. Like PCAF, substrates of P300/CBP include 
proteins other than histones, such as p53 and HIF2.Other HATs include 
Hat1, Hat2 and Elp3. Hat1 is shown to be involved in DNA double strand 
break repair. Elp3 is able to acetylate all four histones. The MYST is named 
after its founding members MOZ, Ybf2/Sas3, Sas2, and Tip60. Other 
members include yeast Esa1, drosophila MOF, human HBO1 and MORF. 
Tip60 participates in specific gene transcriptional activities through local 
histone acetylation, particularly H4 acetylation. Being similar to p53, it also 
responses to DNA damage. MOZ and MORF are found transformed in 
some types of leukaemia. HBO1 may play a role in DNA replication since it 
interacts with replication factors MCM2 and ORC1. Most HATs exist as 
multisubunit complexes in vivo. The complexes are usually more active than 
their respective catalytic subunits alone. In contrast to HATs, HDACs 
remove acetyl groups from histones, usually creating a repressive chromatin 
environment for transcription. Like HATs, HDACs cannot bind directly to 
DNA; recognition of different deacelylation sites mainly depends on the 
cofactors they form a complex with. (for review see (Verdone et al., 2005, 
2006)). 
 
HATs and HDACs target histone through two mechanisms, one is that 
HATs and HDACs are recruited to histones by proteins binding to specific 
DNA sequences. The other mechanism depends on prior histone 
modification serving as the recognitive mark (Clayton et al., 2006), such as 
methylation at H3K4 site (Barratt et al., 1994, Clayton et al., 2000). Most of 
acetylation happens at the flexible and highly basic N-terminal tail of 
histone. However, a lysine (K56) within the core domain of H3 has also 
been found acetylated (Xu et al., 2005). Several mechanisms of how histone 
acetylation affects transcription have been brought up. First, the acetylations 
on lysine residues neutralize charge on histones, thus decreases affinity 
between histones and negatively charged DNA backbone, which leads to 
increased nucleosome mobility. On this respect, biological functions of 
histone acetylation rely on the number of lysines modified. Second, addition 
of an acetyl group to histone creates a new binding surface for transacting 
factors possessing a protein module dubbed as bromodomain (for review see 
(Verdone et al., 2005, 2006)). There are more than 30 bromodomain-
containing proteins in human. They selective recognize acetylated histones, 
for example, Brd2 prefers interaction with H4K12, binds less well to H2B, 
and does not interact with H3 and H2A; TAF1 recognizes H3 and H4, to 
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and H2B (Kanno et al., 2004). Third, some acetylations directly affect 
higher-order chromatin structure; acetylation of H4K16 inhibits formation 
of compacted 30nm fibers since the H4 N-terminal is crucial for contact 
between nucleosomes (Shogren-knaaket al., 2006). New insight into histone 
acetylation suggests it a dynamic process involving rapid acetylation turnover 
on lysine residues (Clayton et al., 2006). Experiments showed that blocking 
acetylation turnover using HDAC inhibitor inhibits transcription of some 
genes (Hazzalin, and Mahadevan, 2005), which might imply histone 
acetylation and deacetylation affect transcription as continuous circuit and 
loss of any link will impair machinery of gene expression. 
1.3.5  Histone methylation  
Compared to acetyltransferases, histone methyltransferases are much more 
specific. They usually methylate one single lysine on a single site (Bannister 
and Kouzarides, 2005). Methylations don’t change electrical state of 
histones. Lysine methylations provide binding of proteins containing 
chromodomain, tudordomain, or PHD domain. Dogmatically, three 
methylation sites are implicated in activating transcription: H3K4, H3K36, 
and H3K79, whereas another three methylation sites are implicated in 
repressing transcription: H3K9, H3K27, and H4K20 (for review see 
(Kouzarides, 2007)). This dogma has been challenged in the last several 
years.  
 
H3K4 is methylated by the Set1 complex in three patterns, mono- 
(enriched at 3’end of the gene), di- (in the middle), and tri-methylation (at 
5’ end) (Pokholok et al., 2005). Monomethylation occurs at a basal level 
without association of Pol II. Set1 associated with elongating Pol II at the 
transcription start region and converts monomethyl to dimethyl and 
trimethyl (Li et al., 2007). H3K4me is able to bind to various proteins 
carrying different biological functions. For instance, as mentioned above, 
H3K4 methylation binds chromodomain-containing protein Chd1, thus 
recruiting HAT GCN5 for histone acetylation. Besides these positive-acting 
transcription effector recruitment activities, H3K4me3 is also found 
associated with negative-acting effector recruitment. In response to DNA 
damage, H3K4me3 recruits the Sin3-Hdac1 HDAC through binding of the 
PHD domain of one of the subunits Ing2 (Shi et al., 2006). One explanation 
about why so many complexes bind to one single PTM (post-translation 
modification) was proposed by Berger (Berger, 2007). She suggested that 
positive acting complexes (such as GCN5, MLL, and NuA3) might be 
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negative-acting complexes (JMJ2D and Sin3-Hdac) during attenuation of 
transcription. Methylation of H3K9 is implicated in gene silencing by 
recruiting HP1 (heterochromatin-like protein 1) to the promoters to form 
pericentromeric heterochromatin (Bannister, Lachner et al., 2001,). 
However, findings recently indicate that H3K9me3 and the γ isoform of 
HP1 are enriched in the coding region of active genes, and actually increase 
when transcription is induced (Vakoc et al., 2005, Brinkman, 2006), a 
phenomenon resembling H3K36. Similarly, methylation of DNA, usually 
occurring at promoters and genes to repress transcription, is reported to 
occur frequently across ORFs of many actively transcribed genes. Taken 
together, H3K9 and DNA methylation may have a similar role as 
methylated H3K36 in transcription, that is, to reestablish the nucleosome 
structures over the transcribed DNA region after Pol II passage (Berger, 
2007). 
 
So far two classes of demethylases have been identified: the LSD1/BHC1 
10 class and the jumonji class. LSD1 demethylates H3K4me1 and H3K4me2 
to repress transcription. However, it demethylates H3K9 to activate 
transcription when presenting in a complex with the androgen receptor. 
Jumonji class demethylases remove H3K4me2, H3K4me3, H3K9me2, 
H3K9me3, H3K36me2, and H3K36me3 (for review see (Berger, 
Kouzarides, 2007)). The selectivity of demetylases for mono-, di-, and tri-
methylation assures a larger functional control of lysine modification (Shi 
and Whetstine, 2007).  
1.3.6 Chromatin  remodelling 
The histone modifications described above regulate nucleosome dynamics 
through transient histone dissociation resulting from the electrical contact 
changes between histones and the DNA backbone. There is another type of 
dynamic nucleosome regulation concerning histone displacement. Unlike 
the former changes, which happen on a millisecond time scale, the latter 
occurs on a time scale of minutes in yeast (Dion et al., 2007). It has been 
reported that during efficient transcription, 80% of all core histones are 
removed from transcribed regions of yeast genes. Maximal removal of core 
histones happens only at high Pol II density, that is, one molecule per 100-
150 bp (Kristjuhan and Svejstrup, Schwabish and Struhl, 2004,). With lower 
Pol II density, partial displacement of histones occurs only with H2A/H2B 
(Nacheva et al., 1989). This observation also coincides with the nucleosome 
stucture where H3/H4 are located centrally in the nuclesome particle and in 
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tetramer and bind to DNA less tightly. Numerous proteins are involved in 
this histone displacement and chromatin remodelling process, including 
actively transcribing Pol II, histone chaperons, and chromatin-remodeling 
complexes. For instance, the protein complex FACT (facilitates chromatin 
transcription), a histone chaperon specially interacting with all core histones, 
assists pol II to remove H2A/H2B from nucleosomes. Besides this, together 
with other histone chaperons such as Spt6, Spt2 and Hir proteins, it helps to 
rebind the H2A/H2B dimer to the nucleosomes in transcribed DNA region 
after Pol II passage (for review see (Kulaeva et al., 2007)). In transcription of 
the yeast PHO5 gene, nucleosomes cannot be reassembled in the absence of 
Spt6, which leads to constitutively active of PHO5 promoter even after 
removal of transcriptional activators (Pho2 and Pho4) from the promoter 
(Adkins and Tyler, 2006). ATP-dependent chromatin-remodeling 
complexes include SWI/SNF, ISWI, RSC, and Mi-2/NuRD. They change 
location or confirmation of nucleosomes. This activity requires the intrinsic 
ATPase activity of the common subunit SWI2/SNF2 (for review see (Naar 
et al., 2001)). Experiments show that recruitment of SNF2 human homolog 
BRG1 to the IFN-β promoter catalyzes removal of nucleosome 25 bp 
downstream from the TATA box, thus facilitating binding of general TF 
(Lomvardas and Thanos, 2001). 
1.4  Transcriptional activity of modification by ubiquitylation 
Ubiquitylation was long regarded solely as mark for proteasome degradation, 
but accumulating evidence indicates also nonproteolytic function of Ub. All 
seven lysine residues in Ub can be used to form isopeptide bonds with 
substrate proteins or another ubiquitin molecule. Different ubiquitin linkage 
patterns may serve different or, in some case, still-to-be-defined biological 
functions. For example, monoubiquitylation has been reported to be 
involved in endocytosis, transcription, and DNA damage response. Multiple 
monoubiquitylations are used in endocytosis. Whereas K48 
polyubiquitylation leads to proteasomal degradation, K63 polyubiquitylation 
results in degradation-free modification of protein, which, for instance, is 
involved in cytokine signalling cascades. K29 polyubiquitylation seems to 
label proteins for lysosomal degradation (for review see (Crosetto et al., 
2006, Herrmann et al., Mukhopadhyay and Riezman, 2007)). The effects of 
ubiquitylation on transcription will be described from two perspectives as 
below: ubiquitylation on chromatin and ubiquitylation on transcription 
factor proteins. 
  371.4.1 Histone  ubiquitylation 
The most studied histone ubiquitylation occur on H2A and H2B. There are 
reports about ubiquitylation of other histones in mammalian cells recently: 
H1 ubiquitylation by TAF1, H3/H4 ubiquitylation by Cul4-DDB-Roc 
complex (Pham and Sauer, 2000, Wang et al., 2006).  H2B ubiquitylation 
generally occurs in euchromatin and is indicative of active gene 
transcription. An ubiquitin moiety is conjugated to lysine 123 (lysine 120 in 
human) at the C-terminal of H2B, mediated by the E2 conjugating enzyme 
Rad6/Bre1. Rad6 has a C-terminal cysteine containing catalytic site 
involved in ubiquitin conjugation and a N-terminal site binding to three 
different E3 ligases, Rad18, Ubr1, and Bre1, which target different substrate. 
In the case of histone ubiquitylation, Rad6 binds to Bre1. RNF20/40 and 
UbcH6 are human homologues of Bre1 and Rad6 respectively. Rad1/Bre1 
is recruited to upstream promoter elements by binding to DNA sequence-
specific activators. Following phosphorylation of the CTD domain of Pol II 
by TFIIH subunit kin28, BUR kinase complex associates with Pol II and 
assists recruitment of the elongation factor PAF that bridges the interaction 
between Rad6/Bre1 and Pol II. This interaction may bring Rad6/Bre1into 
proximity of BUR, which activates the complex by phosphorylating Rad6 
on serine 120. Ubiquitylation of H2B regulates subsequent methylation of 
H3 at lysine 4 and 79. It also promotes removal of H2A/H2B dimer from 
nucleosomes by the histone chaperon FACT (for review see (Osley, 2006, 
laribee et al., 2007)). Another consequence of monoubiquitylation of H2B is 
recruitment of the 19S regulatory subunit of proteasome, which serves as a 
transcription regulator binding to the coding and 3’ end of genes. Chaperon 
activity of the 19S proteasome is required for H3K4me and H3K79me 
regulation. The mechanism behind this regulation is still unclear (Ezhkova 
and Tansey, 2004, Lee et al., 2005, Collins and Tansey, 2006).  
 
Two ubiquitin proteases are found in yeast, Ubp8 and Ubp10. Ubp8 is a 
subunit of SAGA histone acetyltranferase complex, and it deubiquitylates 
H2BK123 in a SAGA dependent manner. Deletion of Ubp8 has similar 
effects on gene expression as H2BK123R mutant, which suggests both 
ubiquitylation and deubiquitylation are important for transcription (Henry et 
al., 2003). Ubp10 usually targets H2B in transcriptionally silenced region, 
like heterochromatin, to keep low level of H2B monoubiquitylation and 
H3K4me/H3K79me, which may help spreading of silencing factors such as 
Sir proteins that prefer to bind unmodified histones (for review see (Osley, 
2006, Kouzarides, 2007, Laribee et al., 2007)). 
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but it is not conserved in yeast. H2A is ubiquitylated at lysine 119 by PcG 
PRC1L (Polycomb-repressive complex-1-like) family regulators and is 
usually associated with transcription repression. PcG PRC1L complex are 
factors required for homeotic gene silencing in flies and vertebrates. Human 
PRC1L have three RING domain subunits, Ring1B, Ring1A, and Bmi1. 
Ring1B possesses E3 ligase activity towards H2A and Ring1A, which is 
promoted by Bmi1 (Wang et al., 2004, Cao et al., 2005). Two PcG 
complexes are responsible for homeotic gene silencing. First, PRC2 with 
histone methylation activity is recruited to polycomb response elements 
(PRE) in promoter, and then methylates H3K37, leading to binding of 
PRC1 to the promoter and, finally, H2A ubiquitylation (Osley, 2006). The 
contribution of H2A ubiquitylation to gene silencing is still to be 
investigated. A JAMM/MPN
+ domain containing H2A deubiquitinase 
complex named as 2A-DUB or KIAA1915/MYSM1was defined recently 
(Zhu et al., 2007). 2A-DUB is found to bind to the p300/CBP-associated 
factor (p/CAF). In addition, 2A-DUB favours H2A monoubiquitylation in 
hyperacetylated nucleosomes. These two sets of data suggest a potential 
coordination of histone acetylation and deubiquitylation (Zhu et al., 2007). 
Experiments also show that H2AK119R mutant dramatically decreased 
number of association of linker histone H1 (Zhu et al., 2007), which is 
consistent with the observation that H2Aub1 enhances H1 association to 
reconstituted nucleosomes (Jason et al., 2005). Further, reduced H2A 
monoubiquitylation was shown to increase H1 phosphorylation that is 
known to promote diassociation of H1 from nucleosomes (de Napoles et al., 
2004, Wang et al., 2004). Put together, H2A monoubiquitylation, might be 
promoted by histone acetyaltion, enhanced H1 phosphorylation and then 
disassociation from nucleosomes (Zhu et al., 2007). 
1.4.2  Role of UPS in gene expression 
The ubiquitin-proteasome system (UPS) regulates gene transcription in 
several ways (for review see (Muratani and Tansey, 2003)). First, it controls 
localization of some transcription activators. For example, NF-κB interacts 
with the inhibitor IκB in cytoplasm. IκB is phosphorylated, ubiquitylated 
and then degraded upon inflammatory signals, leading to release of NF-κB 
from its sequestration. The free NF-κB enters the nucleus where it activates 
transcription (Palombella et al., 2004). Second, UPS can selectively target 
coactivators thereby regulating the activator activity. The ubiqutin ligase 
RLIM recognizes both transcription factor LIM and its coactivator CLIM, 
and specially targets CLIM for degradation (Ostendoff et al., 2002), which 
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reprogramming of the transcription process. The third and most common 
way of UPS to regulate transcription is through controlling activator protein 
level. It has been noticed that transcriptional potency of some activators is 
positively correlated with their turnover rate (unstable when active). For 
instance, proteasome inhibitors that stabilize the estrogen receptor (ER) 
block estrogen-receptor-mediated transcription. In addition, several steroid-
receptor-interacting coactivators, such as Sug1/Trip1, Rsp5/Rpf1, E6-AP 
and Ubc9, have been identified as components of the UPS (for review see 
(Von Mikecz, 2006)). Further more, it has been demonstrated that degrons, 
a specific sequence of amino acids that directs the starting place of 
degradation, in activator largely overlap with certain type of transcription 
activation domain (TAD) (Salghetti et al., 2000), and components of 
transcriptional machinery recruited by TAD can promote destruction of 
activators (Chi et al., 2001, Nelson et al., 2003). Transcription activator can 
be divided to three classes according to their ubiquitin-dependent 
proteolysis (for review see (Lipford and Deshaises, 2003)). Degradation of 
class A activator is completely uncoupled from transcription. Transcription 
efficiency of class A activator relies on their concentration in the cell. 
Samples of this class includ β-catenin, p53, and HIF-1α.  β-catenin is 
phosphorylated by glycogen synthase kinase-3β (GSK-3β), followed by its 
ubiquitylation and degradation. Upon Wnt signalling, GSK-3β is inactivated 
and turnover of β-catenin is shut off, leading to rapid induction of target 
genes (Yost et al., 1996, Aberle et al., 1997, Hart et al., 1999). Class B 
activators are degraded only when bound to DNA, and the rate of 
degradation determines the window of time available to stimulate 
transcription. The activator binds to DNA and recruits GTF, leading to 
recruitment of both Pol II and E3 ligase. The activator will be able to start 
transcription if Pol II comes faster to the promoter than E3, otherwise the 
activator is degraded and transcription fails. Same as class A activators, 
activity of class B activators increases when shutting off their turnover, 
resulting in increase of their concentration. In contrast, degradation of class 
C activators is necessary for transcription induced by them, so obstruction of 
their turnover inhibits transcription. The mechanism might be that 
degradation of the actor disrupt the PIC complex and help the release of Pol 
II for elongation, or that clearance of spent PIC and resemblance of a new 
one is required for each round of transcription, the “single-shot” mechanism 
(Thomas and Tyers, 2000, Lipford and Deshaises, 2003). Examples of this 
class are Gcn4 and Myc. Yeast transcription factor Gcn4 binds to promoter, 
and recruits Pol II. Srb10, a subunit of the Pol II complex, together with 
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leading to its ubiquitylation by SCF
Cdc4 and proteolysis (Chi et al., 2001). 
Indeed, this degradation stimulates Gcn4 induced transcription. Moreover, 
SCF
Cdc4 mutant and ubiquitin mutant that lack proteolysis function impair 
transcription of Gcn4 target genes (Lipford et al., 2005). 
 
Apart from the UPS degradation, the proteasome also regulates 
transcription in a proteolysis-independent manner. Five ATPases of the 19S 
complex have been linked to transcription either biochemically or 
genetically. In yeast, the ATPases assist recruitment the SAGA 
acetyltransferase complex to the Gal1-Gal10 promoter and stimulate 
interaction between SAGA and DNA-binding transcription activators (Lee 
et al., 2005). In the study of yeast CDC20 transcription, 19S lid and base 
components as well as 20S core complex of proteasome are detected at the 
CDC20 promoter. Mutations in a 19S base subunit cause a modest decrease 
of CDC20 transcript whereas mutations in 20S subunits have no effect 
(Morris et al., 2003). 
1.5  The transcription factor Myc  
1.5.1  The bHLH transcription factors in animals and plants 
The basic region/helix-loop-helix (bHLH) proteins constitute a large family 
of DNA-binding transcription factors with important regulatory roles in the 
lives of eukaryotic cells. The basic region binds to so called E-box DNA 
recognition sequences (CANNTG) in regulatory regions of target genes, 
whereas the HLH domain functions to form hetero- or homo-dimers.  The 
bHLH family can be divided into six groups, A to F, according to E-box 
binding, conservation of residues in the other parts of the motif, and the 
presence or absence of additional domains (Atchley and Fitch, 1997, Ledent, 
2002,). The A-group proteins, which are only found in animals, bind to the 
E-box with sequence CAGCTG, while proteins of the B-group, which is 
the most ancient one found in all eukaryotic kingdoms, bind to E-box with 
sequence CACGTG, which is called G-box in plant. The B-group can be 
sub-divided into two groups, one containing a leucine zipper, the other 
without this motif. The leucine zipper motif is involved in homo- and 
heterodimerization and is characterized by leucines or other hydrophobic 
residues at every 7
th position. Group C proteins have a PAS domain and 
bind to ACGTG or GCGTG DNA sequences. Hypoxia-inducible factor 
(HIF) belongs to this group. Group D lacks a basic domain and hence does 
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peptide, binds preferentially to N-box sequences CACGCG or CACGAG. 
Group F has an additional COE domain that is involved in dimerization and 
DNA binding (for review see (Jones, 2004)).  
 
The B-group bHLH genes can be found in all eukaryotic organisms, 
including plants. In Arabidopsis thaliana it constitutes the second largest 
transcription factor family, comprising 162 members (Heim et al 2003, 
Bailey et al 2003, Toledo-Ortiz et al., 2003), only after the biggest MYB 
superfamily with 190 members (Riechmann et al., 2000). The bHLH genes 
in plants and animals are significantly diverged in evolution beyond the 
conserved DNA-binding domain (Buck and Atchley, 2003). The handful of 
plant bHLH genes studied so far are involved in anthocyanin biosynthesis, 
phytochrome signaling, globulin expression, fruit dehiscence, and carpel and 
epidermal development. In contrast to the indispensability of their animal 
counterpart in development, plant bHLH genes are often redundant and 
deletion of individual member has limited phenotypic effects. Interestingly, 
many plant bHLH proteins seem to form networks in similar way as animal 
bHLH genes. For instance, two related phytochrome-interacting factors 
(PIFs) in Arabidopsis, PIF3 and PIF4, can form both homodimers and 
heterodimers and all three dimers can bind to the G-box DNA sequence 
motif CACGTG for subsequent transcriptional regulation (Toledo-Ortiz et 
al., 2003), which resembles the way of Myc/Max/Mad proteins in animals 
(see below). 
1.5.2 Myc/Max/Mad  network 
The animal Myc family, which plays an important role in cell proliferation, 
metabolism, apoptosis and cancer development, is the prototype of the 
bHLHZip group. In this group are also found the Myc heterodimerization 
partner Max and the Mad/Mnt that are alternative heterodimerization 
partners for Max and antagonizers of Myc. With Max in the center, these 
three types of proteins define the so called Myc/Max/Mad network.  
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The Myc family has several members, including c-Myc, N-Myc, and L-
Myc. The myc oncogene was first found in aivan retrovirus and was named 
v-myc, which stands for myelocytomatosis, the disease caused by it (Sheiness 
and Bishop, 1979, Sheiness et al., 1978). Shortly after, a v-myc homologue 
was isolated in chicken and named c-myc (Vennstrom et al., 1982). c-myc is 
evolutionally conserved in all vertebrates and some non- vertebrates such as 
sea star Asteria vulgarisI (Walker et al., 1992) and Drosophila (Gallant et al., 
1996). Subsequently, two other member of myc family, the N- and L-myc 
were identified as amplified or highly expressed genes in the childhood 
tumour neuroblastoma (Kohl et al., Schwab et al., 1983) and in small lung 
cancer (Nau et al., 1985).  
 
Myc comprises an N-terminal TAD domain and a C-terminal bHLHZip 
domain. There are two evolutionally conserved sequences named as Myc 
box 1 and 2 (MB1 and 2) in the TAD domain that are involved in the 
recruitment of various cofactors. MB1 also harbours several closely located 
serine and threonine residues that mediate Myc degradation as well as the 
apoptotic and oncogenic activities of Myc (Sears, 2004, Adhikary and Eilers, 
2005, Hemann et al., 2005). Surprisingly, MB 1 is necessary for cell 
transformation but not for transcription (Kato et al., 1990, Oster et al., 2003, 
Herbst et al., 2005). Myc without MB 2 is defective for cell transformation, 
apoptosis, differentiation, and largely impaired in transcription activity 
(Stone et al., 1987, Freytag et al., 1990, Evan et al., 1992, Cowling et al., 
2006). The precise role of MB2 in Myc function is still unclear and it was 
reported to be dispensable for Myc-driven cell proliferation (Cowling and 
Cole, 2007a). Recently, two other Myc boxes, MB 3 and MB 4, were 
identified, and both seem to be required for cellular transformation. In some 
assay, deletion of MB 3 was reported to promote Myc-induced apoptosis 
while deletion of MB 4 promoted G2 arrest, and both deletions effected 
Myc transactivation much less than MB 2 deletion. MB 4 also seems 
necessary for apoptosis. MB 1, 3, 4, however, are not required for cell 
proliferation (Xiao et al., 1998, Herbst et al., 2005, Cowling et al., 2006)). 
The Myc protein further contains a nuclear localization site (NLS) that is 
important for nuclear import and a central acidic domain with several 
phosphorylation sites that might be important for some unknown aspects of 
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required to heterodimerize with the bHLHZip protein Max (Luscher and 
Larsson, 1999). Heterodimerization with Max is crucial for Myc DNA 
binding to the CACGTG E-box and execution of all Myc functions. There 
is no evidence of Myc homodimers in cells. Max is a ubiquitously expressed 
phospoprotein with several isoforms resulting from differential splicing. The 
most commonly expressed 21 and 22 kDa isoforms have differential DNA 
binding and transcriptional activities (for review see (Hurlin and Huang, 
2006)). Unlike Myc, Max can form homodimers that bind to the E-box 
DNA, and the binding can be inhibited by phosphorylation on its N-
terminal serine residues (Kato et al., 1992, Berberich and Cole, 1992, 
Koskinen et al., 1994). Max also binds to other proteins that antagonize Myc 
activities. These proteins include Mnt (Hurlin et al., 1997), Mad1-4 (Mad1, 
Mxi1, Mad3, and Mad4) (Ayer et al., Zervos, et al., 1993, Hurlin et al., 
1995) and Mga (Hurlin et al., 1999). Mnt, Mad1-4, and Mga are all 
transcriptional repressors. They interact with Sin3A and Sin3B corepressors 
through the N-terminal Sin3-interaction domain (SID) (Ayer et al., 
Schreiber-Agus et al., 1995), which in turn recruits a number of different 
proteins, including HDAC1 and HDAC2 (for review see (Ayer, 1999)). 
The Max/Myc dimers are usually formed in proliferating cells whereas 
Max/Mad in resting or differentiated cells (Ayer and Eisenman, 1993). 
Max/Myc and Max/Mad heterodimers are found essentially mirroring the 
expression of Myc and Mad proteins respectively. Myc also interacts with a 
number of additional proteins through either C- or N-termini. Examples of 
the C-terminal interacting proteins are YY1 (Shrivastava et al., 1993), Ap2 
(Gaubatz et al., 1995), TFII-I (Roy et al., 1993), Miz1 (Peukert et al., 
1997), Nmi (Bao and Zervos, 1996), and Brca1 (Wang et al., 1998).   
Examples of the N-terminal interacting proteins are Skp2 (von der Lehr et 
al, Kim et al., 2003), p107 (Beijersbergen et al., Gu et al., 1994), Bin1 
(Sakamuro et al., 1996), TRRAP (McMahon et al., 1998), and TBP 
(Hateboer et al., 1993). Some interactions related to this thesis will be 
described later. 
1.5.3  Myc in transcription 
Myc binds very ubiquitously throughout the genome. There are tens of 
thousands of genomic Myc-binding sites, encompassing up to 15% of all 
genes (Orian et al., Fernandez et al., 2003, Cawley et al., Patel et al., 2004, 
Bieda et al., 2006). These binding sites are often located in the regions close 
to the CpG islands (Fernandez et al., 2003), the mark for DNA methylation 
resistance, and are rich of H3K4/K79 methylation and H3 acetylation 
  44(Guccione et al., 2006). The fact that the number of binding sites exceeds 
the number of Myc molecules implies that Myc binds to these sites 
temporarily and regulates transcription on a hit-and-run manner (Adhikary 
and Eilers, 2005). In spite of the important roles that Myc plays in cell 
biology, the induction of transcription by Myc is quite weak. Indeed, Myc 
activates the majority of target genes only by two-fold (Patel et al., 2004). 
Besides its role in RNA Pol II transcription, c-Myc associates with E-boxes 
in ribosomal DNA regulatory region and activates RNA Pol I transcription 
(Arabi, et al., 2005). Further, Myc also binds to Pol III-trnscribed genes and 
induces Pol III activity (Gomez-Roman et al., 2003). 
 
An important role of Myc seems to be recruitment of coactivators for 
transcription; TRRAP (Transactivation/transformation Associated Protein) 
is one of the most studied among them. TRRAP is a large protein (3830 
amino acids) with limited homology to the phosphatidyl-inositol-3-kinase 
(PI3K) that binds Myc through the conserved domain MB2. TRRAP was 
shown to be a core subunit of GCN and Tip60 HAT complexes (McMahon 
et al., 1998). In accordance with this, Myc has been demonstrated to recruit 
HAT activity (McMahon et al., 1998, Liu et al., 2003). The Tip60 complex 
acetylates H2A/H4 histones. In vivo, H4 acetylation is more associated with 
Myc target gene activation than H3 acetylation (Frank et al., 2001). The 
other TRRAP complex binding to Myc is a complex containing the 
Swi/Snf-related p400 protein. The consequence of this binding is unclear 
since p400 is devoid of HAT activity (Fuchs et al., 2001). Other HATs 
interacting with Myc are the CREB-binding protein (CBP) and p300. They 
are recruited by Myc to promoters and enhance Myc-induced transcription. 
The binding site of CBP/p300 to Myc is still controversial. One report 
claimed that they bind through the C-terminal domain of Myc whereas the 
other mapped binding site to the N-terminal 100 amino acids (Vervoorts et 
al., 2003, Faiola et al., 2005). Recruitment of the HATs mediated by 
TRRAP suggests that Myc plays a role in chromatin structure regulation. 
Indeed, about half of Myc-bound sites were intergenic (>10 kb away from 
transcriptionalstart sites) (Bieda et al, 2006), implying a potential non-
transcriptional function for Myc on chromatin. Moreover, GCN5 is 
identified not only a coactivator but also a target gene of Myc (Knoepfle et 
al., 2006), which makes a positive feedback loop between Myc-induced 
transcription and Myc-induced chromatin regulation. Myc also binds to two 
ATPase domain-containing proteins found in Tip60 and several other 
chromatin remodeling complexes independent of TRRAP; these are Tip48 
and Tip49 (Wood et al., 2000). A point mutation in Tip49 that abolishes its 
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and enhances Myc-induced apoptosis (Wood et al., 2000, Dugan et al., 
2002).  Some Myc target genes are reported to be transcribed independent 
of increased histone acetylation but still dependent on TRRAP, such as Tert. 
Some are independent of both, such as Cad, Cdk4, and Hsp60 (Eberhardy et 
al., 2000, Nikiforov et al., 2002). Interestingly, Pol II was observed being 
stalled at the Cad promoter in the absence of Myc. It was also found that 
two components of Pol II CTD kinase P-TEFb, Cdk9 and cyclin T1, 
interact with c-Myc through the TAD domain. Myc may therefore activate 
Cad transcription by stimulating promoter clearance, perhaps via recruitment 
of P-TEFb (Eberhardy and Farnham, 2000). 
 
Another coactivator binding Myc through MB2 is Skp2. Skp2 is also an 
ubiqutin E3 ligase of Myc. Binding of Skp2 leads to Myc ubiquitylation and 
degradation as well as enhanced Myc target gene expression. Further, Myc-
driven transcription was shown to be Skp2 dependent. Moreover, Myc-
dependent association of Skp2, ubiquitylated proteins, and subunit of the 
proteasome to c-Myc target gene cyclin 2D was demonstrated in vivo (von 
der Lehr et al., Kim et al., 2003). Another coactivator linking Myc 
ubiquitylation with Myc-induced transactivation is the E3 ligase HectH9 
(also called ARF-BP1, ARF-binding protein 1). HectH9 promotes the 
formation of lysine 63-linked polyubiquitin chain at six lysine residues in the 
C-terminal of Myc in vivo and in vitro. The K63-linked chains do not lead 
to proteasomal degradation of Myc, but seem to be required for 
transcription of Myc target genes, recruitment of the CBP/p300 coactivator, 
and Myc-induced cell proliferation (Adhikary et al., 2005). The binding of 
Skp2 to Myc is competed by the forkhead-associated (FHA) domain-
containing protein SNIP1. SNIP1 was shown as an inhibitor of both TGF-β 
and NF-κB signaling pathway. It blocks the interaction of Smad4 and 
p65/Rel A, respectively, with CBP and p300 (Kim et al., 2000, 2001, Fujii 
et al., 2006). SNIP1 is also a coactivator of Myc that functions to both 
enhance Myc transcriptional activity and inhibit the UPS-mediated Myc 
degradation. The N-terminal of SNIP1, which can interact with the 
CBP/p300 complex, is required for this coactivator function. Interestingly, 
both Skp2 and SNIP1 are oncogenes but they seem to antagonize each 
other for Myc degradation or stabilization. They are differentially expressed 
during cell cycle: SNIP1/c-Myc complexes predominate in G1, whereas 
Skp2/c-Myc complexes predominate in late G1/S (von der Lehr et al., 
2003, Fujii et al., 2006), which may suggests that Myc regulates different sets 
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cycle (Larsson, 2006). 
 
In addition to its role as a transcriptional activator, Myc is also able to 
repress transcription for instance of the cell cycle arrest genes, p15
Ink4b, 
p21
Cip1, and p27
Kip1 (Gartel and Shchors, 2003), when interacting with Miz1. 
Miz1 binds to initiator (Inr) like elements in the promoters of these genes 
and upregulates their expression. Myc suppresses this transcription activating 
function of Miz1 by interacting with it through the C-terminal HLH 
domain (Herold et al., 2002, Peukert et al., 1997, Seoane et al., 2001, Staller 
et al., 2001, Wanzel et al., 2003, Wu et al., 2003). Recently, Miz1 was 
shown to inhibit ubiquitylation of Myc by HectH9, perhaps by competing 
with the binding of c-Myc for this E3 ligase, thereby antagonizing the 
ubiquitylation -dependent transcription activity of Myc (Adhikary et al., 
2005). Another protein that negatively affects Myc transactivation activity is 
the turmour suppressor alterative reading frame protein ARF/p19
Arf. ARF is 
known to activate p53 by suppressing either Mdm2-mediated or HectH9–
mediated p53 ubiquitylation, resulting in inhibition of Myc induced 
turmorigenesis (Sherr et al., 2001, Chen et al., 2005, Honda andYasuda, 
Tao and Levine, Weber et al., 2003). ARF was recently found on Myc 
dependent promoters via direct binding to Myc, and it inhibits 
transactivation of some Myc target genes such as eIF4E, nucleolin, hTERT, 
Cdk4 and Cul1, but does not affect Myc-induced repression of GADD45 
and p15
Ink4b (Datta et al., Qi et al., 2004). This function of ARF is 
independent of p53 expression.  
 
As mentioned above, Max/Mad represses transcription by recruiting 
HDACs. Knockdown of Mad leads to hyperproliferation of cells or 
restoration of growth in myc-/- cells. Mad deficient cells, like Myc 
overexpressed cells, can be transformed by the Ras oncogene. Moreover, 
some Myc target genes can be induced by Mad knockdown, which provides 
a strikingly different view of Myc-mediated gene regulation: Myc may not 
activate gene transcription but disrupt Mad-mediated gene repression (for 
review see (Cowling and Cole, 2006)). 
1.5.4  Myc stabilization and degradation 
Myc protein has very short half-life, about 20-30 minutes. Myc stabilization 
and degradation is regulated via post-translational modifications. Several 
phosphorylation sites have been detected in the N-terminal of Myc. Two 
sites in the MB1 domain of Myc have been investigated intensively; these 
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Myc and c-Myc proteins from human Burkitt’s lymphoma (Bhatia et al., 
1993, Smith-Sorensen et al., 1996). T58 and S62 are followed by proline 
residues in c-Myc, which makes them potential targets of proline-directed 
kinases, such as GSK3, MAP kinases and Cdks. 
 
Three kinases are known to phosphorylate Myc on S62; these are 
extracellular-signal regulated kinase (ERK), c-Jun N-terminal kinase (JNK), 
and Cdk1 for N-Myc (for review see (Hann, 2006)). The ERK-mediated 
S62 phosphorylation can be induced by oxidative stress and mitogenic 
stimuli (Benassi et al., Vogel et al., 2006, Sears, 2004, Wang et al., 2006b). 
Upon mitogenic stimulation, the Ras-Raf signalling pathway activates 
MAPK/ERK kinase 1 or 2 (MEK1/2) dependent on types of stimuli and 
duration of stimulation, which in turn induces ERK, followed by S62 
phosphorylation. JNK is activated through another Ras-dependent pathway, 
the PI3K-Rho-ROCK pathway. Ras sequentially activates PI3K, RhoA/C 
and Rho kinase (ROCK). Inhibition of ROCK prevents c-Myc 
phosphorylation (Watnick et al., 2003,). ROCK induces MAPK/ERK 
kinase kinase-1, resulting in JNK activation (Zhang et al., 2005). All three 
isoforms of JNK are able to phosphorylate S62 on Myc (Noguchi et al, 
1999); JNK1 is more involved in stress-induced apoptosis whereas JNK2 in 
more involved in cell cycle regulation (MacCorkle and Tan, 2005). Besides 
S62, JNK can also phosphorylate another site on Myc N-terminus, S71 
(Noguchi et al., 1999). The third S62 kinase is Cdk1. In vitro, Cdk1 can 
phosphorylate c-Myc at S62 (Lutterbach and Hann, 1994). In complex with 
Cyclin A or B1, Cdk1 phosphorylates N-Myc S62 in G2/M phase of the 
cell cycle (Sjostrom et al., 2005). S62 phosphorylation stabilizes the Myc 
protein (Sear et al., 2000). A prior phosphorylation of S62 is required by 
phosphorylation of T58 (Lutterbach and Hann, 1994) carried out by GSK3 
(Gregory et al., 2003). GSK3β is inhibited by PI3K/Akt pathway, through 
which PI3K induces the Akt kinase that phosphorylates and inactivates 
GSK3β (Liang and Slingerland, 2003).  
 
Myc is degraded through the UPS (Flinn et al., Gross-Mesilaty et al., 
1998, Salghetti et al., 1999). Three E3 ligases, SCF
Skp2, SCF
Fbw7/Cdc4, and 
HectH9, have been shown to ubiquitylate Myc. HectH9 conjugates K63-
linked ubiquitin chain on its C-terminal domain of Myc, which does not 
lead to proteolysis. Skp2 and Fbw7/Cdc4 interact with the N-terminal 
domain of Myc. Ubiquitylation by SCF
Skp2 leads to both degradation of Myc 
and activation of Myc target genes whereas ubiquitylation by SCF
Fbw7/Cdc4 
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MB2 and amino acid 379-418, then ubiquitylates Myc (Kim et al., Von der 
lehr, 2003) efficiently on the amino acid 129-147 where one lysine K144 is 
located (Kim et al., 2003). There is no evidence of dependence on 
phosphorylation for Skp2-mediated ubiquitylation of Myc. In contrast, 
Fbw7/Cdc4-mediated ubiquitylation and degradation of Myc is dependent 
on T58 phosphorylation (Welcker et al., 2004). Sears and colleagues 
suggested that ubiquitylation and degadation of Myc is dependent on T58 
phosphorylation followed by S62 dephosphorylation (Sears et al., 2000). 
Consistent to this model, inhibition of protein phosphatase PP2A that 
dephosphorylates S62 but not T58 significantly inhibits c-Myc proteolysis. 
Further, Pin1 prolylisomerase was suggested to promote c-Myc proteolysis 
via catalyzing the isomerization of proline residues to enhance S62 
dephosphorylation by PP2A (Yeh et al., 2004). Recently, the 
deubiquitylating enzyme, Usp28, was shown to target c-Myc (Popov et al., 
2007). The Fbw7 isoform Fbw7α was suggested to bridge the interaction 
between Myc and Usp28, after which the latter deubiquitylated Myc, 
leading to its stabilization. The Fbw7γ isoform, on the other hand, does not 
have this bridging function and can therefore ubiquitylate and degrade Myc 
(Popov et al., 2007). 
1.5.5  Biological function of Myc  
Myc effects cell cycle progression 
Myc starts to appear at the early G1 phase during cell cycle and targets 
various key cell cycle genes for G1/S checkpoint passage. c-Myc is sufficient 
to overcome the G1/S checkpoint and induce cells into S phase in absence 
of mitogenic stimuli (Eilers, 1999). Moreover, Rat 1a myc-/- cells exhibit a 
much longer doubling time (50 hours) than wild type cells (20 hours) with 
prolonged G1 and G2 phases while c-Myc deficient MEFs exhibit an even 
slower doubling time (100 hours) compared to wild type MEFs (20 hours) 
(de Alboran et al., 2001, Mateyak et al., 1997). CHIP assays show that c-
Myc binds to E-box in promoters of cyclin D1, cyclin D2, Cdk4 ,and cyclin 
B1 (Bouchard et al., 2001, Fernandez et al., 2003, Hermeking et al., 2000, 
Menssen and Hermeking, 2002). Also, the phosphatase Cdc25 that removes 
inhibitory phosphorylation of Cdk2 is also identified as Myc target gene 
(Galaktionov et al., 1996). In addition, Myc directly represses transcription 
of Cdk inhibitor genes such as p15
Ink4b, p21
Cip1, and p27
Kip1  (Claassen and 
Hann, 1999, Gartel et al., Yang et al., 2001). Transcription of the Cks1 
component of the SCF
Skp2 complex, the E3 ligase for p27
Kip1 ubiquitylation 
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functions mentioned above lead to activation of the cyclin E/Cdk2 kinase 
complex, which in turn phosphorylates pRb, resulting in E2F activation. 
Besides, Myc is able to activate the expression of E2F1, E2F2, and E2F3 
genes independent of Cdk kinase activities. Induction of E2F2 and E2F3 by 
Myc could be direct, since a series of Myc binding sites are essential for 
induction of these two genes (Sears et al., 1997, 1999, Leone et al., 1997, 
Adams et al., 2000). Interestingly, E2F2 and E2F3 are essential for Myc to 
induce S phase entry (Leone et al., 2001). Another central player of cell 
proliferation, the pRb protein, has been shown to be inhibited by the HLH 
protein Id2 that is a positively transactivated target gene of c-Myc (Lasorella 
et al., 2000).  
Myc in cancer  
Co-transfection of Ras and myc oncogenes into REFs leads to formation of 
transformed foci containing tumorigenic cells (Land et al., 1983). Myc-
family genes are deregulated in a broad range of cancer such as Burkitt 
lymphoma, neuroblastoma, breast cancer, colon, cervical, small-cell lung 
carcinomas, osteosarcomas, glioblastomas, melanoma and myeloid 
leukaemias (Dang, Nesbit et al., Schlagbauer–Wadl et al., 1999, Henriksson 
and Luscher, 1996). As described above, Myc stability is regulated by Ras 
oncogene. Besides, some Myc target genes involving in cell proliferation are 
controlled by Ras through regulation of FOXO family of transcriptional 
factors that repress expression of these genes by binding to their promoters 
thus inhibiting formation of PIC (Bouchard et al., 2004). Similar to GSK3, 
FOXO factors can be phosphorylated by AKT, resulting in their nuclear 
export. c-Myc is also induced by the Wnt signaling pathway that activates 
the downstream TCF/β-catenin transcriptional factor complex on the c-
Myc promoter (He et al., 1998). A recent report demonstrated that c-Myc 
can activate the Wnt pathway (for review see (Cowling and Cole, 2007)). 
Interestingly, two of the most expressed genes by c-Myc in mammary 
epithelial cells are the Wnt pathway inhibitors DKK1 and SFRP1 (Cowling 
et al., 2007). 
 
In contrast to its transformation capability, Myc can also induce apoptosis 
through two independent pathways. One is the p19
Arf pathway through 
which Myc stabilizes p53. p19
Arf is directly regulated by E2F that is a 
downstream factor of Myc (for review see Adhikary and Eilers, 2006). 
Second, Myc promotes release of cytochrome c independent of Arf/p53 
(Juin et al., 1999). It is reported that mutation at S71 of c-Myc results in low 
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2000), suggesting a role of S71 phosphorylation in Myc-induced apoptosis. 
Experiments also showed that c-Myc expression is essential for activation of 
the pro-apoptotic protein BAX (Juin et al., 2002). During apoptosis, various 
BH3-Only proteins induce BAX dimerization and insertion into outer 
mitochondrial membrane, resulting in release of cytochrome c through 
creation of alteration of membrane pores (for review see (Pelengaris et al., 
2002)).  
Myc in cell growth and differentiation 
Cell division requires not only DNA replication but also doubling of 
proteins and cellular organelles. The first correlation between Myc and the 
cell growth was the discovery that the rate-limiting translation factors eIF4E 
and eIF2α are c-Myc target genes (Coller et al., 2000, Jones et al., 1996). 
Diminished expression of Drosophila dMyc results in smaller but normally 
developed flies whereas overexpression of dMyc leads to larger cells without 
significant change in cell dividing rate (Johnston et al., 1999). In particularly, 
dMyc overexpression increases both the amount of pre-rRNA and nucleolar 
size, resulting in increased ribosome activity (Grewal et al., 2005). dMyc 
transcriptionally regulates ribosome biogenesis, therefore enhances protein 
translation within cells (for review see (de la Cova and Johnston, 2006)). 
Evidences of Myc in growth control also found in mammalian cells: c-Myc 
overexpression in B lymphocytes of transgenic mice results in cell growth 
without cell division (Iritani and Eisenman, Schuhmacher et al., 1999). c-
Myc was reported to associate with ribosomal DNA and activate 
transcription of rRNA genes by RNA polymerase I (Arabi, et al., Grandori, 
et al., 2005). 
 
In addition to promoting cell proliferation Myc often inhibits cell 
differentiation. It has been shown that Myc is down-regulated during 
differentiation and, constitutive overexpression of Myc blocks differentiation 
in various cell types, including neuroblastoma, myeloid cells, 
erythroleukemia cells and teratocarcinoma cells (Coppola and Cole, 1986, 
Freytag, 1988, Gonda and Metcalf, 1984, Lachman and Skoultchi, 1984, 
Larsson et al, 1988, Thiele et al., 1985). This inhibitory function of Myc can 
be achieved by the repression of certain genes important for differentiation; 
for example, Myc represses C/EBPα that induces differentiation in 3T3-L1 
adipocytes (Mink et al., 1996). The promyelocytic leukemia protein PML4 
can induce differentiation by destabilizing Myc when binding to it, which 
followed by reactivation of Myc repressed genes (Buschbeck et al., 2007). 
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necessary to stimulate both proliferation and differentiation in primary B 
cells together with amplified calcium signaling (Habib et al., 2007). 
 
Members of the Mad family, antagonists of Myc, are often expressed in 
differentiating or quiescent cells. Cells in the mad1-/- and mxi1-/- mice 
display an enhanced proliferative capacity (Foley and Eisenman, 1999). 
Increase of both mRNA and proteins level of Mad1 and Mxi1 are detected 
after induced differentiation in hematopoietic cells (Ayer and Eisenman, 
Zervos et al., 1993, Larsson et al., 1994). Increased expression of Mad1 
proteins leads to a shift from Myc/Max complex to Max/Mad complex on 
promoter binding of target genes, such as hTERT and cyclin D2 (Ayer and 
Eisenman, 1993, Hurlin et al., 1995, Larsson et al., 1997, Bouchard et al., 
Xu et al., 2001). Further, MAD1 and p27
Kip1 were reported to cooperate to 
promote terminal differentiation of granulocytes and to inhibit Myc 
expression and cyclin E-Cdk2 activity (McArthur et al., 2002). However, 
just like for Myc, there may be exceptions since Mad 1 inhibits cell growth 
and proliferation but does not seem to promote differentiation in human U-
937 monoblasts (Hultquist et al., 2004). 
1.6  Signaling pathways in the cell  
The cell and its extracellular environment communicate via a variety of 
signaling pathways that mediate the cellular response up to environmental 
changes. There are at least seven major signalling pathways that control cell 
fate decision in animals: Wnt, TGF-β, nuclear receptor, Jak/STAT, 
hedghog (Hh), receptor tyrosine kinase (RTK), and Notch (Gerhart, 1999). 
They regulate target genes expression in response to the binding of a 
signalling ligand to the pathway’s receptor. Three principles underlie the 
signalling pathway regulation. First, “activator insufficiency”: signal-
regulated transcription factor alone is not able to strongly activate gene 
expression, which assures that any given signalling pathway is not sufficient 
to activate transcription of all its target genes. Second, “cooperative 
activation”: robust expression of target genes needs combination of signal-
regulated factors and cell-or tissue-specific local activators. Third, “default 
repression”: signalling pathway target genes are by default repressed in 
absence of signalling (Barolo and Posakony, 2002). Some signalling pathway 
related to this thesis will be discussed as followed. 
  521.6.1 IFN-γ 
Interferons (IFNs) are proteins that belong to the large class of glycoproteins 
known as cytokines. They are produced by immune system cells in response 
to the presence of double-stranded RNA, a key indicator of viral infection. 
Interferons have potent antiviral, growth inhibitory, and 
immunomodulatory functions. Human interferons can be divided into three 
classes according to the receptors they bind to. Type I interferons, including 
IFN-α, IFN-β and IFN-ω, bind to a specific cell surface receptor complex 
known as the IFN-α receptor (IFNAR) that consists of IFNAR1 and 
IFNAR2 chains (Liu, 2005). Type II interferon has only one member, IFN-
γ, binds to interferon-gamma receptor (IFNGR) made up of two subunits 
IFNGR1 and IFNGR2 (Bach et al., Pestka et al., 1997). Type I interferons 
are present in most cells whereas IFN-γ is mainly secreted by T helper type I 
(Th1) lymphocytes and natural killer (NK) cells. Type III interferons consist 
of three IFN-λ molecules referred as IFN-λ1 (IL29), IFN-λ2 (IL28A) and 
IFN-λ3 (IL28B) (Vilcek, 2003). They signal through a receptor complex 
comprising IL10R2 and IFNLR1 (Bartlett et al., 2005). 
 
IFN-γ primarily signals through the JAK-STAT pathway. The players in 
this pathway include the Janus kinase family (JAK 1-3 and TYK2) and the 
signal transducers and activators of transcription proteins, STATs (STAT 1-
6, including STAT5a and STAT5b). Biologically active IFN-γ is a 
noncovalent homodimer that binds to the IFNGR1 receptor. Upon ligand 
binding, JAK2 is autophosphorylated and then activated, and it in turn 
transphosphorylates JAK1. Activated JAK1 phosphorylates tyrosine residues 
Y440 on each chain of IFNGR1, resulting the formation of a docking site 
for the SH2 domain of STAT1. After being recruited to the receptor, 
STAT1 is phosphorylated on the Y701 residue, perhaps by JAK2. 
Phosphorylated STAT1 then dissociates from the receptor and enter the 
nuleus to activate or repress IFN-γ target genes, which are mostly 
transcription factors (for review see (Schroder et al., 2004)). The first wave 
of IFN-γ target gene expression occurs with 15-30 minutes after IFN-γ 
treatment (Kerr and Stark, 1991). 
 
The other IFN-γ induced pathway is the P13K pathway. Activation of 
PI3K leads to production of phosphatidylinositol (3,4,5) P3 or the PIP3 
second messenger. PIP3 recruits PH-containing proteins like PDK and AKT 
to the membrane. IFN-γ induced activation of PI3K and AKT is essential 
for phosphorylation of the serine residue S727 on STAT1 that is required 
for its maximal transcriptional activity towards target genes (Decker and 
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above, IFN-γ also activates Raf-1 and β-Raf kinases, which ultimately leads 
to p42 MAPK activation (David et al., 1995). 
 
Growth inhibition is a common effect of IFN-γ on cells. IFN-γ usually 
arrests cell cycle at the G1/S phase, where they may exit cell cycle and enter 
into G0. IFN-γ inhibits proliferation mainly by inducing CKIs like p21cip1 
and p27kip1 (Chin et al., 1996, Mandal et al., 1998, Takami et al., 2002).  It 
also represses c-Myc expression by either suppressing pRb phosphorylation 
or promoting Mad expression (Dey et al., 1999, Raveh et al., 1996). Anti- 
or pro-apoptotic function of IFN-γ is dependent on the level of activate 
IFNGR receptors. Highly activated IFNGR receptors lead to high 
expression of IFN-regulatory factor-1 (IRF-1) that is required for IFN-γ 
induced apoptosis (for review see (Schroder et al., 2004)). Recent report 
shows that 60% of all deregulated genes during c-myc and Ras induced 
transformation are reverted to the normal levels by IRF-1 (Kröger et al., 
2007). The other IFN-γ induced proapoptotic genes include PKR, DAPs, 
cathepsin D, Fas, and TFN-α receptor (Schroder et al., 2004). 
1.6.2  Retinoic acid (RA) 
Retinoid refers to the naturally occurring compounds derived from vitamin 
A. vitamin A/retinol is taken up from blood and bound to cellular retinol-
binding protein (CRBP) in cytoplasm, hence metabolized by the retinol 
dehydrogenase (RoDH) to retinal. Retinal is then metabolized by 
retinaldehyde dehydrogenases (RALDHs).  Retinoids are key regulators of 
differentiation, proliferation, and inflammation. RA has two isoforms, all-
trans-RA and 9-cis-RA. They bind to nuclear transcription factors, the RA 
receptors RARs (RARα, β, and γ) and the retinoid X receptors RXRs 
(RXRα, β, and γ). RARs and RXRs act as heterodimers and recognize the 
RA-response elements (RAREs) on RA-responsive genes (for review see 
(Maden, 2002)). In absence of ligand, RAR/RXR represses gene expression 
by recruiting HDACs via coreppressors (CoR) and Sin3 (Glass and 
Resenfeld, 2000). Upon ligand binding, a conformational change occurs in 
ligand binding domain, which resulting in dissociation of CoR and binding 
of coactivators (CoAs) from gene promoter. An association between vitamin 
A/ retinoic acid deficiency and carcinogenesis has been known since 1925 
(Wolbach and Howe, 1925). RA induces cell cycle arrest and differentiation 
via degradation of Skp2 and stabilization of p27
kip1 in several cancer cell lines 
(Borriello et al., 2006, Dow et al., 2001, Nakamura et al., 2003, Zancai et 
al., 2005). 
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The general objective of this thesis is to gain more knowledge about the 
function and regulation of the transcription factor and onco protein Myc. 
Further understanding of how Myc is regulated and how Myc regulates its 
target genes during different cellular processes may potentially lead to the 
development of new therapeutic strategies for treatment of cancer. 
 
The thesis can be divided into one animal and one plant part. The animal 
part is based on previous findings from our group, that growth inhibitory 
signal, like IFN-γ, can affect Myc function post-translationally. One of the 
aims of the thesis is to elucidate the mechanism(s) behind this anti-Myc 
activity. Another part of the thesis addresses the question how certain cell 
cycle-regulated transcription cofactors for Myc, such as the E3 ubiquitin 
ligase Skp2, which has been described previously in the group, promotes 
Myc-driven G1/S transition.  
 
The basic mechanisms of cell cycle regulation in plants are similar to 
those in animals. In the plant part of this thesis, we are interested in finding 
out whether Myc-related bHLHZip proteins can be found in plants and 
whether they carry out similar functions as in animals. 
2.1 Specific  Aims 
•  To investigate whether combined RA+IFN-γ treatment affects the 
expression and/or activity of members of the Myc/Max/Mad 
network in N-myc-amplified neuroblastoma cells (paper I). 
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activity, how this is linked to the IFN-•-induced overall reduction 
in Myc phosphorylation and to identify the targeted 
phosphorylation sites (paper II). 
 
 
•  To shed light on the interplay between Myc, Skp2, p27Kip1 and 
cyclinE/Cdk2 in Myc-induced transcription of target genes during 
the G1/S cell cycle transition (paper II, III). 
 
 
•  To investigate whether Myc-related bHLH proteins can be found in 
plants and whether they carry out similar functions as in animals 
(paper IV). 
 
  563  Results and discussion 
3.1 Combined  IFN-γ and retinoic acid treatment induces 
differentiation and targets the N-Myc/Max/Mad1 network in 
N-myc-amplified neuroblastoma cells (paper I) 
Neuroblastoma (NB) is one of the most common solid childhood tumours 
and originates from sympathetic neuroblasts of the peripheral nervous 
system. It occurs primarily in children under 5 years of age with a median 
age at diagnosis of 18 months, and accounts for 7-10% of cancers and 15% of 
childhood cancer deaths. NB tumours usually locate to the adrenal gland and 
the sympathetic ganglia of the abdomen, neck, thorax, and/or pelvis and can 
spread to regional lymph nodes, bone and bone marrow (for review see 
(Brodeur, 2003)). Neuroblastoma tumours can be divided into several 
different types: benign tumours, lower stage malign tumours, highly 
aggressive/ often untreatable tumours, and tumours differentiating 
spontaneously despite of their metastatic spread (Brodeur et al., 1993). N-
myc amplification, ploidy, deletions or loss of heterozygosity of chromosome 
1p, and gains at chromosome 17q have been established as diagnostic and 
prognostic markers for neuroblastomas. N-myc amplification occurs in 25% 
of all neuroblastomas and in 40% of advanced stage cases, strongly 
correlating with advanced disease, drug resistance, and poor outcome 
(Brodeur, 2003, Cohn and Tweddle, 2004, Schwab, 2004). The ectopic 
expression of N-myc in non-amplified neuroblastoma cell lines results in 
enhanced proliferative potential whereas neuroblastoma cell lines that are 
transfected with N-myc antisense (AS) DNA oligos exhibit growth inhibition 
and a more differentiated phenotype (Cohn and Tweddle, 2004, Strieder 
and Lutz, 2002). Further, targeted expression of an N-myc transgene to 
  57neural crest cells has been reported to cause neuroblastoma-like tumours in 
transgenic mice (Weiss et al., 1997).  
 
Retinoic acid (RA) is known to induce differentiation to some extent in 
N-myc amplified neuroblastoma cell lines, often accompanied by decreased 
expression of N-Myc (Schwab, 2004, Strieder and Lutz, 2002). We and 
others have shown that IFN-γ strongly enhances RA induced differentiation 
and growth inhibition of N-myc amplified human neuroblastoma cells in 
vitro (Cornaglia-Ferraris et al., 1992, Guzhova et al., 2001, Wada et al., 
1997, Wuarin et al., 1991). In order to investigate how combined 
RA+IFN-γ treatment affects expression and/or activity of members of the 
Myc/Max/Mad network, the N-myc- amplified human neuroblastoma cell 
lines LA-N-5 and IMR-32 were treated with RA, IFN-γ, or their 
combination, after which differentiation assays, immunoprecipitation (IP), 
Western blot, Northern blot, RT-qPCR, and chromatin 
immunoprecipitation (CHIP) assays were performed. 
 
In the differentiation assays, we found that IFN-γ strongly enhanced RA-
induced differentiation of these cell lines, which is consistent with previous 
reports. The protein level of N-Myc was substantially decreased after 
combined RA+ IFN-γ treatment in both cell lines whereas RA alone only 
modestly reduced N-Myc levels in LA-N-5 cells. In contrast to the previous 
finding that RA+ IFN-γ treatment decreases N-Myc mRNA levels to 
almost 30% in L-A-N-5 cells (Guzhova et al., 2001), the N-Myc mRNA 
levels were only slightly reduced in IMR-32 cells in response to RA+ IFN-
γ treatment, which suggests that RA+ IFN-γ downregulates N-Myc protein 
levels at a posttranslational level in these cells. Another interesting 
observation was that RA+ IFN-γ treatment increased the expression of 
Mad1 in both IMR-32 and LA-N-5 cells, whereas the effects of either agent 
alone varied between the cell lines. Expression of Mad1 mRNA followed 
same pattern as Mad1 protein levels in IMR-32 cells, implying that Mad1 is 
regulated transcriptionally upon RA+ IFN-γ treatment. Neither protein nor 
mRNA levels of Max changed evidently after the different treatments. 
Taken together, RA+ IFN-γ affects the N-Myc/Max/Mad network by 
decreasing N-myc mRNA (LA-N-5 cells), decreasing N-Myc protein levels 
and increasing Mad1 mRNA. 
 
The amount of Max/N-Myc heterodimers was also shown to decrease 
significantly to 15% compared to untreated cells in IMR-32 cells after RA+ 
IFN-γ treatment. This could be partly due to increased N-Myc degradation 
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affecting the formation and/or stabilization of Max/N-Myc heterodimers 
(Bahram et al., 1999). We also wanted to investigate how the occupancy of 
N-Myc, Max, and Mad1 on their target genes was affected by the RA+ 
IFN-γ treatment. CHIP experiments were performed and the association of 
the relevant proteins was investigated on the promoter of the N-Myc target 
gene ODC. We found that after RA+ IFN-γ treatment, binding of N-Myc 
to the ODC promoter decreased to ~40% compared to untreated cells 
whereas binding of Mad1 increased ~2.5-fold. RA alone also induced the 
same phenomenon, but to lesser extent. The association of Max with the 
ODC promoter did not change significantly irrespective of treatment. In 
summary, RA+ IFN-γ treatment of neuroblastoma cells leads to a shift from 
N-Myc/Max towards Mad1/Max complex occupancy on the ODC 
promoter. RA- or RA+ IFN-γ treatment also resulted in a reduction of 
acetylation of histone H4 in the same region of this promoter. This suggests 
that RA and RA+ IFN-γ induce a repressive chromatin state by decreasing 
recruitment of histone acetyltransferases through N-Myc, and/or increasing 
recruitment of histone deacetylases through Mad1. Finally, we investigated 
the effects of the different treatments on the transcription of N-Myc target 
genes by using RT-qPCR. The combined RA+ IFN-γ treatment strongly 
reduced transcription of the ODC and hTERT target genes to around ~20% 
of control whereas both RA and IFN-γ treatments alone reduced mRNA 
levels to lesser extent. 
 
In conclusion, IFN-γ+RA induces differentiation accompanied with 
decreased N-Myc expression and increased Mad1 expression in 
neuroblastoma cells, leading to a shift from N-Myc/Max to Mad1/Max 
complexes on target gene promoters, resulting in reduced transcription of 
N-Myc target genes. 
3.2 IFN-γ increases degradation and ubiquitylation of Myc in a 
Ser-62- dependent manner (paperI, II) 
The U-937 differentiation model was established in 1976 from a patient 
with generalized histiocytic lymphoma (Sundstrom and Nilsson, 1976). U-
937 cells are arrested at a monoblastic stage under normal conditions. They 
can be induced into differentiation by using agents such as phorbol ester 
(TPA), retinoic acid (RA), and vitamin D3 (VitD3) (Olsson and Breitman, 
1982, Olsson et al., 1983, Einat et al., 1985, Larsson et al., 1988, Oberg et 
al., 1991). Treatment with these agents leads to G0/G1 arrest accompanied 
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(Ayer and Eisenman, 1993, Larsson et al., 1994). We previously reported 
that human monocytic U-937 cells constitutively expressing the v-Myc 
protein of the avian OK10 retrovirus, which carries a stabilizing mutation at 
Thr-58, are unable to undergo TPA-induced differentiation. However, the 
TPA-induced differentiation and G1 arrest is restored upon IFN-γ treatment 
(Oberg et al., 1991). We also found that IFN-γ destabilizes the Myc/Max 
complex, which correlates with reduced phosphorylation of Myc (Bahram et 
al., 1999). The aim of paper I and II was to further investigate the 
mechanisms behind the IFN-γ-induced inhibition of Myc functions. 
 
First, we investigated the effects of IFN-γ treatment on c- and v-Myc 
protein stability in v-Myc-transformed U-937-myc6 cells. IFN-γ+TPA 
decreased the half-life of both c- and v-Myc from approximately 30 to 20, 
and 150 to 50 minutes respectively. Correspondingly, IFN-γ+RA, but 
neither RA nor IFN-γ alone, increased the rate of N-Myc protein 
degradation from a half-life of approximately 40 minutes to 15-20 minutes 
in IMR-32 neuroblastoma cells (Paper I). Also, the fluorescence intensity of 
c-Myc/Max BiFC (Bimolecular Fluorescence Complementation) fusion 
pairs was reduced after IFN-γ treatment, which indicated a decrease in c-
Myc protein levels since Max expression is not affected by this treatment 
(Bahram et al., 1999). A similar reduction was observed with the c-Myc-
GFP protein. IFN-γ treatment also increased the c-Myc turnover rate in 
other cell lines, including Colo-320 carcinoma cells with amplified c-myc and 
human 2fTGH fibrosarcoma cells. A cycloheximide (CHX) chase 
experiment performed with 2fTGH cells treated with IFN-γ+TPA showed 
that Myc turnover increased already within 4 hours and was further 
accelerated after 8 hours of treatment. TPA alone did not affect c- or v-Myc 
protein stability.  
 
The IFN-γ induced increase in Myc degradation seems to occur via the 
UPS since evidence showed that increased ubiquitylation of c-Myc 
happened synchronously with increased turnover in 2fTGH cells. IFN-γ 
induced Myc degradation was sensitive to proteasome inhibition in U-937 
cells, and IFN-γ stimulation increased the signal intensity of c-Myc/Ub 
BiFC, reflecting increased c-Myc ubiquitylation. Interestingly, degradation 
of Myc was not affected by IFN-γ in the 2fTGH sublines U3A and U4A 
that lack STAT1 and JAK1 respectively, suggesting that both STAT1 and 
JAK1 are required for IFN-γ induced Myc turnover. There was no evidence 
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redistributed within the cell upon IFN-γ treatment prior to degradation.  
 
As mentioned previously, the stability of Myc is regulated through 
phosphorylation at Ser-62 and Thr-58. Antibodies against phospho-
T58/S62 were used to investigate how IFN-γ affects the phosphorylation 
state of Ser-62 of Myc. U-937-myc6 cells were first treated with IFN-γ for 
24 hours followed by proteasome inhibition for 2 hours prior to harvest in 
order to avoid differences in total Myc levels resulting from different 
sensitivity to Fbw7/Cdc4-mediated degradation. The result showed an IFN-
γ-induced reduction of v-Myc Ser-62 phosphorylation. To investigate 
whether the IFN-γ-induced increase in Myc turnover is dependent on Ser-
62, we transfected Myc-T58A and Myc-S62A plasmids, respectively, into 
2fTGH cells, followed by blocking protein synthesis with CHX. IFN-γ 
treatment increased degradation of Myc-T58A but not of Myc-S62A, 
suggesting that this degradation is Ser-62 dependent. 
3.3  Cyclin E/Cdk2 is a new Ser-62 kinase for Myc (paper II) 
Three kinases, Erk, Jnk, and Cdk1 (for N-Myc), are known to 
phosphorylate Myc on Ser-62. Erk functions via the MAPK/ERK pathway 
whereas Jnk functions via the PI3K-Rho-ROCK pathway (for review see 
(Hann, 2006)). To examine which kinases are involved in IFN-γ induced 
Ser-62 phosphorylation, U2OS cells transfected with c-Myc-T58A (to 
ensure the exclusive study of Ser-62 phosphorylation) were treated with 
inhibitors of these three kinases and of other relevant factors, such as Mek1, 
p38 MARK, GSK3, PI3K, and ROCK, for 4 hours. The proteasome 
inhibitor MG115 was also added to the cells 2 hours prior to harvest in 
order to avoid possible effects of the kinase inhibitors on the Myc-T58A 
turnover. Roscovitine, a Cdk2/Cdk1 inhibitor, reduced Ser-62 
phosphorylation most efficiently whereas Kenpaullone, which inhibits Cdk1 
more efficiently than Cdk2, was not as effective as roscovitine, suggesting 
that Cdk2 is the kinase for IFN-γ-induced Ser-62 phosphorylation of Myc. 
Cdk1 may phosphorylate Myc in mitotic cells (Sjostrom et al., 2005) that are 
only a small fraction of all cells under our experimental conditions, and thus 
Cdk1-specific effects might be undetectable. Indeed, bacterially expressed 
GST-Myc was a substrate of cyclin E/Cdk2 and to a lesser extent of cylin 
A/Cdk2 when Ser-62 was present. Further, phosphorylation of Ser-62 and 
Thr-58/Ser-62 was readily detected in U-937 cells arrested in S phase by 
treatment with the DNA polymerase inhibitor aphidicolin. These 
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Consistently, both IFN-γ alone and IFN-γ+TPA in combination inhibited 
Cdk2 kinase activity. Ser-62 phosphorylation of both c- and v-Myc was 
reduced after 4 hours and more significantly after 8 hours of roscovitine 
treatment. Interestingly, mimicking IFN-γ, roscovitine increased the 
turnover of both c- and v-Myc in U937-myc6 cells, which further 
implicates that Cdk2-dependent phosphorylation of Ser-62 might act to 
antagonize IFN-γ induced Myc turnover.  
3.4  p27Kip1 reduces phosphorylation of Myc on Ser-62 and 
increases turnover of Myc in a Ser-62 dependent manner
 
(paper II) 
p27Kip1 is a well-known inhibitor of the Ckd2 kinase, we therefore  next 
wanted to investigate what potential role p27
Kip1 plays in IFN-γ induced 
inhibition of Cdk2 activity on Myc. p27
Kip1 protein levels were shown to 
increase in U-937-myc6 cells after 2 hours treatment with IFN-γ+TPA and 
thereafter continued to rise gradually, correlating with a decrease in Cdk2 
activity. At the same time, the p27
Kip1:Cdk2 complex formation was 
increased while the stability of Cdk2 kept unchanged. Cells overexpressing 
or lacking p27
Kip1 were used together with wt c-Myc, Myc-T58A, Myc-
S62A, or Myc-T58A/S62A constructs in order to further investigate the 
role of p27
Kip in the phosphorylation and IFN-γ-induced turnover of Myc. 
The results demonstrated that p27
Kip1 reduced the phosphorylation and 
increased the turnover of both the wt and the Myc-T58A mutant, but not of 
the Myc-S62A mutant. Furthermore, IFN-γ-induced Myc degradation 
seems to be dependent on p27
Kip1 since Myc stability was unaltered in p27-/- 
MEF cells after IFN-γ treatment. 
SCF
Fbw7/Cdc4  and SCF
Skp2 are two E3 ligases acting on Myc. Are they 
involved in the IFN-γ induced Myc degradation? To answer this question, 
we transfected p27
Kip1 or control vector into HCT116 Fbw7/Cdc4-/- cells 
and investigated the turnover rate of Myc. Myc proteins were stabilized in 
Fbw7/Cdc4-/- cells as expected. However, the stabilization was eliminated 
by ectopic expression of p27
Kip1. To study if p27
Kip1-induced Myc 
degradation required Skp2, cells were transfected with the dominant 
negative Skp2∆F mutant, which resulting in stabilization of Myc proteins. 
However, p27
Kip1 coexpression increased Myc turnover irrespective of the 
presence of Skp2∆F, suggesting that Skp2 does not participate in p27
Kip1-
induced Myc degradation. 
 
  623.5  Cyclin E/Cdk2 and p27
Kip1 interact with Myc at target 
promoters and regulate Myc-driven transcription (paper II, 
III) 
Since cyclin E/Cdk2 phosphorylates c-Myc we were interested to see 
whether this might occur at Myc target promoters. An interaction between 
Myc and cyclin E was detected by coimmunoprecipitation (coIP) in U937-
myc6 cells. The relatively low signal indicated a weak or transient 
interaction. The presence of Myc, cyclin E, and Cdk2 on Myc target gene 
promoters was investigated by CHIP. Myc bound to the E-box region of 
the cyclin D2 promoter as expected. Cyclin E and Cdk2 were also shown to 
bind on the same region. Further, re-CHIP showed that Myc directly 
associated with Cdk2 at the cyclin D2 promoter (paper III).  
 
We also examined whether interactions between Myc and p27
Kip1 could 
be detected in IFN-γ treated U-937 cells by coIP. Weak but measurable 
amounts of Myc were specifically coIP-ed with p27
Kip1 antibodies. The 
interaction between Myc and p27
Kip1 could be visualized in cells treated with 
IFN-γ, IFN-γ +TPA, and to a lesser extent in TPA-treated cells but was 
hardly detectable in untreated cells. CHIP experiments demonstrated that 
p27
Kip1 indeed associated specifically with the E-box region of the cyclin D2 
promoter. Interestingly, the presence of p27
Kip1 at this promoter increased 
after IFN-γ+TPA treatment. Moreover, a re-ChIP experiment was 
performed, showing that Myc indeed forms complexes with p27
Kip1 at this 
promoter. 
 
Consistent with this, a reduction in Ser-62 phosphorylation of Myc also 
occurred on Myc target gene promoters. By using Q-ChIP, we 
demonstrated that the occupancy of both total and phosphorylated Myc 
decreased substantially at the cyclin D2 promoter in response to IFN-γ 
treatment, as well as the acetylation of histone H4. It is unclear whether the 
reduced presence of Myc is due to its turnover at the promoter or 
degradation independent of its binding to DNA.  
 
We next examined how IFN-γ treatment affects Myc-driven 
transcription using luciferase reporter gene constructs. IFN-γ and IFN-
γ+TPA treatment strongly repressed the reporter activity. Moreover, the 
mRNA expression of two endogenous Myc-activated genes, hTERT and 
ODC, were significantly decreased upon IFN-γ+TPA treatment whereas 
expression of the Myc-repressed gene p21
Cip1 was strongly enhanced. Finally, 
a Myc-driven promoter/luciferase reporter together with Myc and/or 
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cyclinE/Cdk2 overexpression on Myc-induced transcription. Cotransfection 
with cyclinE/Cdk2 strongly increased Myc-induced transcription. 
 
Put together, these data suggest that cyclinE/Cdk2 phosphorylates Myc 
at Ser-62 on target gene promoters. The stabilization of Myc prolongs its 
binding to the target gene promoters and thus enhances the transcription of 
these genes. IFN-γ represses cyclinE/Cdk2 kinase activity by inducing 
p27
Kip1, which is transiently recruited to Myc target gene promoters and 
inhibits the activity of Myc-bound cyclin E/Cdk2, resulting in reduced Myc 
phosphorylation and loss of Myc (and interacting proteins) from chromatin.  
3.6  c-Myc activates late G1/S phase genes in cooperation with 
Skp2 (paper III) 
To study the impact of Skp2 on the regulation of Myc-induced transcription 
of target genes during the cell cycle, the P493-6 human B lymphoid cell line 
carrying a conditional tetracycline (Tc)-regulatable c-myc construct was used. 
Tc turns off c-myc after which the cells go into quiescence. After removal of 
Tc, the myc gene is activated and cells re-enter cell cycle synchroniously 
(Schuhmacher et al., 1999). In agreement with previous publications we 
found that Myc protein levels were strongly increased in these cells within 4 
hours after Tc removal. Expression of cyclin A increased after approximately 
20 hours, indicating progression of cells into S phase, whereas Skp2 protein 
was started to be expressed around 12 hours and kept increasing until 32 
hours, in consistence with the previous finding that Skp2 expression starts in 
mid/late G1 and reaches its maximum in S and G2 phases of the cell cycle 
(for review see Nakayama and Nakayama, 2005). Correspondingly, the 
levels of both Myc and Skp2 mRNA increased after 4 and 12 hours, 
respectively. mRNA levels of Myc target genes, including RFC4, orinthine 
decarboxylase (ODC) and cyclin D2, were also investigated with RT-qPCR 
at the same time intervals. The results showed that ODC mRNA increased 
immediately after c-Myc was activated in early G1. Interestingly, the 
transcription of RFC4 did not start until around 12 hours after induction 
and was maximal at 18 hours, resembling the expression pattern of Skp2.  
 
Myc is known to interact with Skp2 from late G1 in the nucleus (von der 
Lehr et al., 2003, Fujii et al., 2006), and Skp2 is recruited by Myc to target 
promoters, which not only ubiquitylates and degrades Myc but also 
enhances Myc induced transcription and S phase entry. (Kim et al.2003, von 
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role in the induction of Myc target genes at late G1 phase. CHIP 
experiments performed with P493-6 cells showed that Myc binded strongly 
to E-box-containing promoter regions of both the ODC and RCF4 genes 
already at 6 hours after Myc induction, although the expression of RFC4 
was not activated until several hours later. In contrast, ODC mRNA was 
induced with the same kinetics as the Myc binding to its promoter.   
Interestingly, Skp2 only bound to the RFC4 promoter but not to the ODC 
promoter. This occurred only at the later time points, thus correlating with 
the Skp2 expression pattern.  
 
Taken together, we suggest that Myc binds to its target gene promoters 
soon after its activation and may induce transcription of different genes by 
cooperating with different coactivators. Some target genes such as ODC are 
transcribed immediately, perhaps in correlation with the action of the 
coactivator TRRAP. Other genes, like RFC4, are kept silent until certain 
cofactor, in this case possibly Skp2, is recruited at late G1 phase. However, 
it remains to be shown that Skp2 plays an active role in turning on this 
promoter.  
3.7  Intimate connections between Myc, cyclinE/Cdk2, p27
Kip1, 
and Skp2 might provide potential new strategies for cancer 
therapy (paper I, II, III) 
The results mentioned above imply several possibilities of how Skp2 and 
cyclin E/Cdk2 are involved in the regulation of Myc driven transcription 
during G1/S transition. Cyclin E/Cdk2 binds to Myc target gene promoters 
during cell cycle progression, thus enhancing Myc-induced transcription. 
The mechanism by which cyclin E/Cdk2 can carry out a coactivator 
function for Myc is unclear. One possibility is that cyclinE/Cdk2-mediated 
phosphorylation of Ser62 stabilizes Myc, thereby increasing its time of 
association with chromatin. In addition, cyclin E/Cdk2 has been reported to 
repress the Myc antagonist Mad1 (Rottmann et al., 2005). It is possible that 
upon anti-proliferative signals such as IFN-γ, repression of cyclin E/Cdk2 
on Mad1 is released, resulting in a shift from Myc/Max to Mad1/Max 
complexes on Myc target gene promoters. cyclin E/Cdk2 is also able to 
phosphorylate other components in the Myc transcriptional complex such as 
the histone acetyltransferase cofactor CBP (Ait-Si-Ali et al., 1998, Vervoorts 
et al., 2003). The kinase activity of cyclin E/Cdk2 might be repressed by 
  65p27
Kip1 in response to anti-proliferative signals such as IFN-γ, resulting in 
inhibition of Ser-62 phosphorylation. 
This study also implies a possibility that Myc binds to the promoter of a 
subgroup of target gene, but cannot induce transcription until specific 
cofactors such as Skp2 are recruited to the promoter at late G1 phase. 
Recently, Skp2 has been found to antagonize the binding of p53 to p300, 
thus suppressing p300-mediated acetylation of p53 and the transactivation 
capability of p53 (Kitagawa et al., 2008).  This brings up a potential pathway 
in which Skp2 may function in similar way to remove the repression on 
Myc, thereby enhancing Myc induced transcription. We also show that 
p27
Kip1, which is known as a substrate of Skp2-mediated degradation, binds 
to promoters in complex with Myc and might inhibit cyclinE/Cdk2 kinase 
activity towards Myc at the promoter. One interesting hypothesis is that 
Skp2 ubiquitylates and degrades p27
Kip1 at the promoter, thereby releasing its 
inhibition of cyclin E/Cdk2, which in turn would assist the cyclin E/Cdk2-
mediated coactivator function on Myc induced transcription. This, 
however, remains to be investigated.  
Both RA and IFN-γ have been used as single agents for clinical 
neuroblastoma therapy (Matthay et al., 1999, Yang et al., 2003). The effects 
of RA+IFN-γ on the N-Myc/Max/Mad network demonstrated with our 
work suggest a new therapeutic strategy of “differentiation therapy” for 
neuroblastomas with amplified N-myc. In this respect, it is encouraging that 
even transient inactivation of c-myc in c-Myc-driven tumours is sufficient to 
induce permanent tumour regression (for review see (Pelengaris et al., 
2002)). While Myc and cyclin E are well established oncoproteins, a role of 
p27
Kip1 in tumor formation has been postulated but has only become 
apparent recently (Sicinski et al., 2007). Thus the Myc/Cyclin E/Cdk2/ 
p27
Kip1 axis may also provide a target for intervention. Indeed, many 
cytokines or other agents that stimulate p27
Kip1 expression (Blain et al., 2003) 
as well as specific inhibitors of Cdk2/Cdk1 (Goga et al., 2007; Shapiro, 
2006) are already in clinical use or under development, and could in the 
light of our new findings be of relevance for combined multi-drug therapies 
for patients with aggressive Myc–driven tumours.  
3.8  Several Arabidopsis B-group bHLH genes show expression 
pattern correlated to cell cycle regulation  
The plant Arabidopsis bHLH group, containing 162 genes (Heim et al 2003, 
Bailey et al 2003, Toledo-Ortiz et al., 2003), is the second largest 
transcription factor family in Arabidopsis thaliana. Most of the plant bHLH 
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processes, including regulating trichome and root hair initiation (Bernhardt 
et al., 2003; Payne et al., 2000; Zhang et al., 2003), carpel development 
(Heisler et al., 2001), regulating fruit opening (Liljegren et al., 2004; Rajani 
and Sundaresan, 2001), regulation of light signalling (for reviews see (Duek 
and Fankhauser, 2005; Monte et al., 2007), regulation of stress and hormone 
signalling. The basic mechanisms of cell cycle regulation in plants are similar 
to those in animals (for review see (De Veylder et al., 2007)), but the 
understanding about how transcription factors regulate the cell cycle in 
plants is very limited. Many regulators of the cell cycle that are controlled by 
Myc in animal are fairly conserved in plants, such as cyclins, Cdks, CKIs, 
Rb/E2F. Therefore in this paper we investigated if Myc-related bHLH 
proteins could be found in plants and if they would carry out similar 
functions.  
 
First we tried to identify myc-like B-group genes in Arabidopsis thaliana (At). 
The bHLH domain of Myc, Max, and Mad are highly conserved in 
different species, and can be used for screening the genome of Arabidopsis. 
The bHLHZip domains of a number of animal Myc, Max and Mad proteins 
were used to screen At databases utilizing the Psi- and Phi-BLAST 
programs. We identified 84 B-group At bHLH sequences that characterized 
by a characteristic H-E-R “fingerprint”.  This “fingerprint” is made of H at 
position five, E at position eight, and R at position thirteen out of the 13 
amino acids in the basic region, and functions crucially for recognition of 
the CACGTG E-box sequence.  
 
A neighbour-joining phylogenetic tree was constructed with amino acid 
sequences of the bHLHZip domains of these At genes using MEGA 4.0. 
Accordingly, these At genes were divided into15 phylogenetic subfamilies 
with high predictive values (bootstrap support of 50 or greater) and 8 orphan 
genes that could not be grouped into any of these subfamilies. This 
classification is overlapping but not entirely identical what was proposed in 
previous reports (Heim et al 2003, Bailey et al 2003, Toledo-Ortiz et al., 
2003). All 15 subfamilies were evolutionary separated from the 
myc/max/mad genes and all other animal bHLH genes. 
 
The sequence similarity between animal myc/max/mad genes and these At 
genes exits the highest in the bHLH domain. But many of these At genes 
also seem to contain, at least partly, a leucine zipper (Zip). However, no 
significant similarity was found outside the bHLHZip domain. No particular 
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mad-like than the other, although all of them had many features in common.  
Here we argue that the At B-group bHLH family genes are all more or less 
“myc-like”.  
 
Since the expression of the animal myc genes are cell cycle regulated, to 
investigate whether these At bHLH genes might function in a similar way as 
the animal myc genes, we next examined the expression patters of the At 
bHLH genes using several cell cycle systems. These included shoot apex, 
flower, leaf, silique/seed and root development systems (Birnbaum et al., 
2003, Jacqmard et al., 2003; Mordhorst et al., 1998; Zhang et al., 2005) as 
well as auxin-induced early lateral root initiation (Himanen et al., 2004, 
Vanneste et al., 2005) and sucrose-induced suspension culture systems 
(Menges and Murray, 2002). 
 
Four cell cycle regulatory genes were used as reference genes, including 
the G1 cyclins cyclin D3;3 and cyclin D3;1, the transcription factor E2Fa, and 
the Cdk inhibitors KRP1 and/or KRP2. The E2Fa and the G1 cyclins 
genes are highly expressed in proliferative tissues, whereas the opposite of 
KRP1 (Menges and Murray, 2002). 15 At bHLH genes showed expression 
profiles correlating with proliferative status in shoot apex, flowers, leaves 
and/or siliques/seeds. 
 
Among these, three genes, including At1g10120, At1g68810 and 
At3g25710, were coregulated with cyclin D3;3, cyclin D3;1 and E2Fa in all 
four tissues. 5 genes, including At1g26260, SPATULA, EGL3, At3g61950, 
and At5g53210, were coregulated with these cell cycle genes in three out of 
four tissues; while others had similar expression patters as the cyclins in some 
tissues, but resembled more the expression of KRP1 in other tissues. Some 
of the genes were differentially expressed between tissues or during the 
development of a certain tissue, but in a way that seemed unrelated to the 
cell cycle.  
 
Similar bioinformatic study was done also in published microarray 
expression profiling data from Arabidopsis root (Beemster et al., 2005; 
Birnbaum et al., 2003). The three root developmental stages 1, 2, and 3 
represent active cell proliferation, cell longitudinal expansion, and cell 
maturation, respectively. As expected, highest expression of cyclin D3;1 and 
cyclin D3;3 and lowest expression of KRP1 and KRP2 was found in stage 1 
and vice versa in the stage 3. Nine of the At genes showed expression 
  68patterns that were similar to the cyclins, including At3g25710 that were 
amongst the genes that were coregulated with cyclins in the all of the 
previous tissues, and At1g26260, SPATULA,  EGL3 and At3g61950 that 
were coregulated in three out of four of the previous tissues. Two of the 
genes showed an expression pattern that was similar to KRP 1 and 2. 
 
We next looked at the expression of these At genes in an auxin-induced 
early lateral root initiation system (Himanen et al., 2004). In this system 
pericycle cells in root are synchronized by using 1-N-naphthylphthalamic 
acid (NPA), followed by lateral root initiation and cell cycle progression 
induced by auxin. The published microarray expression data from Vanneste 
et al. (Vanneste et al., 2005) were used in this study. The dominant auxin 
signalling mutant solitary root (slr1) that is defective in induction of key cell 
cycle components, including cyclin D3;1 (Vanneste et al., 2005), was used as 
negative control. Interestingly, gene At1g26260, which was coregulated 
with cyclin D3 in four out of the five tissues studied above, was strongly 
induced after 6 hrs of auxin treatment in wt plants but not in the slr1 
mutant, suggesting that it plays a role in auxin-signalling and further 
implicates its role in cell cycle regulation.  
 
After the bioinformatic study mentioned above, RT-qPCR was used to 
investigate the mRNA expression kinetics of these selected At genes in 
sucrose-induced Arabidopsis suspension cell cultures. In this system, the cells 
are synchronized in G0 by sucrose starvation, followed with cell cycle re-
entry induced by re-addition of sucrose (Menges and Murray, 2002). The 
expression patterns of these At bHLH genes fell into three different 
categories: cyclin D3-like genes, immediate early transiently expressed genes, 
and  KRP1/2-like genes. Three out of the four cyclin D3-like genes, 
At1g10120, At5g50915 and ALCATRAZ, were coregulated with cyclin D3 
genes in 4-5 different systems. There were three immediate early transiently 
expressed genes, At1g26260, SPATULA and At3g61950. They were all 
coregulated with the cyclins in 5-6 other systems. Finally, we have three 
KRP1/2-like genes, PIF3, EGL3 and At1g68810. PIF3 has shown KRP-
like expression patterns in two other systems, whereas EGL3 and At1g68810 
have rather been expressed in a cyclin-like pattern is most other systems. 
 
In summary, our study characterized several Arabidopsis B-group bHLH 
genes that showed expression pattern correlated to cyclin D or KRP, 
respectively, which may offer a platform for future study about functions of 
these genes in plant cell cycle regulation. 
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  704 Conclusion 
Combined IFN-γ and retinoic acid treatment induces differentiation 
and targets the N-Myc/Max/Mad1 network in N-myc-amplified 
neuroblastoma cells. 
 
IFN-γ increases degradation and ubiquitylation of Myc in a Ser-62- 
dependent manner. 
 
Cyclin E/Cdk2 is a new Ser-62 kinase for Myc. 
 
p27
Kip1 reduces phosphorylation of Myc on Ser-62 and increases 
turnover of Myc in a Ser-62 dependent manner. 
 
Cyclin E/Cdk2 and p27
Kip1 interact with Myc at target promoters and 
regulate Myc-driven transcription. 
 
c-Myc activates late G1/S phase genes in cooperation with Skp2. 
 
Intimate connections between Myc, cyclinE/Cdk2, p27
Kip1, and Skp2 
might provide potential new strategies for cancer therapy. 
 
Several Arabidopsis B-group bHLH genes show expression pattern 
correlated to cell cycle regulation 
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Abstract
The MYCN protooncogene is involved in the control of cell
proliferation, differentiation, and survival of neuroblasts.
Deregulation of MYCN by gene amplification contributes
to neuroblastoma development and is strongly correlated
to advanced disease and poor outcome, emphasizing the
urge for new therapeutic strategies targeting MYCN
function. The transcription factor N-Myc, encoded by
MYCN, regulates numerous genes together with its
partner Max, which also functions as a cofactor for the
Mad/Mnt family of Myc antagonists/transcriptional
repressors. We and others have previously reported that
IFN-; synergistically potentiates retinoic acid (RA)–
induced sympathetic differentiation and growth inhibition
in neuroblastoma cells. This study shows that combined
treatment of MYCN-amplified neuroblastoma cells with
RA+IFN-; down-regulates N-Myc protein expression
through increased protein turnover, up-regulates Mad1
mRNA and protein, and reduces N-Myc/Max heterodime-
rization. This results in a shift of occupancy at the
ornithine decarboxylase N-Myc/Mad1 target promoter
in vivo from N-Myc/Max to Mad1/Max predominance,
correlating with histone H4 deacetylation, indicative of
a chromatin structure typical of a transcriptionally
repressed state. This is further supported by data showing
that RA+IFN-; treatment strongly represses expression of
N-Myc/Mad1 target genes ornithine decarboxylase and
hTERT. Our results suggest that combined IFN-; and
RA signaling can form a basis for new therapeutic
strategies targeting N-Myc function for patients with
high-risk, MYCN-amplified neuroblastoma. [Mol Cancer
Ther 2007;6(10):2634–41]
Introduction
Neuroblastoma originates from sympathetic neuroblasts of
the peripheral nervous system and is one of the most
common solid childhood tumors, accounting for 7% to 10%
of the childhood cancers and around 15% of childhood
cancer deaths (1). Twenty-two percent of neuroblastomas
and f40% of advanced stage cases exhibit amplification of
the MYCN protooncogene, a condition that is strongly
correlated with advanced disease, drug resistance, and poor
outcome (1–3). Targeting expression of MYCN to neuro-
ectodermal cells has been reported to cause neuroblastoma
in transgenic mice, further suggesting a crucial role of
deregulated MYCN in neuroblastoma development (4).
Moreover, ectopic overexpression of MYCN in neuroblas-
toma cell lines lacking MYCN aberrations results in
enhanced growth potential and tumorigenicity, whereas
antisense MYCN experiments have the opposite effect (2, 5).
MYCN is a member of the MYC gene family, including
MYC, MYCN, and MYCL.A l lMYC family genes stimulate
cell growth and proliferation, counteract terminal cell
differentiation, sensitize cells to apoptosis in a similar
fashion, and are all involved in the development of various
types of tumors when deregulated (for review, see 6–8).
The MYC family is a subfamily of the basic region/helix-
loop-helix/leucine zipper class of transcription factors
which bind E-box DNA recognition sequences in pro-
moters of target genes by heterodimerization with the
obligatory partner Max, thereby activating transcription
(for review, see refs. 6–8). However, Max also forms
heterodimers with the Mad/Mnt family of basic region/
helix-loop-helix/leucine zipper proteins, including Mad1,
Mxi1, Mad3, Mad4, and Mnt/Rox, as well as with Mga,
thereby forming alternative E-box–binding complexes
(6, 9–11). Mad/Mnt proteins repress c-Myc–induced
transcription, cell proliferation, and transformation and
are therefore considered to be antagonists of Myc. To
repress transcription, Mad/Mnt proteins interact with
the repressor protein Sin3, which is part of repressor
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c-Myc, on the other hand, activates transcription at least
in part by recruiting histone acetyltransferases complexes
to target promoters through interaction with the cofactor/
adaptor protein TRRAP (6–8). Modulation of chromatin
structure is therefore one way for both the Myc and Mad/
Mnt family proteins to regulate transcription. Recent
reports suggest that c-Myc may control up to 10% to 15%
of all genes in the genome, thereby affecting numerous
fundamental cellular processes, including cell cycle, cell
growth, protein synthesis, metabolism, apoptosis, senes-
cence, differentiation, genomic stability, angiogenesis,
adhesion, etc. (6–8, 12).
Based on the gene expression patterns during develop-
ment and differentiation and the antagonistic functions of
the Myc and Mad family proteins, one current hypothesis
suggests that the Myc/Max/Mad network proteins consti-
tute a molecular switch that determines cell fate by
regulating an overlapping set of genes. This model is
supported by evidence showing that the occupancy of
E-box–containing regions of the CYCLIND2 and hTERT
target gene promoters in vivo shifts from c-Myc/Max
toward Mad1/Max predominance during hematopoietic
differentiation, correlating with histone deacetylase recruit-
ment, histone deacetylation, and repression of gene activity
(13, 14). It is still unclear how large fraction of c-Myc target
genes are coregulated by the Mad/Mnt family, but both
families also seem to control unique sets of genes by
interacting with alternative partners that bind non–E-box
motifs, such as Miz-1, which is used by c-Myc for
repression of certain genes (8, 12, 15, 16).
The poor outcome of patients with MYCN-amplified
neuroblastoma despite intensive therapy has called for
development of alternative therapeutic strategies. Studies
using mouse models have shown that even temporary
inactivation of c-Myc in c-Myc–driven tumors is sufficient
for irreversible tumor cell differentiation and growth arrest,
or alternatively apoptosis, in both cases resulting in
permanent tumor regression (for review, see ref. 17).
Identifying ways of down-regulating the expression or
activity of N-Myc or alternatively to up-regulate expression
or activity of Mad/Mnt family proteins in MYCN-ampli-
fied neuroblastomas could therefore be of potential
therapeutic interest. Treatment of neuroblastoma cell lines
with retinoic acid (RA) induces neuronal differentiation
linked to growth inhibition and is accompanied by
reduction of MYCN expression (3, 5). This raised the
question whether ‘‘differentiation therapy’’ for neuroblas-
tomas could improve event-free survival, in particular for
treatment of minimal residual disease (18). Indeed, high
dose 13-cis RA treatment of patients with high-risk
neuroblastoma after autologous bone marrow transplanta-
tion showed encouraging results in a phase III clinical trial
(19). We and others have previously reported that IFN-g
strongly enhances RA-induced differentiation and growth
inhibition of MYCN-amplified human neuroblastoma cell
lines in vitro (20–23) and, synergistically with RA,
represses their tumor growth in nude mice (21). The
purpose of the present study was to determine whether
combined RA+IFN-g treatment affects expression and/or
activity of members of the Myc/Max/Mad network in
MYCN-amplified neuroblastoma cells. We show that
RA+IFN-g down-regulates N-Myc through increased pro-
tein turnover, up-regulates Mad1 expression, and reduces
N-Myc/Max heterodimerization. This alters N-Myc/Mad1
occupancy at a target promoter in vivo in favor of Mad1,
resulting in strong repression of N-Myc target genes. These
results suggest that combination therapy with IFN-g could
be of interest for treatment of patients with neuroblastoma
harboring MYCN amplification.
Materials and Methods
Cell Cultures and Induction of Differentiation
The human neuroblastoma cell lines LA-N-5 and IMR-32
were cultured in RPMI 1640 and DMEM, respectively,
supplemented with 10% FCS and antibiotics. Cells plated
the day before at 1  10
5 cells per 6-cm dish were induced
to differentiate in medium containing 1 Amol/L all-trans
RA (Sigma), 100 to 200 units/mL IFN-g (generously
provided by Dr. G.R. Adolf, Ernst-Boehringer Institute) or
their combination. Cell number and viability were deter-
mined by trypan blue exclusion. The morphology of the
cells was evaluated under a phase contrast Zeiss micro-
scope (Carl Zeiss), and photographs were taken through an
Olympus phase contrast microscope. The percentage of
morphologically differentiated cells was determined by
counting at least 100 randomly chosen cells, wherein cells
exhibiting neurites at z50 Am were scored as positive.
Neurite outgrowth index (24) was defined as the product of
the percentage of cells with neurites at z50 Am and the
average total neurite length.
Immunoprecipitations andWestern Blot Analysis
Cell labeling and immunoprecipitation were done as
described previously (25). Briefly, cells were labeled for 50
min in 1.5 mL of methionine (Met)–free RPMI 1640
containing 0.2 mCi of
35S-Met. For high and low stringency
precipitations, cells were lysed in AB and Tris lysis buffer,
respectively (25), and immunoprecipitated with specific
antibodies. An equal number of TCA-precipitable counts
were used for each sample. The washing procedure for high
andlowstringencyimmunoprecipitationshasbeendescribed
(25). The samples were analyzed on 10% to 15% SDS-PAGE
gels. For studies of protein turnover, cells were pulse labeled
for 40 min as above, followed by chase in medium containing
1m m o l / Lc o l dM e ta n d1 0Ag/mL cycloheximide. Western
blotanalysiswascarriedoutasdescribed(25).Theantibodies
used for immunoprecipitation were C-19 Mad1 antibodies
(Santa Cruz Biotechnology), IG-7 pan-Myc antiserum (25),
AB-1 N-Myc antibodies (Oncogene Science), and C-17 Max
antibodies(SantaCruz).Radioactivesignalswerequantitated
with a Phosphor Imager (Bio-Rad).
Quantitative ReverseTranscription ^PCR and North-
ern Blot Analysis
Total RNA (4 Ag) was converted to cDNA with Revert-
Aid M-MuLV reverse transcriptase (Fermenta). Ornithine
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and probes for reverse transcription–PCR were designed
by the software Primer Express (Perkin-Elmer Applied
Biosystems). As reference genes, GAPDH, b-ACTIN, and
a-TUBULIN were used. Primer sequences are provided
upon request. Quantitative PCR reactions were done in
triplicates, using the Taqman PCR Core Reagent kit
(Applied Biosystems) with the ABI PRISM 7700 Sequence
Detector (Perkin-Elmer).
Northern blot analysis was carried out as described (23).
For MAD1, a 1.1-kb NotI/EcoRI fragment from the cDNA
clone pVZ1mad (kindly provided by D. Ayer) was used,
whereas for MAX, a 540-bp EcoRI fragment from the MAX
cDNA clone pVZ1max (kindly provided by R. Eisenman)
was used. The probes for MYCN and GAPDH have been
described (23).
Chromatin Immunoprecipitation Assays
Cells were lysed and crosslinked with formaldehyde as
described (13). Chromatin DNA was sonicated to an
average size of 300 to 500 bp. Immunoprecipitations were
carried out in radioimmunoprecipitation assay buffer with
the following antibodies: IG0 (preimmune serum), anti-
Max, anti–N-Myc, and anti-Mad1 from Santa Cruz and
anti–acetyl histone H4 from Upstate. Immunoprecipitates
were collected with protein G–sepharose beads, washed,
and eluted in TE, 1% SDS. Purified DNA samples were
analyzed by quantitative PCR as above using primers
specific for an E-box–containing regulatory region of the
ODC gene (7). As control, a non–E-box region of the FasL
was used. Quantitative PCR primer sequences are provided
upon request.
Results
Combined RA+IFN-; Treatment Reduces N-Myc and
Induces Mad1 Expression Correlating with Robust Dif-
ferentiation in MYCN-Amplified Neuroblastoma Cells
IFN-g has been reported to potentiate RA-induced
differentiation in MYCN-amplified neuroblastoma cell
lines (20–23). To investigate whether such cooperative
effects correlate with regulation of N-Myc and/or Mad1
protein expression, we used IMR-32 and LA-N-5 cells,
both with very high copy numbers of MYCN (3) and very
high N-Myc expression (Supplementary Fig. S1).
6 Sup-
plementary Table S1
6 shows that IFN-g enhanced RA-
induced differentiation measured as the percentage of
morphologically differentiated cells with neurites as
reported previously (23). Furthermore, in contrast to the
effect of each agent alone, complete growth arrest rather
than only growth retardation was induced by their
combination (data not shown; Supplementary Table S1;
6
ref. 23).
A substantial decrease of N-Myc protein expression, as
determined by immunoprecipitation of
35S-Met–labeled
cell lysates, was observed in both cell lines in response to
the combination RA+IFN-g, whereas RA alone led only to
a modest reduction in LA-N-5 cells (Fig. 1A and B),
as quantitated in Fig. 1D (top). This is in agreement with
previous reports on MYCN mRNA expression in LA-N-5
cells (22, 23). In contrast, only a slight reduction in
MYCN mRNA expression was observed in IMR-32 cells
in response to RA+IFN-g treatment (Fig. 1C and D;
ref. 23).
RA and RA+IFN-g treatment increased the expression of
Mad1 in IMR-32 cells (Fig. 1B and D). In contrast, in LA-N-5
cells, RA+IFN-g and IFN-g alone increased Mad1 expres-
sion (Fig. 1A and D). This may suggest that RA-induced or
IFN-g–induced signals alone may regulate Mad1 expres-
sion differently in different neuroblastoma tumors. The
reason for this difference is unclear but may be due to
deregulation in tumor cells of one or the other of the
diverse signaling pathways that activate Mad1 expression.
The combination of RA+IFN-g is therefore more likely to
result in Mad1 induction than either treatment alone.
The expression of MAD1 mRNA, analyzed in IMR-32 cells
(Fig. 1C and D), followed the same pattern of expression,
suggesting that Mad1 is regulated at the level of transcrip-
tion in response to signaling, as reported previously in
other cells types (9–11). We did not have access to
antibodies of high enough quality for protein analysis of
Mxi1, Mad3, Mad4, or Mnt. Northern blot analysis,
however, did not reveal increased expression of the
corresponding genes in response to treatment with RA,
IFN-g or their combination (data not shown). No major
changes in Max protein and mRNA expression were
observed after the different treatments (Fig. 1).
In summary, the cooperative effects of RA+IFN-g on
differentiation and growth arrest correlated with decreased
N-Myc and increased Mad1 expression.
RA+IFN-; Costimulation Induces Increased N-Myc
ProteinTurnover
Interestingly, Fig. 1 suggests that RA+IFN-g down-
regulates N-Myc protein expression posttranscriptionally,
because the steady-state level of MYCN mRNA was only
slightly affected in IMR-32 cells. We therefore continued to
explore this phenomenon in IMR-32 cells. To investigate
whether RA+IFN-g affects the turnover rate of N-Myc, cells
were pulse labeled with
35S-Met, followed by chase, in
excess cold Met, after which remaining labeled N-Myc was
assessed at various time points. Figure 2A shows that
RA+IFN-g, but not either treatment alone, increased the
speed of N-Myc protein degradation from f40 min to 15 to
20 min half-life, as quantitated in Fig. 2B.
This suggests that RA+IFN-g affects the N-Myc/Max/
Mad network at three levels by decreasing MYCN mRNA
(LA-N-5 cells), increasing MAD1 mRNA, and increasing
the rate of N-Myc protein turnover.
IFN-; Costimulation Results in Reduced N-Myc/Max
Complex Formation
Because N-Myc requires heterodimerization with Max
for its activity, we next studied whether N-Myc/Max
heterodimerization were altered in response to treatment in
6 Supplementary material for this article is available at Molecular Cancer
Therapeutics Online (http://mct.aacrjournals.org/).
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extents RA and IFN-g alone, significantly reduced the
concentration of N-Myc/Max heterodimers (15% of un-
treated cells; Fig. 3B) beyond the effect on total N-Myc
expression (60% of untreated cells; Fig. 1B and D). These
results are in agreement with earlier studies in monocytic
cells, wherein IFN-g treatment in combination with 12-O-
tetradecanoylphorbol-13-acetate was shown to destabilize
Myc/Max heterodimers (25). Unfortunately, we were not
able to measure Mad1/Max complexes in the neuroblasto-
ma cells because they were below the level of detection in
this assay. The slight reduction in total Max protein levels
after the treatments was found to be not significant (Fig. 3).
We conclude that RA+IFN-g in particular decreased the
level of N-Myc/Max complexes in the IMR-32 cells, in part
via increased N-Myc turnover and possibly also via other
posttranslational effects on N-Myc/Max complex forma-
tion and/or stability.
Figure 1. Expression of N-Myc, Mad1, and Max
protein and mRNA in MYCN-amplified neuroblastoma
cells during induced differentiation. LA-N-5 cells
(A, D) and IMR-32 cells (B, C, and D) were treated
with 1 Amol/L RA, 200 units/mL of IFN-g, or their
combination for 3 days as indicated. A and B, cells
were pulse labeled with
35S-Met as described in
Materials and Methods, after which cell lysates were
immunoprecipitated with anti-Mad1 (C19), anti–N-
Myc (AB-1), or anti-Max (C17) antibodies and
analyzed with SDS-PAGE. An equal number of TCA-
precipitable counts were used for each sample. C,
total RNA was prepared from the cells, and the mRNA
expression of indicated genes was determined by
Northern blot analysis as described in Materials and
Methods. GAPDH was used as a reference gene. An
equal amount of total RNA was loaded per well.
D, quantitation of protein (top) and mRNA (bottom)
expression of the indicated genes/gene products was
done using a Phosphor Imager. The results are based
on at least two independent biological experiments
and are presented as percentage of the signal
obtained from untreated cells. The mRNA expression
values have been normalized to those of GAPDH.
*P < 0.05, **P V 0.01 relative to untreated cells
based on Student’s t test. Values for RA-treated versus
RA+IFN-g–treated cells are indicated by brackets.
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cy at the ODC Target Gene Promoter af ter RA+IFN-;
Costimulation
We next investigated N-Myc, Mad1, and Max occu-
pancy of the ODC gene, a target for both N-Myc and
Mad (26–28), in vivo by performing quantitative chro-
matin immunoprecipitation assays. As shown in Fig. 4,
a-N-Myc and a-Max antibodies readily immunoprecipi-
tated an E-box–containing fragment of the ODC pro-
moter from unstimulated IMR-32 cells, whereas only a
weak signal was obtained using a-Mad1 antibodies.
Neither preimmune control antibodies nor any immuno-
precipitation of the non–E-box, but MEF2-binding,
region of the Fas ligand gene, used as a reference, gave
signals above background. After RA+IFN-g treatment,
the N-Myc signal decreased to f40% of untreated
cells, whereas binding of Mad1 increased f2.5-fold.
RA alone also decreased and increased N-Myc and Mad1
associations with promoter, respectively, but to lesser
extents. The association of Max did not change signifi-
cantly after the treatments. RA and RA+IFN-g–induced
differentiation also resulted in a decreased acetylation
of histone H4 in the same region of the promoter, indi-
cative of alteration of the chromatin structure into a
more repressed state during the process, a hallmark of
decreased Myc and/or increased Mad activity at target
promoters.
In conclusion, our results suggest that the ODC promoter
occupancy shifted from N-Myc/Max predominance in
untreated cells toward Mad1/Max predominance after
RA+IFN-g–induced and, to a lesser extent, RA-induced
differentiation, resulting in a more condensed chromatin
structure at the promoter.
The ODC and hTERT N-Myc/Mad1Target Genes Are
Repressedin Response to RA+IFN-; Costimulation
We next investigated whether the treatments affect the
expression of N-Myc/Mad1 target genes. mRNA expres-
sion of the ODC and hTERT target genes of N-Myc
and Mad (14, 26–30) was therefore measured in IMR-32
cells by quantitative reverse transcription–PCR. As
s h o w ni nF i g .5 ,ODC and hTERT expression was reduced
to various degrees in response to RA or IFN-g alone.
However, RA+IFN-g in combination led to strong rep-
ression of ODC and hTERT expression to around 20% of
control.
Taken together, these results suggest that the combined
treatment with RA+IFN-g regulates expression of N-Myc
and Mad1, as well as N-Myc/Max heterodimerization,
resulting in a shift from N-Myc/Max toward Mad1/Max
occupancy at N-Myc/Mad1 target promoters. This in turn
results in altered chromatin structure and transcriptional
repression.
Figure 3. N-Myc/Max complex formation in MYCN-amplified IMR-32
cells during induced differentiation. A, the cells were treated as described
in Fig. 1, after which unlabeled cell lysates were immunoprecipitated with
anti-Max (C17) antibodies under low stringency conditions. Western blot
analysis was then done using anti–N-Myc (AB-1) to visualize coimmuno-
precipitated N-Myc or anti-Max (C17) antibodies. Equal amounts of protein
were loaded per well. B, the chemiluminescent signals in (A) were
quantitated using a Fujifilm LAS-3000. The results are presented as
percentage of the signal obtained in untreated cells. **P V 0.01.
Figure 2. RA+IFN-g induces increased N-Myc turnover in MYCN-
amplified IMR-32 cells. A, cells were stimulated as above with the
indicated inducers, thereafter pulse labeled with
35S-Met, chased in
excess cold Met for the indicated time points, and analyzed for remaining
labeled N-Myc protein by immunoprecipitation. B, the signals were
quantitated as described in Fig. 1 and plotted as percentage remaining
protein (note the logarithmic scale) with chase time.
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IFN-g is reported to potentiate RA-induced growth
retardation and differentiation in several MYCN-amplified
neuroblastoma cell lines (20–23). We show here that this
correlates with reduced and increased expression of N-Myc
and Mad1, respectively. In IMR-32 cells, the drop in N-Myc
protein in response to RA+IFN-g is much more pro-
nounced than the slight reduction in MYCN mRNA
expression, and we show that this is the result of increased
turnover of the N-Myc protein. Recently, we have made
similar observations in v-myc–transformed U-937 mono-
blastic cells, wherein combined IFN-g and 12-O-tetradeca-
noylphorbol-13-acetate treatment results in ubiquitin/
proteasome-mediated degradation of v-Myc.
7 Elucidating
the mechanism by which combined IFN-g treatments
increase Myc turnover will require further investigation.
In contrast, Mad1 seems to be regulated at the mRNA level,
as has been shown in other cell systems (9–11). In addition,
RA+IFN-g treatment and, to a lesser extent, RA and IFN-g
alone seemed to regulate N-Myc/Max heterodimerization,
suggesting that these signals regulate N-Myc activity
posttranslationally at different levels. This is also reminis-
cent of the situation in v-myc–transformed U-937 cells,
wherein 12-O-tetradecanoylphorbol-13-acetate+IFN-g
treatment inhibits v-Myc DNA binding and heterodimeri-
zation with Max (25, 31). Our present results further show
that N-Myc/Max complexes were exchanged by Mad1/
Max complexes at the ODC target promoter in RA+IFN-g–
differentiated and, to a lesser extent, RA-differentiated
cells. This correlated with deacetylation of histone H4 in the
same region of the promoter, suggesting that RA and
RA+IFN-g induces a repressive chromatin state by
increased recruitment of histone deacetylases and/or
reduced recruitment of histone acetyltransferases through
Mad1 and N-Myc, respectively. These results are in good
agreement with previously reported exchanges of c-Myc/
Max to Mad1/Max complexes on the CYCLIND2 and
hTERT target promoters during differentiation of human
myeloid HL60 cells (13, 14). Finally, our results show that
RA+IFN-g represses expression of the N-Myc/Mad1 target
genes ODC and hTERT much more efficiently than either
agent alone, thus demonstrating a functional consequence
of the cooperative signaling. Our results suggest that both
the down-regulation of N-Myc and the up-regulation of
Mad1 in response to RA+IFN-g treatment contribute to this
shift in N-Myc/Max/Mad1 promoter occupancy and
repression of promoter activity. Because RA alone accom-
plished H4 deacetylation at least as well as RA+IFN-g,i ti s
likely that also other aspects of Myc-regulated transcription
are affected by the combined treatment.
Apart from the N-Myc/Max/Mad network, it is likely
that RA and IFN-g also affects other regulators that may
contribute to the differentiation of MYCN-amplified neu-
roblastoma cells. For instance, the cyclin-dependent kinase
inhibitor p21Cip1 is up-regulated by IFN-g via the Janus-
activated kinase–STAT pathway in various cells (32). In
addition, both p21Cip1 and p27Kip1 have been shown to be
up-regulated during RA treatment of neuroblastoma and
Figure 4. N-Myc/Mad1 target promoter occupancy in vivo during IFN-g–
enhanced differentiation of MYCN-amplified IMR-32 cells. IMR-32cells were
stimulated with RA, IFN-g,o rR A + I F N - g or were left untreated, after which
quantitative chromatin immunoprecipitation assay was done using the
indicated antibodies. Quantitative PCR primers specific for an E-box–
containing region of the ODC target gene promoter (columns 1-4 in each
panel) or the non–E-box MEF2-binding region of the FasL gene (column 5 in
eachpanel)were used.Resultsare presented as DNA recoveryaspercentage
of total chromatin input and are based on at least two independent biological
experiments. *P <0 . 0 5 ,* * P V 0.01.
7 Bahram et al. (in preparation).
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p27Kip1 have been shown to cooperate in promoting
granulocytic differentiation and in regulating self-renewal/
differentiation of hematopoietic stem cells (37, 38). IFN-g
was recently shown to restore promyelocytic leukemia
protein nuclear body formation in neuroblastoma cells (39).
Because promyelocytic leukemia protein interacts with
Sin3-containing corepressor complexes and is required for
the transcriptional repressor function of Mad1 (40),
promyelocytic leukemia protein may contribute to the
observed repression of N-Myc/Mad1 target genes in
response to IFN-g costimulation once Mad1/Max com-
plexes have bound to their target promoters. Furthermore,
recent reports suggest that promyelocytic leukemia protein
may also regulate c-Myc function (41, 42).
The concept of ‘‘differentiation therapy’’ for cancer has
gained considerable interest in recent years. Today, RA is
used successfully in therapy for patients with acute
promyelocytic leukemia (43) and treatment of neuroblas-
toma patients with high-dose 13-cis RA treatment after
myeloablative therapy and autologous bone marrow
transplantation have shown encouraging results (1, 19,
44). The synergistic effects of RA+IFN-g for differentiation
of MYCN-amplified neuroblastoma cells, shown in vitro
(20, 22, 23) as well as in vivo by inhibition of tumor
formation of LA-N-5 neuroblastoma cells injected in nude
mice (21), are further substantiated here by the demonstra-
tion of direct effects on the N-Myc/Max/Mad1 network.
This suggests that RA+IFN-g combination therapy may be
of therapeutic value for treatment of patients with MYCN-
amplified neuroblastomas. In this respect, it is encouraging
that even transient inactivation of c-Myc in c-Myc–driven
murine tumors is sufficient for permanent tumor regression
(17). The fact that both RA and IFN-g have been used
already as single agents in clinical trials for neuroblastoma
therapy (19, 45) and that their combination synergistically
inhibits neuroblastoma tumor growth as xenografts in mice
(21) should facilitate this approach. IFN-g acts synergisti-
cally with a number of signal pathways, for instance, in the
induction of apoptosis by Fas-L and TRAIL in neuroblas-
toma cells (46–49). It would be interesting to study if IFN-g
can cooperate also with other retinoids, such as fenretinide
(4HPR), which, unlike at-RA and 13-cis-RA, induces
apoptosis rather than differentiation and has also been
used in clinical trials in neuroblastoma (44). Although the
clinical use of RA and IFN-g may also have limitations due
to side effects and development of drug resistance, insights
into the precise molecular mechanisms by which IFN-g,
RA, and other agents cooperatively regulate the N-Myc/
Max/Mad1 network will be essential for the development
of novel therapeutic strategies, including new drug design
for treatment of patients with high-risk neuroblastoma with
MYCN amplification.
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Abstract 
 
The c-myc oncogene is tightly regulated at multiple levels, including 
ubiquitin/proteasome-mediated turnover of its gene product. We 
have shown previously that interferon (IFN)- stimulates monocytic 
differentiation by antagonizing Myc function through post-
translational mechanisms. Here we show that IFN- signaling inhibits 
phosphorylation of Myc at Ser-62, resulting in increased 
ubiquitylation and proteasome-mediated turnover. The latter occurs 
independent of the phosphorylation site at Thr 58 and the two E3 
ubiquitin ligases Fbw7/hCdc4 and Skp2 that previously have been 
implicated in Myc turnover. Our data suggest that cyclin E/cyclin-
dependent kinase 2 (Cdk2) acts as a Ser-62 kinase both in vitro and in 
vivo, and that the inhibition of Ser-62 phosphorylation and increased   2
Myc turnover in response to IFN- signaling is mediated through 
induction of the Cdk inhibitor p27Kip1. We further show that IFN- 
treatment results in reduced association of total and in particular 
phosphorylated Myc at target promoters in cells, correlating with 
reduced histone H4 acetylation and repression of Myc target genes. 
In conclusion, our results suggest that p27Kip1 and c-Myc promotes 
ubiquitylation and degradation of each other in a mutually 
antagonistic manner in response to signaling. This finding may 
potentially be of therapeutic relevance for tumors with deregulated 
Myc-expression. 
Introduction 
The The c-myc proto-oncogene encodes a transcription factor that regulates 
a large number of genes involved in numerous fundamental cellular 
processes, including cell cycle progression, cell growth, apoptosis and 
metabolism [1, 2]. In addition, c-Myc has recently been reported to 
participate in non-transcriptional regulation of DNA replication [3]. 
Deregulated expression of myc family genes has been implicated in the 
development of many types of human cancers. The basic region helix-loop-
helix/leucine zipper (bHLHZip) motif in the C-terminus of c-Myc 
mediates dimerization with the bHLHZip protein Max, which enables it to 
bind specifically to E-box DNA elements in promoters of target genes [1, 2, 
4]. The N-terminus contains a transactivation domain (TAD), which 
includes two highly conserved regions known as Myc boxes 1 and 2 (MBI 
and MBII). The TAD and the C-terminus mediate interactions with a 
number of cofactors important for transcription regulation by Myc, 
including TRRAP, TIP48/TIP49, Miz-1, the Mediator, Skp2, the APIS 
complex, CBP/p300, HectH9 and P-TEFb [1, 2].  
 
Expression of c-Myc is tightly regulated at multiple levels including rapid 
protein turnover via the ubiquitin (Ub)-proteasome pathway. Two E3 Ub 
ligases mediating c-Myc turnover, SCFSkp2 [5, 6] and SCFFbw7/Cdc4 [7, 
8], have been identified. A third E3-ligase, HectH9, is involved in non-
proteolytic regulation of c-Myc [9]. Skp2- and HectH9-directed 
ubiquitylation of Myc occurs as an integrated coactivator function for Myc-
regulated transcription [5, 6, 9]. The Fbw7/Cdc4 pathway on the other 
hand seems to work entirely as a negative regulator of Myc [7, 8]. Efficient 
turnover of Myc requires phosphorylation at Thr-58 in MBI, a residue that 
is mutated in a high percentage of human Burkitt’s lymphomas and in 
several avian retroviral (v)-myc genes and is recognized by Fbw7/Cdc4. 
Mutation of Thr-58 results in decreased ubiquitylation and stabilization of 
Myc. These mutants still promote cell proliferation but are deficient in 
apoptosis, resulting in enhanced transforming potential [10]. 
Phosphorylation of Thr-58, mediated by glycogen synthase kinase 3 (GSK-
3), requires “priming” phosphorylation at Ser-62 (for reviews see [11, 12]. 
The latter has been suggested to be targeted by Erk and to stabilize Myc   3
[13]. Efficient ubiquitylation by Fbw7/Cdc4 seems to require phospho-
Thr-58-dependent and Pin1-assisted removal of the Ser-62 phosphorylation 
by PP2A [14], a process that was recently shown to be further regulated by 
the deubiquitylating enzyme Usp28 [15] and the CIP2A regulator of PP2A 
[16].  
Extra- and intracellular signaling also contribute to this complex 
regulation of c-Myc. Skp2-induced degradation is regulated during the cell 
cycle [6], while the Fbw7/Cdc4 pathway is regulated for instance by Ras- 
and PI3-kinase/Akt signaling [2]. We showed previously that the v-Myc 
protein of the avian OK10 retrovirus, which like c-Myc in many human 
Burkitt’s lymphomas carries a stabilizing mutation at Thr-58, blocked TPA-
induced differentiation in the human monocytic U-937 model system. 
However, in combination with IFN-, TPA-induced differentiation and G1 
arrest were restored (Figure 1A) [17]. We found that IFN- destabilized 
Myc:Max complexes, which correlated with reduced overall Myc 
phosphorylation [18]. The aim of the present study was to further elucidate 
the mechanism(s) by which IFN- inhibits Myc function. We find that 
IFN- induces expression of the Cdk-inhibitor p27Kip1 (here referred to as 
p27), which was shown to control Myc activity and stability by reducing 
Ser-62 phosphorylation. Further, we identified cyclin E/Cdk2 as a major 
Ser-62 kinase and the target of p27 activity. Importantly, IFN- treatment 
resulted in reduced Ser-62 phosphorylation of Myc at promoters, loss of 
Myc from chromatin, and repression of Myc target genes. These findings 
shed new light on the regulation and function of Myc, but also points out 
new ways by which cyclin E/Cdk2 and p27 influence gene expression 
during the cell cycle. 
 
Results 
IFN- increases degradation and ubiquitylation of Myc 
Addressing possible mechanism(s) for IFN--induced anti-Myc activity, we 
first investigated v- and c-Myc protein stability. v-Myc runs slightly faster 
than endogenous human c-Myc in SDS-PAGE gels as demonstrated in v-
Myc-expressing U937-myc6 cells and parental U-937-GTB cells (Figure 
1B), in agreement with previous observations [18]. U-937-myc6 cells were 
treated with or without IFN-+TPA for 24 hrs and pulse/chased with 35S-
Met (Figure 1C, D). In untreated control cells, endogenous c-Myc had an 
expected short half-life of 30 minutes. v-Myc exhibited a half life of 
approximately 160 minutes due to the Thr-58 mutation [19]. IFN-+TPA 
treatment increased both c- and v-Myc turnover from approximately 30 to 
20 and 150 to 50 minutes, respectively (Figure 1D, note the logarithmic 
scale on the Y-axis). The non-linear slopes of the curves might reflect the 
existence of different subpopulations of Myc proteins with different stability, 
as reported [20]. TPA treatment alone did not alter c-Myc or v-Myc   4
stability (data not shown), while IFN- alone had similar effects on Myc 
turnover as the combination IFN-+TPA (data not shown, see below).   
IFN-+TPA increased c- and v-Myc turnover also in complex with Max 
(data not shown). IFN- enhanced c-Myc turnover also in Colo-320 colon 
carcinoma cells with amplified c-myc (Figure 1D, right panel and 
Supplementary Figure 1A) and human 2fTGH fibrosarcoma cells (Figure 
1E, left panel and Supplementary Figure 1 B). Thus IFN- increases the 
turnover rate of c-Myc in several cell types, and notably also of v-Myc with 
a stabilizing Thr-58 mutation. 
 
Many of the biological effects of signaling via the IFN- receptor are 
mediated through activation of the JAK/STAT1 pathway [21]. Indeed IFN-
 treatment did not affect Myc turnover in the 2fTGH sublines U3A and 
U4A that lack STAT1 and JAK1, respectively, indicating that both STAT1 
and JAK1 are required for IFN--induced Myc degradation (Figure 1E and 
Supplementary Figure 1B). The increased turnover rate in 2fTGH cells was 
accompanied by increased c-Myc ubiquitylation (Figure 1F). IFN--
induced degradation of c- and v-Myc in U-937-myc6 cells occurs via the 
proteasome since it was sensitive to the proteasome inhibitor LLnL (Figure 
1G). 
 
No difference in the subcellular localization of a c-Myc-GFP fusion 
protein was observed in response to IFN- (Figure 2A). The same was true 
for c-Myc complexed with Max as determined by Bimolecular Fluorescence 
Complementation (BiFC) [22]  (Figure 2B). The BiFC and Myc-GFP 
fluorescence intensity was reduced with similar kinetics after IFN--
stimulation, reflecting increased degradation (Figure 2A-C). Increased YFP 
fluorescence intensity of a c-Myc/Ub BiFC fusion pair, indicative of 
increased c-Myc ubiquitylation, was observed in IFN- stimulated 
compared to non-stimulated cells after proteasome inhibition, (Figure 2D 
and E). The fluorescence seemed to be predominantly localized to the 
nucleoli, suggesting that this could be a site of rapid Myc turnover.  
IFN- reduces phosphorylation at Ser-62 and induces 
degradation of Myc in a Ser-62-dependent manner 
The stability of Myc is regulated by phosphorylation at Thr-58 and 
Ser-62 (Figure 3A). We used phospho-specific c-Myc antibodies to 
determine whether IFN- affected phosphorylation at these two sites. 
Figure 3B demonstrates that both the phospho-S62 and, to a 
somewhat lesser extent, the phospho-T58/S62 antibodies recognizes 
singly phosphorylated Ser-62 as determined by expression of wt c-
Myc and a T58A mutant, while none of the antibodies recognized 
S62A and T58A/S62A mutants (Figure 3B). Since Thr-58 
phosphorylation requires priming phosphorylation of Ser-62 (Figure 
3A) the phospho-T58/S62 antibody will not recognize the S62A 
mutant even though it has intact Thr-58.    5
Immunoblotting of U-937 cell extracts with pan-Myc antibodies 
in the mini-gel system applied in Figure 3C shows that the v-Myc 
protein runs closer to c-Myc than in the longer gel system used in 
Figure 1B above. IFN- treatment of U-937-myc6 cells resulted in a 
reduction of v-Myc Ser-62 phosphorylation (since v-Myc carries a 
Thr-58 mutation) (Figure 3D). In these experiments cells were 
treated with the proteasome inhibitor MG115 prior to harvest to 
avoid differences in total Myc levels, e.g. due to different sensitivity 
to Fbw7/Cdc4-mediated degradation. Endogenous c-Myc levels 
were downregulated by these treatments due to transcriptional shut 
off of the c-myc gene [18].  
 
To examine whether Ser-62 is essential for IFN--induced Myc 
degradation, the turnover of T58A and S62A Myc mutants were 
studied by blocking de novo protein synthesis with cycloheximide 
(CHX) in 2fTGH cells. IFN- increased the rate of degradation of 
Myc-T58A but not of Myc-S62A (Figure 3E and Supplemental 
Figure 1C). Taken together these results suggest that IFN- treatment 
decreases Myc phosphorylation at Ser-62 and that IFN--induced 
Myc degradation is Ser-62 dependent. 
Cdk2 phosphorylates Myc at Ser-62 in vivo and in vitro 
Reduced Myc Ser-62 phosphorylation in response to IFN- treatment 
could be the result of inhibition of a kinase and/or stimulation of a 
phosphatase. To identify relevant kinases, U2OS cells transfected with c-
Myc-T58A (to ensure exclusive study of Ser-62 phosphorylation) were 
treated with kinase inhibitors. To avoid possible effects on the turnover of 
Myc-T58A, the cells were treated with the proteasome inhibitor MG115. 
The Cdk2/Cdk1 inhibitor roscovitine [23] most efficiently reduced Ser-62 
phosphorylation (Figure 4A). Since kenpaullone, which inhibits Cdk1 more 
efficiently than Cdk2, and PD98059, an Erk inhibitor, were not as effective 
as roscovitine, we considered Cdk2 as a candidate kinase. Indeed bacterially 
expressed GST-Myc was a substrate of cyclin E/Cdk2 and to a lesser extent 
of cyclin A/Cdk2 when Ser-62 was present (Figure 4B). We concluded 
from these results that Cdk2 phosphorylates Myc at Ser-62 in vitro and that 
the Cdk2/Cdk1 inhibitor roscovitine inhibits Ser-62 phosphorylation in 
vivo. 
 
To further investigate whether Cdk2 could be an in vivo Ser-62 kinase 
regulating c-Myc during the cell cycle, we arrested U-937 cells in early S-
phase by aphidicolin (which inhibits DNA polymerases) and treated the cells 
with MG115. Phosphorylation of Ser-62 and Thr-58/Ser-62 was readily 
observed in these cells (Figure 4C). Importantly, phosphorylation was 
strongly reduced in response to roscovitine, suggesting that Cdk2 is a major 
Ser-62 kinase during early S-phase. In addition, roscovitine increased the 
rate of degradation of both c- and v-Myc in U937-myc6 cells (Figure 4D   6
and Supplementary Figure 1D). Thus roscovitine mimics IFN--induced 
degradation of c- and v-Myc, further implicating Cdk2-dependent 
phosphorylation of Ser-62 in Myc turnover. Our findings support a role of 
Ser-62 phosphorylation in Myc stabilization as suggested previously [13]. 
However this modification can also enhance turnover by stimulating Thr-58 
phosphorylation, which might explain why IFN- and roscovitine 
destabilize Thr-58 mutants more efficiently than wt Myc (Figure 1D and 
4D).. 
IFN- controls Myc phosphorylation and stability by inducing 
p27Kip1  
We next investigated whether IFN- affects Cdk2 activity in U-937-myc6 
cells. In response to IFN-+TPA, Cdk2 activity was strongly reduced 
within 4 hrs of treatment as determined by in vitro kinase assays (Figure 
5A). In addition reduced phosphorylation of the retinoblastoma protein 
pRb, a cyclin E/Cdk2 substrate was observed (data not shown). IFN-
+TPA and IFN- treatment both inhibited Cdk2 activity, while TPA 
alone had minor effects (data not shown). The Cdk2 inhibition correlated 
with increased p27Kip1 protein expression, which was elevated by 2 hrs of 
stimulation and thereafter continued to rise gradually (Figure 5B). This was 
accompanied by increased p27:Cdk2 complex formation, while the steady 
state levels of Cdk2 were unaltered (data not shown). Also the expression of 
p21Cip1 increased albeit transiently (Supplementary Figure 2A). In parallel 
Ser-62 phosphorylation of both c- and v-Myc was reduced by 4 hrs and 
more prominently by 8 hrs (Figure 5C). Myc turnover began to increase 
already within 4 hrs and was further accelerated by 8 hrs of IFN-+TPA 
treatment (Figure 5D and Supplementary Figure 1E). Myc degradation 
therefore correlated kinetically with Myc dephosphorylation, inactivation of 
Cdk2 and upregulation of CKIs in response to IFN-. To rule out that 
these IFN- effects were due to indirect effects on the cell cycle, the cell 
cycle distribution was analyzed in response to IFN-+TPA or roscovitine 
treatments (Supplementary Figure 2B). Although G1 accumulation was 
indeed observed at 24 hours after the treatments as previously reported [17] 
(Supplementary Figure 2B and data not shown), none of the treatments 
altered the cell cycle distribution at early time points, when the effects on 
Myc phosphorylation and stability were first observed. The IFN--induced 
reduction of Myc-Ser-62 phosphorylation might also be explained by 
upregulation of the serine/threonine phosphatase PP2A [14]. However, no 
noticeable changes in PP2A activity occurred after IFN-+TPA treatment 
(Supplementary Figure 2C). In conclusion, these results suggested 
inactivation of Cdk2 by p27 as a key regulatory step in the reduced Myc-
Ser-62 phosphorylation and the increased Myc degradation in response to 
IFN- treatment.   7
Ser-62-dependent Myc stability is regulated by p27 independent 
of SCF
Fbw7/Cdc4
The role of p27 in Myc phosphorylation and turnover was analyzed 
further by enforced expression of p27. Coexpression of p27 reduced 
phosphorylation of both wt Myc and Myc-T58A (Figure 6A). A T58/S62A 
double mutant was used as a negative control. Further, p27 reduced the 
levels of wt Myc and Myc-T58A, but not of a Myc-S62A mutant (Figure 
6B). Thus p27 mimicked the effects of IFN-. Furthermore IFN--induced 
degradation of c-Myc was p27-dependent since IFN- treatment did not 
affect the steady state levels of Myc in p27-/- MEF cells (Figure 6C).  
 
Next we addressed whether the SCFFbw7/Cdc4 E3 Ub ligase complex, 
which previously has been shown to operate via MB1, was involved in p27-
induced degradation of c-Myc. As expected, c-Myc was stabilized in 
Fbw7/Cdc4-/- HCT116 cells (Figure 6D and Supplementary Figure 1F). 
However, ectopic p27 expression induced increased c-Myc turnover even 
in the absence of Fbw7/Cdc4, indicating that this F-box protein is not 
relevant. Since Fbw7/Cdc4-mediated ubiquitylation of Myc is phospho-
Thr-58-dependent [7, 8], this result is also in agreement with the ability of 
p27 to induce degradation of Myc-T58A (Figure 6B).  The SCFSkp2 E3 
ligase, which does not operate via MB1 [5, 6], also did not seem to 
participate in p27-induced Myc degradation (data not shown), suggesting 
that a novel E3 ligase is involved. 
IFN- treatment reduces phosphorylated and total Myc at 
chromatin and represses Myc-driven transcription of target genes 
To study if IFN- affected the status of Myc at target promoters, 
quantitative chromatin immunoprecipitations (Q-ChIP) was performed 
using phospho-Myc and pan-Myc Ab and primers for the cyclin D2 
promoter [24]. The presence of total and in particular phosphorylated Myc 
decreased substantially at the promoter in response to IFN- (Figure 7A, 
upper panel). Acetylation of histone H4, a well-established function 
associated with Myc, decreased after treatment (Figure 7A, lower panel). 
The same Abs gave very low signals from the non-E-box region of the Fas 
ligand gene promoter used as a reference gene, and preimmune serum gave 
only background signals.  
 
To examine the effect of IFN- on Myc-driven transcription, a minimal 
tk promoter driven by four E-boxes in front of a luciferase reporter, 
m4mintk-Luc, was transfected into U-937-myc6 cells. IFN- and IFN-
+TPA treatment strongly repressed the reporter activity (Figure 7B, upper 
panel). Similar results were obtained with an a-prothymosin Myc target 
promoter/reporter construct, containing two Myc-binding E-boxes in the 
first intron (Figure 7B, lower panel). Constructs lacking (mintk-Luc and a-
proTDE) or with mutated E-boxes were insensitive to IFN- treatment.   8
We next measured the mRNA expression of three endogenous Myc 
target genes, hTERT and ODC, which are activated by Myc, and p21Cip1, 
which is repressed by Myc, using RT-qPCR. IFN-+TPA treatment 
substantially decreased the expression of hTERT and ODC and strongly 
induced the expression of p21 (Figure 7C). These results are consistent with 
the ChIP results and suggest that IFN- represses Myc-regulated 
transcription by reducing Myc association with chromatin. 
 
Discussion 
The function and stability of the oncoprotein Myc is controlled by 
posttranslational modifications. Here we uncovered a new mode of 
regulation involving phosphorylation by cyclin E/Cdk2 during the cell 
cycle, in addition to the previously described Erk kinase that phosphorylates 
Ser-62 in response to serum, Ras and stress signaling [13, 25].  We further 
demonstrate signal-mediated regulation of this interaction by the cyclin-
dependent kinase inhibitor p27. 
 
What is the role of cyclin E/Cdk2-mediated phosphorylation of Ser-62? 
Since the Cdk2/Cdk1-inhibitor roscovitine accelerates Myc turnover 
(Figure 4), one role of Ser-62 phosphorylation could be to stabilize Myc, 
thereby increasing its time of association with chromatin. The phosphate 
group at Ser-62 could for instance inhibit binding of an as yet unidentified 
E3 ligase to Myc, either directly or by recruiting a third protein that 
prevents this binding. The regulation of Myc stability via Ser-62 
phosphorylation is, however, complex, since it “primes” Thr 58 
phosphorylation and thereby promotes turnover via the 
GSK3/Fbw7/Cdc4-pathway (Figure 3A). In agreement with this, the 
relative effect of roscovitine treatment on Myc turnover is more striking for 
v-Myc, which carries a Thr 58 mutation.     
 
The identification of cyclin E/Cdk2 as Ser-62 kinase was based on 
sensitivity to small molecule kinase inhibitors and to p27 in vivo, on in vitro 
kinase assays, and on the correlation of Ser-62 phosphorylation and Cdk2 
activity during the cell cycle. We did observe some reduction in Ser-62 
phosphorylation upon inhibition of Mek1, an upstream activator of Erk, 
which is compatible with Erk being a Ser-62 kinase [13], although this 
reduction was not as efficient as after inhibition of Cdk2/Cdk1. This, 
however, could be related to cell type or culture conditions. Recently, 
Cdk1 was suggested to phosphorylate Ser-54 of N-Myc, the equivalent 
amino acid of Ser-62 in c-Myc, during mitosis in neural precursor cells 
undergoing differentiation [26]. Even though more selective inhibitors of 
Cdk1 did not have as strong effects as roscovitine in our system, it is possible 
that Cdk1 plays a role in phosphorylating c-Myc during mitosis. The 
fraction of mitotic cells would have been rather low under our experimental   9
conditions and thus possible CDK1-specific effects might have remained 
undetected.  
 
An important finding presented here is that growth inhibitory signaling 
by IFN- can interfere with Myc function, an activity that seems to be 
linked to inhibition of Ser-62 phosphorylation (Figures 3 and 5). This 
correlates with inhibition of Cdk2 activity and IFN--induced expression of 
p27 (Figure 5). Further, ectopic expression of p27 inhibited Ser-62 
phosphorylation (Figure 6), suggesting that IFN- can impinge on the 
Myc/cyclin E/Cdk2 cooperativity by inducing the expression of p27. This 
coincides with reduced Myc phosphorylation, loss of Myc, and reduced 
histone acetylation at the promoter (Figure 7). In addition, IFN- repressed 
Myc-regulated transcription from target promoters in an E-box-dependent 
manner in agreement with the chromatin binding data (Figure 7).  
 
Our results further demonstrate that IFN- stimulates ubiquitylation and 
degradation of Myc in a Thr-58-independent but Ser-62-dependent 
manner (Figure 1, 3 and 5), and that p27 is both required and sufficient for 
this process (Figure 6). Ser-62/cyclin E/Cdk2 therefore seems to regulate at 
least two distinct pathways that control Myc ubiquitylation and degradation, 
one involving Thr-58/GSK3/Fbw7/Cdc4, the other a signal-mediated 
pathway engaging p27 that is independent of both Fbw7/Cdc4 and Skp2 
and implicates an as yet unidentified E3 Ub ligase. The identification of this 
E3 ligase will be an important task for the future.  
 
It is unclear whether the loss of Myc from chromatin in response to 
IFN- treatment is due to turnover at target promoters, as has been 
proposed for Skp2-induced Myc turnover [6], or whether degradation 
occurs independent of DNA. From the fluorescence studies using Myc-GFP 
fusions and BiFC, there was, however, no clear evidence that Myc or 
Myc:Max were redistributed within the cell in response to IFN- treatment 
prior to degradation (Figure 2). In our previous studies, we concluded that 
IFN-g destabilized Myc:Max complexes and thereby reduced the DNA-
binding capacity of Myc [18]. Of interest is a report that suggested enhanced 
c-Myc recruitment to the g-GCS promoter as a consequence of Erk-
mediated Ser-62 phosphorylation in response to oxidative stress [25]. 
Reduced Ser-62 phosphorylation could therefore have the opposite effect. 
It is, however, not entirely clear from this work or from our previous study 
[18] whether the increased binding of c-Myc to DNA reflects increased 
Myc stability and thus higher Myc levels or whether Ser-62 phosphorylation 
modulates the recruitment or the affinity to DNA. This remains to be 
determined. 
 
Myc is known to promote Cdk2-mediated degradation of p27 in 
response to proliferative signals, thereby promoting cell cycle progression. 
Here we demonstrate that p27 in turn is able to regulate Myc in response to 
anti-proliferative signals such as IFN- by inhibiting Cdk2. It is notable that   10
this negative regulation of c-Myc also applies to the stabilized Myc with 
mutated Thr-58, which is common in Burkitt’s lymphoma. Thus our 
findings establish an additional link between Myc and cyclin E/Cdk2. It is 
worth mentioning that the function of Mad1, a Myc antagonist, cooperates 
with p27 to promote granulocytic differentiation [27] and is repressed by 
cyclin E/Cdk2 [28], further supporting the intimate relationship of the 
Myc/Max/Mad network with cyclin E/Cdk2/p27 in the control of the cell 
cycle. While Myc and cyclin E are well established oncoproteins, a role of 
p27 in tumor formation has been postulated but has only become apparent 
recently [29]. Thus the Myc/Cyclin E/Cdk2/p27 axis may provide a target 
for intervention. Indeed, many cytokines or other agents that stimulate p27 
expression [30] as well as specific inhibitors of Cdk2/Cdk1 [31, 32] are 
already in clinical use or under development, and could in the light of our 
new findings be of relevance for combined multi-drug therapies for patients 
with aggressive Myc–driven tumors. 
 
Experimental procedures 
Cell culture and transfections  
Cells were cultured in RPMI-1640 (U-937, 2fTGH, Fbw7/Cdc4-/-
HCT116) or Dulbecco’s modified essential medium (DMEM) (Cos 7, HeLa 
and U2OS) medium supplemented with 10% fetal calf serum and 
antibiotics. The U937 clone myc6 expresses the OK10 v-myc gene [17]. 
Exponentially growing U-937 cells (10
5/mL) were treated with 1.6 x 10
8 
mol/L TPA (Sigma, St Louis, MO) and/or 100 U/mL IFN- (1000U/ml 
for 2fTGH cells) (generously provided by Dr G.R. Adolf, Ernst-Boehringer 
Institute, Vienna, Austria). To block cells in S-phase, 10 g/ml aphidicolin 
was applied for 16-24 hrs. For gene transfer, subconfluent cells were 
transfected using FuGENE6 (Boehringer Mannheim) or Superfect (Qiagen) 
according to manufacturers instructions, or were electroporated as described 
[18]. The following plasmids were used in transfections: CMV-Myc, CMV-
MycT58A and CMV-MycT62A, pCIneo-p27, pCMV-cyclin E and 
pCMV-Cdk2. In luciferase assays the m4mintk-Luc, mintk-Luc, -proT-
Luc, -proTE and pEQ176 (-gal) reporter plasmids were used.  
Protein, mRNA and ChIP assays 
Pulse chase, immunoprecipitation and immunoblot analyses were performed 
as described previously [6, 18]. The following antibodies were used in these 
assays: -c-Myc (C33X), -c-Myc (N262), -Max (C-17X), -9E10HRP, 
-p27 (C-19), -cyclin A (BF683X), -cyclin E (C-19), -Cdk2 (D-12), 
(all from Santa Cruz Biotechnology Inc. (SCB, Santa Cruz, CA, USA), 
phospho-Thr-58/Ser-62 specific Ab (Cell Signaling), phospho N-Myc 
(S54) Ab A300-206A, which also recognizes c-Myc phospho-Ser-62   11
(Figure 3B) (kindly provided by Dr. A-M. Kenney and purchased from 
Bethyl Laboratories Inc), - PP2A (05-421, Upstate), -Flag M2 (Sigma), 
-Ub clone FK2 (Affiniti) and IG-C rabbit pan-Myc antiserum. 
 
The proteasome inhibitor Z-leu-leu-leu-H aldehyde (MG115) (Peptides 
International) and N-acetyl-leucinyl-leucinyl-norleucinal-H (LLnL) (Sigma) 
or vehicle were added to the cells 2 hrs before harvest at a concentration of 
50 μM. Roscovitine (Sigma), kenpaullone, PD98059, AR-A014418 and 
Y27632 (all from Calbiochem) were used at a concentration of 10 M, 
fascaplysin (Calbiochem) at 0.5 M, wortmannin (Sigma) at 0.1 M and 
SB203580 (Calbiochem) either at 10 or 50 M. The block protein 
synthesis, cycloheximide (CHX) was applied at a concentration of 100 
g/ml.  
 
Chromatin immunoprecipitations were performed as detailed [6]. Briefly, 
cells were crosslinked with 1% formaldehyde on ice for 6 minutes. Nuclear 
chromatin was sonicated on ice to fragments from 0.3 kb to 0.5 kb. Nuclear 
chromatin equivalent to 2.5x10
7 cells was immunoprecipitated with 2μg 
antibody. The following antibodies were used in CHIP: -pan-Myc (IG-
C),  -Ac-H4 (#06-866)(Upstate), -Phospho-Thr58/Ser62-Myc 
(#9401S)(Cell Signaling), and pre-immune serum (IG-0). The primer 
sequences for the cyclin D2 promoter (E-box binding site region) and the 
Fas ligand gene, (non-E-box MEF2 binding site region) used in Quantitative 
real-time PCR are provided upon request. 
 
Expression and purification of human cyclin A or E/Cdk2 complexes 
from insect cells and in vitro kinase assays were carried out as described [33]. 
For PP2A phosphatase assays, 400 μg of cell lysate was IP-ed with -PP2A 
antibody as described above, after which a non-radioactive, malachite 
green-based phosphatase assay kit (Upstate Biotechnology, Lake Placid, NY) 
based on phosphate release was used according to manufacturer’s 
instructions. 
 
RT-qPCR analysis of mRNA expression of was performed as described 
[6]. The primer sequences are provided upon request.  
Fluorescence microscopy 
2fTGH cells were cotransfected with constructs containing Myc-GFP 
together with CFP. BiFC was performed essentially as described [6] using 
constructs containing c-Myc fused to the C-terminal fragment of YFP 
(MycYC), Max fused to the N-terminal fragment of YFP (MaxYN) or Ub 
fused to the N-terminal fragment of YFP (YNUb) (kindly provided by T. 
Kerppola, Ann Arbor, Michigan). Fluorescence emissions were observed in 
living cells using an inverted microscope (Zeiss Axiovert 200M, Goettingen, 
Germany) together with software from Improvision (OpenLab 4.0.1), and 
black and white images were captured with a Hamamatsu ORCA-ER   12
digital camera, where non-treated cells were used as reference for exposure 
settings. CFP, GFP and YFP fluorescence was measured by excitation at 
436, 470 and 513 nm, respectively, and emission at 470, 505 and 535 nm, 
respectively. Quantification of fluorescence intensities was performed via 
software from Improvision (Volocity 3.0), on images captured and processed 
as described above.  
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Figure Legends 
Figure 1. IFN- treatment increases the rate of Myc degradation 
and ubiquitylation  
(A) IFN- reverses the v-Myc block of monocytic differentiation. Schematic 
picture describing the U-937 differentiation model system.  
(B) Detection of v- and c-Myc in v-Myc transformed U-937-myc6 and c-
Myc in parental U-937-GTB cells after 
35S-labeling as indicated. v-Myc 
migrates faster than c-Myc in SDS-PAGE gels. 
(C-D) Combined IFN- and TPA treatment (24 hrs) increases 
degradation of v- and c-Myc in U937-myc6 cells and of c-Myc in c-myc-
amplified Colo320 cells (D, right panel). v-Myc contains a point mutation 
at Thr-58, resulting in its stabilization. 
35S-Met pulse-chase was followed by 
IP using a pan-Myc antiserum and SDS-PAGE. (D) Quantitation of c-Myc 
turnover by phosphor imager. Note the logarithmic scale of the Y-axis.  
(E) IFN--induced c-Myc degradation is JAK/STAT1 dependent. Parental 
2fTGH fibrosarcoma cells and U3A STAT-deficient and U4A JAK1-
deficient sublines were treated with IFN- for 24 hrs, pulse chased and 
analyzed as above. 
(F) IFN- increases c-Myc ubiquitylation. 2fTGH cells were treated as 
indicated for 24 hours and cell lysates were IP-ed with Myc Ab followed by 
WB using Ub Ab. Note that endogenous proteins are analyzed and none of 
the components was ectopically expressed. 
(G) IFN--induced Myc degradation is proteasome-dependent. Pulse chase 
analysis was performed in U-937-myc6 cells treated with IFN-+TPA for 
24 hours in the presence or absence of the proteasome inhibitor LLnL as 
indicated.  
Figure 2.    Visualization of c-Myc turnover and ubiquitylation in 
living cells. 
(A-C) IFN- treatment increases c-Myc and c-Myc/Max degradation in 
living 2fTGH cells. The micrographs show a time lapse for the indicated 
time points after IFN- treatment of 2fTGH cells expressing a c-Myc-eGFP 
fusion protein together with an eCFP construct (A), and a BIFC experiment 
(B) with c-Myc-YC and Max-YN. Quantification is shown in C with mean 
values and standard deviations of 50 cells analyzed.  
(D and E) IFN- treatment increases c-Myc ubiquitylation in living 2fTGH 
cells as determined by BiFC (c-Myc-YC and YN-Ub). The micrographs 
show 2fTGH cells pretreated with the proteasome inhibitor MG115 
followed by IFN- treatment for 4 hours or left untreated. Quantification is 
shown in E with mean values and standard deviations of 10 cells analyzed.    16
Figure 3. IFN- decreases Myc Ser-62 phosphorylation and 
induces Myc degradation in a Ser-62 dependent manner  
 (A) Schematic picture showing the function of the phosphorylation sites in 
MB1 and their regulation. (1) Phosphorylation of Ser-62 by a priming 
kinase enables (2) GSK3 to phosphorylate Thr-58 (3) that is recognized by 
SCFFbw7/Cdc4 leading to ubiquitylation and degradation.  
(B) Specificities of the phospho-Ser62 and phospho-T58/S62 Myc Abs. 
Cos-7 cells were transfected with FLAG-tagged wt c-Myc, T58A, S62A 
and T58/S62A Myc mutants as indicated. The c-Myc proteins were IP-ed 
with FLAG Ab, followed by WB analysis using pan-Myc Ab (upper panel), 
phospho-T58/S62-Myc (middle panel) or phospho-S62-Myc Ab (lower 
panel).  
(C) Immunoblot analysis of v-Myc and c-Myc expression in v-Myc-
expressing U-937-myc6 and parental U-937-GTB cells using a mini-gel 
system. 
(D) IFN- decreases Myc-Ser-62 phosphorylation. v-Myc expressing U-
937myc6 cells were treated as indicated for 24 hours and for the last two hrs 
with the proteasome inhibitor MG115. Cell extracts were IP-ed with pan-
Myc Ab followed by WB analysis using phospho-T58/S62 (upper panel) or 
pan-Myc Ab (lower panel).  
(E) IFN- induces Myc degradation in a Ser-62 dependent manner. 2fTGH 
cells were transfected with FLAG-tagged T58A or S62A c-Myc mutants, 
treated with or without IFN- for 24 hr, and CHX added for the indicated 
times. c-Myc was IP-ed with Flag Ab followed by WB analysis using pan-
Myc Ab. Quantification was performed using a CCD camera.  
Figure 4. Cdk2 is a major c-Myc Ser-62 kinase regulating c-Myc 
turnover.  
(A) Effect of kinase inhibitors on the phosphorylation of c-Myc Ser-62. 
U2OS cells expressing FLAG-tagged c-Myc-T58A were treated with the 
indicated inhibitors (4 hrs) and MG115 (2 hrs). c-Myc proteins were IP-ed 
with FLAG Ab, followed by WB analysis using phospho-T58/S62-Myc Ab 
(upper panel). WB analysis of total cell lysates using FLAG Ab (lower 
panel). The following kinase inhibitors were used (targets within brackets): 
Roscovitine (Cdk2 and Cdk1), kenpaullone (Cdk1 more efficiently than 
Cdk2), fascaplysin (Cdk4 more efficiently than Cdk1 and Cdk2), PD98059 
(Mek1), SB203580 (p38 MAPK and less efficiently Jnk), AR-A014418 
(GSK3), wortmannin (PI3K) and Y27632 (ROCK). 
(B) Cdk2 phosphorylates Myc at Ser-62 in vitro. Purified wt and mutant 
Myc GST-fusion proteins were phosphorylated using recombinant cyclin E 
or A/Cdk2 in presence of 
32P--ATP. Histone H1 was used as a control for 
Cdk2 activity.  
(C) Roscovitine inhibits phosphorylation of c-Myc during S phase. U-937 
cells were arrested in S-phase by treatment with aphidicolin for 24 hrs. 
Roscovitine or vehicle was added during the last two hours of aphidicolin   17
treatment. Myc phosphorylation was measured using P-S62 (upper panel) 
and P-T58/S62 (middle panel) Ab and compared with total c-Myc using 
pan-Myc Ab (lower panel).  
(D) Roscovitine induces v- and c-Myc degradation. U937-myc6 cells were 
treated with roscovitine for 2 hrs prior to CHX chase. Myc was IP-ed with 
pan-Myc Ab followed by WB analyses with pan Myc Ab. Quantitation was 
performed as in Figure 3E. Note the logarithmic scale of the Y-axis. 
Figure 5. IFN--induced p27
Kip1 expression correlates with Cdk2 
inactivation, reduced Myc phosphorylation and increased Myc 
turnover 
 (A)  IFN- inhibits cyclin E/Cdk2. Lysates from U-937-myc6 cells 
stimulated as indicated were IP-ed with cyclin E Ab and assayed in vitro for 
histone H1 phosphorylation. Rosc, roscovitine.  
(B) Kinetics of p27 expression following stimulation with IFN-+TPA. p27 
expression was determined by immunoblot analysis. 
(C) Kinetics of reduced Myc phosphorylation. The assay was performed as 
in Figure 3D using indicated cell extracts.  
(D) Kinetics of induced Myc turnover. A CHX chase experiment with 
quantitation was performed as in Figure 3E using cells treated with IFN-
+TPA for 0, 4 or 8 hrs as indicated. 
Figure 6. p27 promotes reduced phosphorylation and Ser-62 
dependent degradation of Myc and is required for IFN--induced 
Myc turnover 
(A) p27 reduces phosphorylation of Myc Ser-62. Flag-tagged wt c-Myc or 
Myc-T58A were cotransfected with p27 into HeLa cells. c-Myc was IP-ed 
with Flag Ab followed by WB analysis using phospho-Myc (upper panel) or 
pan-Myc Ab (lower panel). A T58A/S62A double mutant was used as a 
negative control.  
(B) p27 reduces c-Myc levels in a Ser-62 dependent manner. Flag-tagged 
wt c-Myc and indicated mutants were cotransfected with p27 into HeLa 
cells. The total c-Myc levels were determined as described in (A).  
(C) IFN--induced degradation of c-Myc is p27-dependent. wt and p27
-/- 
MEF cells were stimulated with murine IFN- for 24 hrs and the steady 
state level of c-Myc was determined as above.  
(D) Fbw7/Cdc4 is not required for p27-induced turnover. p27 or a control 
vector were transfected into HCT116 Fbw7/Cdc4
-/- cells after which Myc 
turnover was determined by CHX chase as described in Figure 3.     18
Figure 7.   IFN- treatment reduces phosphorylated and total Myc 
at chromatin and represses Myc-driven transcription of target 
genes. 
(A) IFN- regulates association of phosphorylated and total Myc as well as 
acetylated histone H4 with chromatin. U-937-myc6 cells treated with IFN-
+TPA for 6 hrs were analyzed by ChIP using the pan-Myc and phospho-
Myc Ab (upper panel), acetylated histone H4 Ab (lower panel) and primers 
specific for an E-box-containing region of the cyclin D2 promoter. 
Preimmune serum (pre-Im) was used as negative control. The non-E-box 
region of the Fas ligand gene was used as a reference gene.  
(B) IFN- and IFN-+TPA repress Myc-driven transcription of target 
promoter/reporter gene constructs. m4mintk-Luc (containing four E-boxes 
in front of a minimal tk promoter) and mintk-Luc (lacking the E-boxes) 
(upper panel) and -prothymosin containing two Myc-responsive E-boxes 
in the 1
st intron (lower panel) were electroporated into U-937-myc6 cells, 
and the day after divided into four aliquots and treated as indicted. The next 
day cells were harvested and analyzed for luciferase activity.  
(C) mRNA expression of the indicated Myc target genes were analyzed by 
Q-RT-PCR in U-937-myc6 cells +/-24 hrs of IFN+TPA treatment.  
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Supplemental Information 
Supplementary Figure 1. Analysis of Myc turnover.  
 (A) IFN-g+TPA treatment increases c-Myc degradation in Colo-320 colon 
carcinoma cells. Gel corresponding the experiment described in Figure 1D, 
right panel.  
(B) IFN-g-induced c-Myc degradation is JAK/STAT1 dependent. Gel 
corresponding the experiment described in Figure 1E. 
(C) IFN-g induces c-Myc degradation in a Thr-58-independent manner. 
Gel corresponding the experiment described in Figure 1F. 
(D) Roscovitine induces v- and c-Myc degradation. Gel corresponding the 
experiment described in Figure 3D. 
(E) Kinetics of IFN-g-induced Myc turnover. Gel corresponding the 
experiment described in Figure 4E. 
(F) Fbw7/Cdc4 is not required for p27-induced turnover. Gel 
corresponding the experiment described in Figure 5D. 
Supplementary Figure 2. Kinetic analysis of p21Cip1 expression, 
cycle distribution and PP2A activity after IFN-g+TPA treatment of 
U-937-myc6 cells. 
(A) IFN-g+TPA, but not IFN-g alone, upregulates p21Cip expression. 
35S-Met-labeled cell lysates from cells treated as indicated were IP-ed with 
p21Cip1 Ab followed by SDS-PAGE and phosphor imager analysis.  
(B) Kinetics of IFN-g + TPA-induced G1 cell cycle arrest. The cell cycle 
distribution was determined by FACS analysis. Data are presented as 
percentage of cells in the G1/G0, S and G2/M phases of the cell cycle.  
(C) IFN-g does not affect PP2A activity. The cells were treated with 
TPA+IFN-g for indicated times. Phosphatase activity in cell extracts 
measured as phosphate release was assayed as described in Materials and 
Methods. 
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Abstract 
The c-Myc transcription factor/oncoprotein regulates a large number of 
genes involved in cell growth and proliferation, apoptosis, metabolism, 
differentiation and many other processes in the cell. c-Myc expression is 
turned off in quiescent cells but reactivated in response to mitogenic signals 
and plays an important role in the activation of cells from G0 to G1 and in 
the progression of the cell cycle from G1 into S phase. We and others have 
shown previously that the E3 ubiquitin ligase Skp2 interacts with and 
ubiquitylates c-Myc at the G1/S border, stimulates c-Myc-induced S-phase 
entry and is required for c-Myc-driven transcription of certain genes. We 
have further shown recently that the cell cycle regulator cyclin E/Cdk2 
phosphorylates c-Myc at Ser-62 during the G1/S transition. This 
phosphorylation is negatively regulated by the Cdk inhibitor p27Kip1 in 
response to interferon (IFN)- signaling. Using P439-6 lymphoma cells with 
Tet-regulatable Myc, we confirm that induction of c-Myc in quiescent cells 
results in its rapid association with target promoters and activation of genes 
like  ODC. In contrast, we show here that S-phase-specific direct Myc 
targets, such as RFC4, were not induced until late G1 despite early c-Myc 
binding to its promoter. Interestingly, we demonstrate that Skp2, which is   2
induced in mid G1, binds to the promoter of the late G1 RFC4 but not to 
the early ODC promoter, correlating kinetically RFC4 gene activation. We 
also show that cyclin E/Cdk2 binds to c-Myc target gene promoters and 
enhances c-Myc-driven transcription. IFN- treatment leads to binding of 
p27Kip1 to c-Myc target promoters, decreased association of total Myc, 
phosphorylated Myc and cyclin E/Cdk2 as well as strong repression of 
transcription. These findings suggest that regulation of S-phase genes by c-
Myc seems to involve an intricate interplay between the cell cycle regulators 
and potential cofactors p27Kip1, Skp2 and cyclin E/Cdk2.   
 
Introduction 
The c-myc proto-oncogene encodes a short-lived transcription factor that 
plays an important role in cell proliferation, apoptosis and cancer 
development (for review see Oster et al., 2002). Two regions are required 
for transcriptional regulation and oncogenic transformation by c-Myc, the 
N-terminal transactivation domain (NTAD) and the C-terminal 
basic/helix-loop-helix/leucine zipper (bHLHZip). The bHLHZip domain 
mediates dimerization with the cofactor Max, which is required for the 
binding of c-Myc to E-box elements at target gene promoters and therefore 
for activation of transcription. The highly conserved region Myc-box 2 
(MB2) within the NTAD is required for interaction with a number of 
proteins, including the coactivator TRRAP, which is a component of 
histone acetyl transferase (HAT) complexes that participates in the 
regulation of chromatin structure. c-Myc can also repress transcription by 
interacting with the initiator-binding zinc finger protein Miz-1. A growing 
number of target genes regulated by c-Myc have been identified, and recent 
estimations suggest that these cover 10-15 % of the genome, including genes 
involved in the cell cycle, cell growth, apoptosis, metabolism, differentiation 
and immortalization (Oster et al., 2002).   
 
c-Myc is degraded via the ubiquitin/proteasome pathway (for review see 
Amati 2004). Ubiquitylation of c-Myc involves recognition by at least three 
E3 ubiquitin ligases, SCFSkp2, SCFFbw7/hCdc4 and HectH9 (Adhikary et 
al., 2005, Kim et al.2003, von der Lehr, 2003, Welcker et al., 2004). 
HectH9 conjugates K63-linked ubiquitin chains on the C-terminal domain 
of c-Myc, which does not lead to proteolysis. SCFFbw7/hCdc4 interacts 
with phosphorylated residues in MB1 at the N-terminal domain of c-Myc, 
leading to ubiquitylation and degradation of c-Myc. SCFSkp2 interacts with 
c-Myc through MB2 and the C-terminus. In contrast to SCFFbw7/hCdc4, 
SCFSkp2 does not only ubiquitylate and degrade c-Myc but also enhances 
c-Myc induced transcription. Skp2 is in fact recruited by c-Myc to target 
gene promoters, correlating with ubiquitylation of chromatin-associated 
proteins (that could be c-Myc and/or other proteins) (von der Lehr et al., 
2003). The proteasome is also found associated with promoters in a c-Myc-
dependent manner. The 19S regulatory subunit and possibly the whole 
proteasome seem to play a positive role in transcription since siRNA-  3
mediated knockdown of the proteasomal subunit Sug1, like knockdown of 
c-Myc or Skp2, reduces c-Myc-driven transcription (von der Lehr et al., 
2003a, 2003b, for review see Jin and Harper, Lipford and Deshaies, 2003). 
Skp2 is a cell cycle regulated protein that interacts with c-Myc from late G1 
(von der Lehr et al., 2003, Fujii et al., 2006). Skp2 was originally identified 
as a cyclin/Cdk-interacting protein, and plays a role in activating cyclin 
E/Cdk2, which is the cyclin/Cdk complex that normally triggers the G1/S 
transition. The substrates of cyclin E/Cdk2 include the retinoblastoma 
protein Rb and the cyclin-dependent kinase inhibitor p27Kip1. The Rb 
family proteins play a crucial role in the cell cycle by controlling the 
expression of E2F-dependent genes that are necessary for S phase entry. 
p27Kip1 is a tumor suppressor that controls G1/S transition by inhibiting 
cyclin E/Cdk2 activity. Phosphorylation on Thr187 of p27Kip1 by cyclin 
E/Cdk2 leads to its degradation mediated by SCFSkp2 (Kossatz et al., 
2006). Skp2, p27Kip1, cyclin E/Cdk2 and Rb therefore constitute an 
autoinduction loop: cyclin E/Cdk2-induced phosphorylation of p27Kip1 
triggers its degradation, which leads to further activation of cyclin E/Cdk2, 
resulting in further Rb phosphorylation, release of E2F, and further E2F-
dependent cyclin E and Skp2 expression. (Yung et al., 2007, 
Ungermannova et al., 2005, for review see Assioan and Yung, 2008). It has 
been shown that the different functions of c-Myc during cell cycle 
progression are entangled in a variety of ways with the cyclin E/Cdk2 
kinase complex. First, c-Myc binds to E-boxes in the promoters of cyclin 
D1, cyclin D2, and CDK4 (Bouchard et al., 2001, Fernandez et al., 2003, 
Hermeking et al., 2000, Menssen and Hermeking, 2002). The cyclin 
D/Cdk4 complex functions to activate the cyclin E/Cdk2 complex by 
sequestering p27Kip1. Second, c-Myc induces the phosphatase Cdc25, 
which dephosphorylates and activates Cdk2 (Galaktionov et al., 1996). 
Third, c-Myc directly represses transcription of Cdk inhibitor genes such as 
p15Ink4b, p21Cip1, and p27Kip1 (Claassen and Hann, 1999, Gartel et al., 
Yang et al., 2001). 
 
It is known that c-Myc induces transcription of both genes early in G1 
and genes that are first expressed in late G1/S phase. However, it is at 
present unclear whether the late genes are indirect targets of c-Myc, and the 
mechanisms behind these differential inductions therefore remain to be 
investigated. We know that Skp2 is expressed at late G1 phase and enhances 
c-Myc induced transcription (von der Lehr et al, 2003). This might indicate 
that Skp2 is a transcriptional cofactor for a subpopulation of c-Myc target 
genes of relevance for the G1/S transition of the cell cycle. Cyclin E/Cdk2 
has been well known to play a crucial role in G1/S transition and has 
recently been shown to be a kinase for c-Myc (Bahram et al., paper II). In 
this study, we are addressing the possibility of interplay between c-Myc, 
Skp2, p27Kip1 and cyclin E/Cdk2 in the regulation of c-Myc-induced 
transcription during G1/S cell cycle transition.   
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Results 
Induction of c-Myc target genes at early and late G1 phase 
In order to study c-Myc-induced transcription during the cell cycle, the 
P493-6 human lymphoid B cell line carrying a conditional tetracycline 
(Tc)-regulatable  c-myc construct was used. Proliferation of these cells is 
strictly dependent on the expression of c-myc. In presence of Tc, c-myc is 
turned off and the cells go into quiescence. When Tc is removed, c-myc is 
activated within a few hrs, after which the cells will enter the cell cycle 
synchronously (Schuhmacher et al., 1999). 
 
We first investigated the expression of Skp2 and cyclins during cell cycle 
progression in the P493-6 cells after c-Myc activation from quiescent cells. 
Both protein and mRNA levels of c-Myc were strongly induced within 4 
hrs after Tc removal (Fig. 1, 2). Expression of cyclin A increased after 20 hrs  
(Fig. 1), indicating the progression of cells into S phase at this time point, in 
agreement with previous reports (Pajici et al., 2000). Skp2 mRNA and 
protein expression started to increase around 12 hrs and kept increasing until 
32 hrs post Tc removal (Fig.1, 2), consistent with previous reports that Skp2 
expression starts in mid/late G1 and reaches its maximum during the S and 
G2 phases of the cell cycle (for review see Nakayama and Nakayama, 2005). 
 
We next addressed the question whether there are direct c-Myc target 
genes that are specifically activated late in G1 phase or whether all c-Myc 
targets are induced shortly after c-Myc induction.  Schuhmacher et al.   
reported that the replication factors RFC4, MCM4, and the E2F 
dimerization partner DP-1 were induced late after c-Myc activation in 
P493-6 cells (Schuhmacher et al., 2001), making these genes our candidates, 
although it was not clear if these were direct c-Myc targets. Q-PCR was 
therefore performed to measure RFC4 mRNA expression levels compared 
to the previously well characterized direct c-Myc target genes ornithine   
decarboxylase  (ODC) and cyclin D2 (Fig.2) As shown in Figure 2, ODC 
mRNA levels increased at the latest 6 hrs after Tc removal, i.e. immediately 
after c-Myc is activated in early G1. Interestingly, the expression of RFC4 
did not start to increase until around 12 hrs after c-Myc-induction, and was 
maximal at 18 hrs and thereafter, which is in agreement with Schuhmacher’s 
observations. Thus the induction of RFC4 followed the expression pattern 
of Skp2. cyclin D2 mRNA levels exhibited a biphasic expression pattern 
during G1 (data not shown), suggesting that the regulation of this gene is 
quite complex. 
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Skp2 is found at the promoter of the late G1 c-Myc target gene 
RFC4 but not at the early gene ODC 
The relatively late induction of Skp2 expression in combination with our 
previous finding that Skp2 acts as a cofactor for c-Myc-induced 
transcription at the cyclin D2 promoter (von der Lehr et al., 2003a) 
prompted us to raise the question whether Skp2 could play a role in the 
induction of late c-Myc target genes as opposed to early genes. To answer 
this question, CHIP experiments were performed in P493-6 cells. As shown 
in Figure 3, c-Myc bound strongly to the E-box-containing promoter 
regions of both ODC and RCF4 already at 6 hrs after Tc removal, although 
the expression of RFC4 was not activated until several hrs later. In contrast, 
ODC was activated with the same kinetics as the c-Myc binding to its 
promoter.  Interestingly, Skp2 exclusively bound to the RFC4 promoter 
and not to the ODC promoter. Skp2 binding to the promoter of RFC4 
occurred only at the later time points, thus correlating with Skp2 
expression. These results are compatible with a role of Skp2 as cofactor for 
c-Myc induced activation of late G1 genes such as RFC4.   
Cyclin E/Cdk2 binds to c-Myc target gene promoters and acts as 
a cofactor that enhances c-Myc-driven transcription  
The cyclin E/Cdk2 complex plays a key role in the promotion of cell cycle 
progression into S-phase that is intertwined with c-Myc and Skp2 (Bahram 
et al, Paper II, Assioan and Yung, 2008). Cyclin E/Cdk2-mediated 
phosphorylation of c-Myc occurs in late G1 (Bahram et al., paper II), we 
therefore wanted to investigate a possible direct involvement of cyclin 
E/Cdk2 in c-Myc-induced transcription of late G1 genes. We first 
examined whether the interaction between c-Myc and cyclin E could be 
detected by coimmunoprecipitation (coIP) in U-937 cells, the system where 
we conducted most of our previous phosphorylation studies (Bahram et al, 
Paper II). U-937 cells are human histiocytic lymphoma cells, that can be 
induced to differentiate from monoblasts to monocytes/macrophages with 
substances such as the phorbol ester TPA and interferon (IFN)- . As shown 
in Figure 4A, low but measurable amount of c-Myc specifically coIP-ed 
with cyclin E. A substantial amount of total c-Myc coIP-ed with Max as 
expected. This indicates a relatively weak or more transient interaction 
between c-Myc/cyclin E than between c-Myc/Max. It is conceivable that 
cyclin E/Cdk2 “touches” c-Myc during the process of Ser-62 
phosphorylation (Bahram et al., paper II).  
 
To investigate whether c-Myc and cyclin E/Cdk2 also interact on 
chromatin, we performed CHIP experiments in U-937 cells using 
antibodies against cyclin E or Cdk2 respectively. c-Myc was detected on the 
cyclin D2 promoter (Bouchard et al., 2001) (Fig.4b). Importantly, specific 
signals were also detected using two different antibodies each for cyclin E 
and Cdk2, while the two negative control antibodies gave only background   6
signals. This suggests that cyclin E and Cdk2 indeed associate specifically 
with E-box regions in the cyclin D2 promoter. To investigate whether c-
Myc associates directly with these factors at the cyclin D2 promoter, re-ChIP 
experiments were performed, where protein/DNA complexes IP-ed with 
anti-c-Myc antibody were released and reprecipitated with anti-Cdk2 or 
pre-immune serum. Fig 4c demonstrates that Cdk2 antibodie produced 
signals above background, suggesting that c-Myc indeed forms complexes 
with Cdk2 at the cyclin D2 promoter. Unfortunately, CHIP signals for 
cyclin E/Cdk2 were too weak to be picked up in P493-6 cells. 
 
These results indicate that cyclin E/Cdk2 may act as a transcriptional 
cofactor for c-Myc at certain promoters. To measure the effect of cyclin 
E/Cdk2 overexpression on c-Myc-induced transcription, we cotransfected a 
c-Myc-driven promoter/luciferase reporter (m4mintk-Luc) together with c-
Myc and/or cyclin E/Cdk2 into U2OS cells. Cotransfection with cyclin 
E/Cdk2 substantially enhanced c-Myc-driven transcription (Fig.4d), thus 
supporting the hypothesis that cyclin E/Cdk2 could be a cofactor for c-
Myc-driven transcription. 
IFN- treatment decreases c-Myc and cyclin E binding and 
increases p27Kip1 binding at c-Myc target gene promoters 
We have reported previously that the combination of IFN- and TPA 
treatment overrides the transforming activity of c-Myc and induces 
differentiation and G1 arrest in v-Myc-transformed U-937 cells (Bahram et 
al., 1999). Recently, we showed that IFN-+TPA treatment induces the 
expression of the Cdk-inhibitor p27Kip1, which inhibits cyclin E/Cdk2-
mediated phosphorylation of c-Myc at Ser-62, including chromatin-
associated c-Myc (Bahram et al., Paper II). Our results show that p27Kip1 
interacts with c-Myc in U937 cells from coimmunoprecipitation 
experiments  (Fig. 4a), and CHIP experiments also demonstrate that 
p27Kip1 indeed associates specifically with the E-box region of the cyclin 
D2 promoter (Fig.4b). The interaction between c-Myc and p27Kip1 is also 
visualized in HL-60 cells treated with IFN-, IFN-+TPA and to a lesser 
extent in TPA-treated cells, but was hardly detectable in untreated cells, in 
agreement with the expression pattern of p27Kip1 (Fig.5a). We therefore 
next investigated whether IFN-+TPA treatment of these cells affects the 
association of c-Myc and cyclin E with the early and late G1 c-Myc target 
genes, ODC and RFC4, respectively. Fig. 5b shows that not only c-Myc 
but also cyclin E associates with the promoters of both genes in non-
synchronized cells, whereas preimmune serum gave only background 
signals. After IFN-+TPA treatment, the presence of c-Myc at the 
promoters of both genes decreased. Interestingly, also the cyclin E binding 
to these promoters decreased. The same antibodies gave very low signals 
from the non-E-box region of the Fas ligand gene promoter used as a 
reference gene (Fig. 5b, lower panel). Correspondingly, IFN-+TPA 
treatment resulted in the reduction of the mRNA levels of both ODC and   7
RFC4 (Fig 5c). Consistent with this, the association of p27Kip1 with the 
cyclin D2 promoter also increases upon IFN-+TPA treatment (Fig. 5d). 
Interestingly, re-CHIP using antibodies against c-Myc and p27Kip1 
demonstrates that p27Kip1 antibodies produce signals above background, 
suggesting that c-Myc indeed forms complexes with p27Kip1 at the cyclin 
D2 promoter (Fig. 5e). 
 
Together with the results above, these data suggest that binding of cyclin 
E/Cdk2 to c-Myc target gene promoters during cell cycle progression 
enhances c-Myc-induced transcription, and that p27Kip1 inhibits 
cyclinE/Cdk2 kinase activity at the promoter, thereby repressing 
transcription.    
 
Discussion 
c-Myc-induced transcription, like the activity of other DNA-binding 
activator proteins, requires cofactor activity. For example, TRAAP is 
known to be necessary for transactivation of some c-Myc target genes, such 
as  hTERT. Other c-Myc target genes, such as CAD, are transcribed 
independently of TRAAP. This phenomenon suggests the possibility that c-
Myc may induce transcription of different genes by cooperating with 
different coactivators. Former work performed in our group has 
demonstrated that Skp2 interacts with c-Myc in the nucleus, associates with 
c-Myc target gene promoters in a c-Myc-dependent manner, and is 
required for c-Myc-induced transcription and S phase entry (von der Lehr 
et al., 2003). Here we show that Skp2 is recruited specifically to the 
promoter of the c-Myc target gene RFC4 during late G1 and S phase of the 
cell cycle, but does not associate with the promoter of the immediate early 
c-Myc target gene ODC, not even late after c-Myc induction when this 
gene is still expressed and Skp2 expression is also high. Other cofactors, such 
as TRRAP, may be involved in ODC transcription. Taken together, we 
suggest that c-Myc binds to its target gene promoters soon after its 
activation, and that some target genes such as ODC are transcribed 
immediately. Other genes, like RFC4, are kept silent until a certain 
cofactor, in this case Skp2, is recruited at late G1 phase.  
 
What could be the role of Skp2 in c-Myc induced transcription of late 
G1 genes, such as RCF4? To answer these questions, more experiments 
need to be performed. For instance, siRNA could be used to investigate the 
effects of knockdown of Skp2 on the transcription of RCF4. It should also 
be investigated whether Skp2 binds to promoters in complex with c-Myc. 
However, at this point we can show that Skp2, in a still unclear way, is 
correlated to c-Myc-induced transcription during G1/S transition. 
 
The cyclinE/Cdk2 complex is another important player during G1/S 
transition. Here we show that cyclin E interacts with c-Myc and enhances 
c-Myc-induced transcription. Importantly, cyclin E/Cdk2 interacts with   8
chromatin-bound c-Myc, thereby possibly participating in the regulation of 
c-Myc target genes. We recently showed that c-Myc is phosphorylated at 
Ser 62 by cyclin E/Cdk2 during late G1 and S-phase, and that cyclin 
E/Cdk2-mediated phosphorylation of Ser62 is likely to occur at c-Myc 
target gene promoters (Bahram et al., Paper II). In addition, we have 
demonstrated that the growth inhibitory cytokine IFN- represses c-Myc-
regulated transcription from target promoters in an E-box dependent 
manner (Bahram et al., Paper II), in agreement with our present finding that 
both c-Myc and cyclin E binding to c-Myc target gene promoters decrease 
whereas p27Kip1 binding increases upon IFN- treatment. 
 
Put together, these results imply several possibilities of how Skp2 and 
cyclin E/Cdk2 could be involved in c-Myc driven transcription during 
G1/S transition. One possibility is that Skp2 functions as a transcriptional 
cofactor of c-Myc; i.e. that c-Myc binds to target gene promoters but 
cannot induce transcription until Skp2 is recruited to the promoter. 
Recently, Skp2 has been found to antagonize the binding of p53 to p300, 
thus suppressing p300-mediated acetylation of p53 and the transactivation 
ability of p53 (Kitagawa et al., 2008).  This brings up a potential pathway in 
which Skp2 may function in a similar way to remove the repression on c-
Myc, thereby enhancing c-Myc induced transcription. We also show that 
p27Kip1, which is known as a substrate of Skp2-mediated degradation, 
binds to c-Myc target gene promoters in complex with c-Myc. One 
interesting hypothesis is that Skp2 ubiquitylates and degrades p27Kip1 at the 
promoter, thereby releasing its inhibition of cyclin E/Cdk2, which in turn 
would assist the coactivating function of cyclin E/Cdk2 on c-Myc induced 
transcription. This, however, remains to be investigated. The mechanism by 
which cyclin E/Cdk2 carries out a coactivator function for c-Myc is also 
unclear. One possibility is that the c-Myc transactivation function is 
enhanced through Ser62-dependent phosphorylation. Cyclin E/Cdk2-
mediated phosphorylation of Ser62 stabilizes c-Myc, thereby increasing its 
time of association with chromatin (Bahram et al., Paper II). Cyclin E/Cdk2 
is also able to phosphorylate other components in the Myc transcriptional 
complex such as the histone acetyl transferase cofactor CBP (Ait-Si-Ali et 
al., 1998, Vervoorts et al., 2003). Finally the kinase itself may serve as an 
adaptor for recruitment of other factors. It is therefore conceivable that 
cyclin E/Cdk2 assists c-Myc in the regulation of a subpopulation of genes of 
relevance for G1/S cell cycle transition. In conclusion, further investigations 
are required to fully understand the possible role Skp2 and cyclin E/Cdk2 
in the complex mechanisms by which the activation of different subsets of 
c-Myc target genes are regulated.   
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Methods and materials  
Cell culture  
Cells were cultured in RPMI-1640 (U-937-myc6, p493-6) or DMEM 
(HL-60, U2OS) medium supplemented with 10% fetal calf serum and 
antibiotics. To synchronize the P493-6 cells, exponentially growing cells 
were treated with 0.1mg/ml tetracycline in RPMI-1640 supplemented with 
0.25% serum for 72hr. Thereafter, in order to activate c-Myc, cells were 
washed with cold PBS and re-cultured in RPMI-1640 medium 
supplemented with 10% serum without tetracycline and harvested at the 
indicated time points. Exponentially growing U-937 cells were treated with 
1x10
-7 mol/L TPA (Sigma, St Louis, MO) and 100 U/mL IFN- for 6 hrs.   
Transfections and reporter activity analysis  
Subconfluent U2OS cells were transfected using FuGENE6 (Boehringer 
Mannheim). The plasmids used are CMV-Myc, pCMV-cyclin E and 
pCMV-Cdk2. The m4mintk-Luc reporter plasmids were used in luciferase. 
Protein and ChIP assays  
Immunoprecipitation and immunoblot analyses were performed as described 
previously (Bahram et al., 1999; von der Lehr et al., 2003). The following 
Abs were used: -c-Myc (C33X), -c-Myc (N262), -Max (C-17X), -
cyclin E (C-19), and -cyclin A (BF683X), (all from Santa Cruz 
Biotechnology Inc. (SCB, Santa Cruz, CA, USA), and pre-immune serum 
(IG-0). 
 
Chromatin immunoprecipitations were performed as described (von der 
Lehr et al., 2003). Briefly, cells were crosslinked with 1% formaldehyde on 
ice for 6 minutes. Nuclear chromatin was sonicated on ice to fragments of 
0.3 kb to 0.5 kb. Nuclear chromatin equivalent to 2.5x10
7 cells was 
immunoprecipitated with 2μg antibody and analyzed by PCR. In the re-
CHIP assay, 50μl release buffer (1%SDS, 10mM DTT, TE pH 7.5) was 
added to the beads after the first immunoprecipitation step, and incubated 
30 min at 37 °C. The supernatant was then used for immunoprecipitation 
with a second antibody as in the ChIP assay.assay. 
 
The following antibodies were used in ChIP: -pan-Myc (IG-C), -Skp2 
p45 (H-435)X, -cyclin E (HE-111x), -cyclin E (M-20), -CDK2 (M-2), 
-CDK2 (H-298), -P27 (C-19), -P27 (F-8), -Gal4(DBD)(sc-577) (all 
from Santa Cruz) and pre-immune serum (IG-0). The primer sequences for 
the cyclin D2, ODC, and RFC4 promoters (E-box binding site region) and 
the Fas ligand gene (non-E-box MEF2 binding site region) used in 
Quantitative real-time PCR are provided upon request.   10
RT-qPCR assay  
Total RNA was extracted from P493-6 or U-937-myc6 cells using 
QIAshredder spin columns and RNeasy mini kit (Qiagen Sciences). 
Samples were DNase-treated before cDNA synthesis was performed with 
oligo(dT) and RevertAid M-MuLV Reverse transcriptase from Fermentas. 
cDNA was used as template in quantitative PCR reactions with DyNAmo 
HS SYBR Green qPCR kit from Finnzymes. The comparative Ct method 
was used for relative quantification of expression levels. The expression 
levels of the genes of interest were normalized to the expression level of b-
actin. The primer sequences are provided upon request 
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Figure Legends 
Figure 1. Expression of c-Myc, Skp2, and cyclin A protein levels 
after c-Myc activation in P493-6 cells.  
Cells were harvested at different time points after Tc removal and analyzed 
by western blot using specific antibodies as indicated.  
Figure 2. Kinetics of c-Myc-induced expression of ODC and 
RFC4 target genes.  
Q-PCR analysis showing relative mRNA levels of c-myc, skp2 and the c-
Myc target genes ODC and RFC4 was performed in P493-6 cells harvested 
at indicated time points after Tc removal. 
Figure 3. c-Myc and Skp2 occupancy at RFC4 and ODC c-Myc 
target  promoters.   
ChIP experiments were performed with chromatin prepared from P493-6 
cells harvested at indicated time points after removal of Tc using indicated 
antibodies and primers. pre-Im, preimmune serum. The non-E-box region 
of the Fas ligand gene was used as a reference gene. 
Figure 4. CylinE/Cdk2 interacts with c-Myc on the cyclin D2 
promoter and enhances c-Myc-driven transcription.  
A) Cyclin E interacts with c-Myc. c-Myc was coIP-ed from extracts from 
U-937-myc6 cells treated with IFN- for 24 hrs using indicated antibodies, 
after which Western blot analysis was performed using pan-Myc antibodies.  
B) Cyclin E ,Cdk2 and p27 associate with an E-box-containing region of 
the cyclin D2 promoter. Exponentially growing U-937-myc6 cells were used 
for ChIP using the indicated cyclin E, Cdk2, p27Kip1 and c-Myc 
antibodies. Preimmune serum (PI), GFP and Gal4 antibodies were used as 
negative controls.  
C) c-Myc interacts with Cdk2 at the cyclin D2 promoter. Re-ChIP analysis 
using the indicated antibodies was performed as described in Materials and 
Methods.  
D) CylinE/Cdk2 enhances c-Myc-driven transcription. The reporter 
construct m4mintk-Luc, containing four E-boxes in front of a minimal tk 
promoter, was cotransfected with c-Myc and/or cyclin E/Cdk2 expression 
vectors into U2OS cells. Luciferase activity was measured 48 hrs later.    14
Figure 5. IFN- regulates the association of c-Myc, cyclin E and 
p27Kip1 with target promoters.  
A) The interaction between c-Myc and p27Kip1 increases after stimulation 
with IFN- and/or TPA. CoIP of c-Myc and p27Kip1 was performed 
using extracts from HL-60 cells treated with IFN- for 24 hrs.  
B) IFN- + TPA treament reduces association of c-Myc and cyclin E with 
RFC4 and ODC promoters. U937-myc6 cells were treated with IFN- 
(100 U/ml) and TPA (10
-7 M) for 6 hrs. ChIP experiments were performed 
with indicated antibodies and pre-immune serum.   
C) IFN-+TPA represses the expression of ODC and RFC4. RT-qPCR 
was performed using mRNA extracted from U973-myc6 cells treated with 
IFN-+TPA for 24 hrs.  
D) IFN- regulates association of p27Kip1 with chromatin. U-937-myc6 
cells treated with IFN-+TPA for 6 hrs were analyzed by ChIP using 
antibodies against p27Kip1 and  preimmune serum (pre-Im). The non-E-
box region was used as a reference gene as in Fig 3.  
E) c-Myc interacts with p27Kip1 at the cyclin D2 promoter. Re-ChIP 
analysis using the indicated antibodies was performed as described in 
Materials and Methods.  
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Abstract 
 
Transcription factors (TF) of the basic region helix-loop helix (bHLH) 
family constitute the second largest TF family in the plant Arabidopsis 
thaliana (At) and play role in many developmental processes and in signal 
transduction, for instance in response to light and stress. Little is, however, 
known about the transcriptional regulation of cell division in plants. In 
animals, bHLHZip genes of the MYC family play important roles in cell 
proliferation by regulating, for instance, cell cycle genes such as cyclins, 
cyclin-dependent kinases (CDKs) and CDK inhibitors. The MYC family 
genes are conserved throughout animal evolution and are regulated in a cell 
cycle-dependent manner. We asked whether there exist MYC-like genes in 
plants with similar functions as in animals. Using the very conserved 
bHLHZip domains of animal Myc-family proteins, we searched the 
Arabidopsis genome and found 84 bHLH genes belonging to the same 
ancient B subgroup of eukaryotic bHLH genes as MYC. These could be 
further subdivided into 15 subfamilies that were evolutionary separated from 
the animal bHLH genes. Examination of a Myc-family “fingerprint” of 21 
conserved amino acids in the bHLH domain revealed that 18-20 of these 
amino acids were conserved at the identical positions in most of the 15 At 
bHLH subfamilies, suggesting that they are “Myc-like” to some extent. To 
gain insight into the potential functions of the At bHLH genes, we  
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examined the expression profile of these genes in proliferative tissues of 
Arabidopsis. Seven different cell division systems were studied, including 
shoot apex, flowers, leaves, siliques/seeds, root as well as auxin-induced 
early lateral root initiation and sucrose-induced cell cycle progression in 
suspension cultures. We found that one gene in particular, At1g26260, was 
auxin-induced and regulated in a cell cycle-dependent manner in six out of 
the seven systems. Four other genes, At1g10120, SPATULA, At3g25710 
and At3g61950 were cell cycle regulated in five systems, and a total of 15 At 
bHLH genes scored positive in at least two of the systems. This suggests that 
some of these genes may potentially have a role in cell proliferation in 
general, while others may have more cell type-specific proliferative 
functions. Interestingly most of these genes clustered in 3 subgroups of At 
genes. Homozygous disruption by T-DNA insertion did, however, not 
result in phenotypic aberrations in six of these genes, this possibly due to 
redundancies. In conclusion, we have identified a number of “Myc-like” 
bHLH genes that are regulated in a cell cycle-dependent manner and that 
may potentially play a role in cell division in plants.   
 
Introduction 
Transcription factors of the bHLH-family play important regulatory roles 
during neurogenesis, myogenesis, hematopoiesis, cell proliferation, 
differentiation, cell lineage determination, sex determination and other 
important processes in animals. The common bHLH domain of these 
proteins is around 60 amino acids long and consists of a basic region (b), 
which binds specifically to E-box DNA recognition sequences in regulatory 
regions of target genes, and the HLH domain, which mediates protein-
protein interactions, leading to the formation of homo- or heterodimers. 
The HLH domain forms two amphipathic a-helices separated by a small 
loop, where helix I forms a continuous a-helix with the basic region (for 
review see (Lüscher and Larsson, 1999).  
 
The bHLH-family can be subdivided into six different groups, A-F, 
based on their sequence similarity, DNA-binding specificity and the 
presence or absence of additional domains (Atchley and Fitch, 1997; Ledent 
et al., 2002; Ledent and Vervoort, 2001). The A-group proteins, which are 
only found in animals, typically bind E-boxes with the sequence CAGCTG 
or CACCTG and include factors involved in animal neurogenesis, 
myogenesis, hematopoiesis and other developmental processes. The 
prototype of this subgroup is MyoD, a factor involved in muscle 
differentiation. bHLH B-group have been found in animals, fungi and 
plants, and is thought to be a evolutionary more ancient group (Atchley and 
Fitch, 1997). The c-Myc oncoprotein is the proto-type of this group, which 
further includes the animal SREBP, USF, TFE, and fungal Esc, Cbf and Ino 
and a very large group of plant genes (see below). These proteins bind E-
boxes (called G-boxes in plants) with the sequences identical or similar to 
CACGTG. The B-group can be subdivided into members containing or  
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lacking a leucine zipper (Zip) motif, which is involved in homo- and 
heterodimerization and is characterized by leucines or other hydrophobic 
residues at every 7th position. Group C contains PAS domain proteins, such 
as hypoxia inducible factor (HIF) and the Drosophila SIM protein, that bind 
ACGTG or GCGTG DNA sequences, while group D contains HLH 
proteins lacking the DNA-binding region, including the Id proteins that 
negatively regulates many bHLH proteins by forming unproductive 
heterodimers unable to bind DNA. Recently two new subgroups have been 
found, E, including the Drosophila Hairy and Enhancer of split genes, 
which contains an orange domain and a WRPW motif and preferentially 
bind to so called N-box sequences (CACGCG or CACGAG), and F, which 
contains a COE-domain involved in dimerization and DNA binding 
(Ledent et al., 2002; Ledent and Vervoort, 2001). 
 
The plant Arabidopsis thaliana contains up to 160 bHLH genes that can be 
further divided into a number of subgroups (Bailey et al., 2003; Buck and 
Atchley, 2003; Heim et al., 2003; Riechmann et al., 2000; Toledo-Ortiz et 
al., 2003). This constitutes the second largest transcription factor family in 
Arabidopsis after the MYB superfamily of around 190 members. Most of the 
plant bHLH genes belong to the B group and are involved in a number of 
different processes. Among these are the R subfamily gene TT8, which 
regulates the expression of genes required for flavonoid/anthocyanin 
biosynthesis (Nesi et al., 2000), GL3 and EGL3, regulating trichome and 
root hair initiation (Bernhardt et al., 2003; Payne et al., 2000; Zhang et al., 
2003), SPATULA, involved in carpel development (Heisler et al., 2001), 
ALCATRAZ and INDEHISCENT, regulating fruit opening (Liljegren et 
al., 2004; Rajani and Sundaresan, 2001), SPEECHLESS,  MUTE and 
FAMA, involved in stomata development (MacAlister et al., 2007; Pillitteri 
et al., 2007). A number of bHLH proteins take part in positive or negative 
regulation of light signaling, either by direct interaction with phytochrome 
A and/or B photoreceptors, including PIF3 (Ni et al., 1998), HFR1 
(Fairchild et al., 2000), PIF4 (Huq and Quail, 2002), PIF1/PIL5 (Huq et al., 
2004; Oh et al., 2004; Yamashino et al., 2003), PIF5/PIL6, PIF6/PIL2 
(Khanna et al., 2004; Yamashino et al., 2003), and PIL7 (Leivar et al., 
2008), or as downstream transmitters of light signals such as PIL1 (Khanna et 
al., 2006; Yamashino et al., 2003), for reviews see (Duek and Fankhauser, 
2005; Monte et al., 2007). bHLH proteins also play a role in other types of 
signaling, for example responses to drought stress and the plant hormone 
abscisic acid (ABA) (AtMyc2, AtMyc3 and AtAIG1) (Abe et al., 2003; Kim 
and Kim, 2006; Smolen et al., 2002), in jasmonate signaling (AtMyc2) 
(Boter et al., 2004), cold stress (ICE) (Chinnusamy et al., 2003) and to 
brassinosteroids (BEE genes) (Friedrichsen et al., 2002). Most of these 
bHLH proteins cooperate with other transcription factors, in particular 
members of the Myb-family that play important roles in a variety of 
processes. 
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The knowledge about transcription factors regulating the cell cycle in 
plants is relatively limited. The basic mechanisms of cell cycle regulation in 
plants are similar to those in animals (for review see (De Veylder et al., 
2007)). There are two major cyclin-dependent kinases, CDKA and CDKB, 
which regulate the transition from the G1 to S and G2 to M phases of the 
cell cycle, respectively. CDKA associate with G1 cyclins of the cyclin D 
group (CYCD) and later in S phase with cyclin A (CYCA), whereas CDKB 
associates with G2/M cyclins CYCA and cyclin B (CYCB). There are 
several CDK inhibitors (CKIs) related to the animal p27Kip1 family, called 
Kip-related proteins, KRP (or ICK). The animal Rb/E2F pathway is also 
conserved in plants. The E2F transcription factor that controls expression of 
S-phase specific genes associates with the retinoblastoma protein-related 
corepressor RBR in G1 to keep these genes silenced. In late G1, 
CYCD/CDKA phosphorylates RBR resulting in release of E2F and 
activation of S-phase genes (for review see (De Veylder et al., 2007)). The 
AP2-related factor AINTEGUMENTA (ANT), the KNOTTED-like 
HOMEOBOX (KNOX) proteins and the WOX homebox protein STIP 
are among transcription factors that have been implicated in coordinating 
cell division and cell growth in meristematic tissues and to directly or 
indirectly regulate expression of D-type cyclins (for reviews see (Gegas and 
Doonan, 2006; Traas and Bohn-Courseau, 2005)). Further, TCP and 
MYB-type transcription factors have been reported to regulate B-type 
cyclins.   
 
In animals, the B-group bHLHZip proteins of the MYC-family 
(including c-, N- and L-Myc among others), play an important role in 
regulating the cell cycle, cell growth and metabolism and are thought to be 
key coordinators of these processes (Adhikary and Eilers, 2005; Oster et al., 
2002). The Myc-family proteins cannot homodimerize but needs the 
obligatory bHLHZip protein Max to form DNA-binding heterodimers. 
Max also forms heterodimers with the members of the Mad/Mnt-family, 
which all are transcriptional repressors that compete with and antagonize 
Myc. The MYC genes are conserved throughout animal evolution and 
some similar proteins have also found in fungi (Atchley and Fernandes, 
2005). It controls 10-15 % of all genes in mammalian cells, including D- 
and B-type cyclins, G1 CDKs, several CKIs, E2F, Cdc25 and E3 ubiquitin 
ligases involved in cell cycle control. Since many regulators of the cell cycle 
are fairly conserved between animals and plants, we were interested to see if 
Myc-related bHLH proteins could be found in plants and if they would 
carry out similar functions. The bHLH domain of MYC contains a number 
of highly conserved residues that can be used as a “fingerprint” for Myc-like 
genes in distantly related species (Atchley and Fernandes, 2005; Lüscher and 
Larsson, 1999), and we therefore used this domain for screening the genome 
of Arabidopsis. Further, since the expression of the animal Myc genes are cell 
cycle regulated, we investigated the expression of Arabidopsis bHLH genes 
in several cell cycle and cell growth systems. Our results demonstrate that 84 
B-group bHLH genes exist in Arabidopsis that evolutionary separated from  
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animal bHLH genes but are still “Myc-like” to a certain extent. 15 of these 
genes were expressed in a cell cycle-dependent manner in one or more 
proliferative tissues.   
 
Results 
Classification of Arabidopsis B-group bHLH genes. 
In an attempt to identify MYC-like B-group genes in Arabidopsis thaliana 
(At), the bHLHZip domains of a number of animal Myc, Max and Mad 
proteins from different species (Supplemental Fig. 1S) were used to screen 
At databases utilizing the BLAST Psi- and Phi-BLAST programs. We 
identified 84 B-group At bHLH sequences out of the total number of 
approximately 160 bHLH genes. This group is characterized by a 
characteristic H-E-R “fingerprint”, namely H at position five, E at position 
nine and R at position thirteen out of the 13 amino acids in the basic region 
(Ref). These amino acids are all found on same side of the alpha helix of the 
basic region and are involved in recognition of the CACGTG E-box 
sequence. A neighbor-joining phylogenetic tree was constructed with 
amino acid sequences of the bHLHZip domains of these At genes using 
MEGA 4.0. As shown in Fig. 1, the tree divides the At B-Type bHLH 
genes into 15 phylogenetic subfamilies (which we named from 1-15) with 
high predictive values (bootstrap support of 50 or greater) and 8 orphan 
genes that could not be grouped into any of these subfamilies. These 
subfamilies are overlapping but not entirely identical to some the 15, 12 and 
21 subfamilies of At bHLH genes proposed by Buck et al., Heim et al. and 
Toledo-Ortiz et al., respectively (Buck et al., 2003, Heim et al., 2003, 
Toledo-Ortiz et al., 2003). The reason for this could be that we used also 
the Zip regions in our search and may have used slightly different criteria 
for the selection of the genes. In agreement with these reports, we find that 
the 15 plant B-group bHLH subfamilies are all separated evolutionary from 
the animal MYC/MAX/MAD family genes. Also after inspecting the amino 
acid “fingerprints” typical of the Myc/Max/Mad family proteins as a whole 
or of the in individual subfamilies of Myc, Max and Mad proteins, 
respectively (Supplemental Fig. 1S), it was not possible to identify any 
particular At B-group bHLH subfamily that was much more MYC, MAX or 
MAD-like than the other, although all of them had many features in 
common (data not shown).  Among the 21 amino acids that are conserved 
in the basic region, helix one, loop and helix two during animal evolution 
of MYC/MAX/MAD family genes (Supplemental Fig. 1S), most of the At 
subfamilies have 18-20 of these amino acids conserved in the same positions. 
Many of these genes also seems to contain a leucine zipper (Zip), or at least 
parts thereof, continuous with the bHLH domain, another hallmark of the 
animal Myc/Max/Mad family proteins. From these points of view one 
could argue that the At B-group bHLH family genes are all more or less 
“Myc-like”. However, these similarities do not go beyond the bHLHZip  
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domain, and we have for instance not found any sequences in the plant 
genes resembling the conserved Myc-boxes in the transactivation domains 
of the animal genes. 
 
Identification of Arabidopsis bHLH genes expressed in a cell 
cycle-regulated manner in shoot apex, flowers, leaves and/or 
siliques/seeds 
We have thus identified 84 B-group At bHLH genes that to some extent 
exhibit similarities with the animal MYC/MAX/MAD family genes. As 
described above, the MYC- and MAD-family gene products are involved in 
regulation of cell cycle genes such as cyclins and CKIs and are themselves 
also usually differentially regulated during the cell cycle. MYC and MAD 
family expression in animal cells often correlates with G1 cyclin and CKI 
expression, respectively, whereas the common heterodimeric partner MAX 
is ubiquitously expressed). To investigate whether At bHLH genes might 
show functional similarities with the animal MYC/MAX/MAD family 
genes, we investigated the expression patterns of the 84 At genes with 
respect to proliferative tissues of the plant by searching the AtGenExpress 
microarray database (for address see Supplemental Table 1S). Supplemental 
Table 1S shows the retrieved data for 15 At bHLH genes that showed 
expression profiles correlating with proliferative status in shoot apex, 
flowers, leaves and/or siliques/seeds  (Jacqmard et al., 2003; Mordhorst et 
al., 1998; Zhang et al., 2005). Among these were four genes described 
previously, SPATULA (SPT), ALCATRAZ (ALC), EGL3 AND PIF3 (see 
above). The details of developmental stages etc of the tissues studied are 
found in Supplemental Table 2. As reference genes, four genes encoding 
cycle regulators genes were used; the G1 cyclins CYCD3;3 and CYCD3;1, 
the transcription factor E2Fa, and the Cdk inhibitor KRP1. The expression 
of these reference genes showed very good correction with proliferative 
status of the tissues, CYCD3;3, CYCD3;1 and E2Fa being highly expressed 
in proliferative tissues and vice versa for KRP1. 
 
As shown in Table 1, three of these genes, such as At1g10120, 
At1g68810 and At3g25710, were coregulated with CYCD3;3, CYCD3;1 
and E2Fa in all four tissues. Others were coregulated with these cell cycle 
genes in three out of four tissues, while others had similar expression patters 
as the cyclins in some tissues, but resembled more the expression of KRP1 
in other tissues. Some of the genes were differentially expressed between 
tissues or during the development of a certain tissue, but in a way that 
seemed unrelated to the cell cycle. This suggests that some of these genes 
may have roles in cell proliferation in general, while others may have more 
cell type specific proliferative functions, others may have more complex 
roles and finally, some genes are not likely to play a direct role in cell 
division. 
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Expression of At bHLH genes during the proliferative stage of 
root development 
To investigate whether any of these bHLH genes are coregulated with cell 
cycle genes in other tissues as well, we utilized published microarray 
expression profiling data from Arabidopsis root (Beemster et al., 2005; 
Birnbaum et al., 2003). Root developmental can be divided into three 
stages that roughly correspond to the distance from the apical meristem. The 
first stage of active cell proliferation and differentiation originating from the 
apical meristem occurs in the dividing zone in the root tip, the second stage 
is when longitudinal expansion begins in the elongating zone, and at stage 3, 
cells and root hairs are fully elongated and found in the mature region. As 
expected, highest expression of CYCD3;1 and CYCD3;1 and lowest 
expression of KRP1 and KRP2 was found in stage 1 in the dividing zone 
and vice versa in the stage 3 in the mature region (Fig. 2 and Supplemental 
Table 3S). Nine of the bHLH genes showed expression patterns that were 
similar to the cyclins, including At3g25710 that were amongst the genes that 
were coregulated with cyclins in the all of the previous tissues, and 
At1g26260, SPT, EGL3 and At3g61950 that were coregulated in three out 
of four of the previous tissues. Two of the genes showed an expression 
pattern that was similar to KRP 1 and 2 (Fig. 2 and Supplemental Table 3S, 
summarized in Table 1). 
Expression of At bHLH genes during auxin-induced early lateral 
root initiation and cell cycle progression 
We next looked at the expression of the bHLH genes in an auxin-induced 
cell division system, early lateral root initiation (Himanen et al., 2004). In 
this system pericycle cells are blocked in G1 by germination in the presence 
of 1-N-naphthylphthalamic acid (NPA), resulting in roots lacking lateral 
root initiation sites. By transfer to media containing auxin, lateral root 
initiation and cell cycle progression is induced synchronously. Here we 
utilized published microarray expression data from Vanneste et al. (Vanneste 
et al., 2005), where both wt Arabidopsis plants and the dominant auxin 
signaling mutant solitary root (slr1) were analyzed using this system.  The 
mutant plants are defective in auxin-induced lateral root initiation, which is 
linked to defective induction of key cell cycle components, including 
CYCD3;1  (Vanneste et al., 2005). Interestingly, the bHLH gene 
At1g26260, which was coregulated with CYCD3 in four out of the five 
tissues studied above (Table 1), was strongly induced after 6 hrs of auxin 
treatment in wt plants but not in the slr1 mutant, suggesting that it plays a 
role in auxin-signaling and further implicates it in cell cycle regulation (Fig. 
3 and Supplemental Table 3S, summarized in Table 1). The expression of 
two bHLH genes, At3g25710 and PIF3, was repressed by auxin signaling in 
wt but not in mutant plants. 
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Expression of At bHLH genes during sucrose-induced cell cycle 
progression in suspension cultures 
To further investigate the expression of the selected At bHLH genes during 
the cell cycle, we utilized an Arabidopsis suspension cell culture system in 
which the cells are synchronized in G0 by sucrose starvation. After re-
addition of sucrose to the medium the cells enter and traverse the cell cycle 
synchronously (Menges and Murray, 2002). Cultures were harvested at 
different times after sucrose addition, after which total RNA was prepared. 
The mRNA expression of the selected At bHLH genes was analyzed by Q-
RT-PCR. Fig. 4a shows that the expression of CYCD3;3 was induced and 
reached a peak already within two hours, while the induction of CYCD3;1 
was slower and reached its maximum level 6 hrs after sucrose treatment in 
agreement with previous reports (Menges et al., 2005; Menges et al., 2003). 
The expression of KRP2 slightly increased transiently at 2 hrs and then 
declined as reported (Menges et al., 2005).  Analysis of the expression of the 
At bHLH genes showed that they fell into three different categories (Fig. 4). 
Four genes, At3g07340, At1g10120, At5g50915 and ALC, exhibited an 
expression pattern that were similar to the CYCD3 genes, i.e. they were 
induced with different kinetics, reached their peaks at different time points 
and gradually declined back to basal level (Fig. 4b). With the exception of 
At3g07340, these genes are all coregulated with CYCD3 genes in 4-5 
different systems (Table 1). At3g07340 has in three systems shown similar 
expression patterns as KRP1/2  but a similar pattern as cyclins in 
siliques/seeds. Another group of three genes, At1g26260, SPT and 
At3g61950 were all induced very rapidly and reached high peaks levels 
already at 2 hrs post treatment, after which they rapidly fell back to basal 
levels (Fig. 4c), and we refer to these as immediate early transiently 
expressed genes. They are all genes that are coregulated with the cyclins in 
5-6 other systems (Table 1). Finally, we have a category of three genes, 
PIF3, EGL3 and At1g68810, that shows an expression pattern similar to 
KRP1/2 (Fig. 4d). They all drop to levels lower than the basal level after 
sucrose induction, PIF3 after an initial slight and transient increase that also 
resembles  KRP2.  PIF3 has shown KRP-like expression patterns in two 
other systems, whereas EGL3 and At1g68810 have rather been expressed in 
a cyclin-like pattern is most other systems (Table 1). 
 
After microarray analysis of gene expression in a similar sucrose 
starvation/re-addition suspension culture system in Arabidopsis, Menges et al 
(Menges et al., 2003) obtained similar results as we did for At3g07340 and 
At5g50915, but had opposite results for EGL3 and At1g10120. The reason 
for this discrepancy is unclear at present, but we have used different 
methods for measuring mRNA expression, utilized different cell suspension 
systems and included sorbitol in the medium to avoid osmotic stress. 
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T-DNA insertion mutants of cell cycle regulated At bHLH genes 
do not display gross phenotypic aberrations 
To approach the question of the biological function of the above studied 
bHLH genes, we identified and obtained Arabidopsis lines with T-DNA 
insertions in six of the bHLH genes from the SALK Institute. These were 
verified by PCR analysis and predicted to knock out the functions of 
At1g26260, At1g10120, At3g61950, EGL3, ALCATRAZ, and SPATULA. 
We obtained homozygous mutants that were seeded out for phenotypic 
examination. Under normal culture conditions, no gross phenotypic 
aberrations were observed. We also obtained spt and alc homozygous 
mutants, which exhibited the expected gynoecia phenotypes. When 
crossing these homozygous mutants with each to obtain double mutants in 
all combinations, our preliminary data suggests that these double mutants do 
not display phenotypic aberrations under these culture conditions (data not 
shown). Exceptions were as expected any mutants containing spt and alc, 
which, however, did not show any further phenotypic alternations other 
than those of the single mutants (data not shown). 
 
Discussion 
The overall aim of the present study was to try to explore whether MYC-
like bHLH genes could be found in the plant Arabidopsis thaliana and if so, 
whether such genes might carry out similar functions as in animals, i.e. 
control genes involved in cell proliferation. We identified 84 B-type bHLH 
genes, likely to encode proteins recognizing the Myc binding site 
CACGTG. The genes could be subclassified into 15 subgroups, but these 
were all separated evolutionary from animal bHLH genes and none of these 
were more similar to animal MYC/MAX/MAD-family genes than the 
other. On the other hand, when comparing 21 conserved amino acid 
residues in the bHLH domain that are conserved during animal evolution of 
the Myc/Max/Mad-family, 18-20 were conserved at identical positions in 
most of the 15 At subfamilies, suggesting that they are “Myc-like” to a 
certain extent. Many of these subgroups also seem to contain a functional 
Zip-domain, which is always found in Myc/Max/Mad proteins, in 
particular in group 1, where most of our cell cycle regulated genes were 
found. These observations suggest that the function to bind CACGTG E 
(G)-box sequence elements by forming hetero- or homodimers is 
conserved. However, no similarities were found to other regions of Myc, 
including the conserved Myc boxes in the transactivation domain. This was 
on the other hand not so expected, since transactivation domains are much 
less conserved in evolution. 
 
The question remains if any of these At bHLH genes could be involved 
in control of cell proliferation similar to the MYC-network genes? 
Investigation of the expression patterns of the genes in proliferative tissues of 
the plant could give some indications of their functions. Indeed, most  
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Myc/Max/Mad-family genes, with the exception of Max, are cell cycle 
regulated. Expression profiling in shoot apex, flowers, leaves and 
siliques/seeds indicated that 15 of the 84 bHLH genes seemed to be 
differentially regulated in proliferative tissues in at least some of these 
systems. Further analysis of root development, auxin-induced early lateral 
root initiation and sucrose-induced cell cycle progression in suspension 
cultures narrowed down the selection to around 10 genes of interest. 
Summary of the analysis in the seven different cell proliferation systems 
revealed that one gene, At1g26260, is auxin-induced and coregulated with 
the cyclins in 6 systems, four genes, At1g10120, SPT, At3g25710 and 
At3g61950, are coregulated with cyclins in five systems, two genes, 
At5g50915 and ALC, in 4 systems, two other genes, At1g68810 and EGL3 
also coregulated with cyclins in four systems but sometimes with KRP1/2 in 
other systems (Table 1). Other genes are more often coregulated with 
KRP1/2, such as At3g07340 and PIF3, and the remaining only show cell 
cycle regulation in a few tissues. We find it likely that at least some of the 
former genes play a role in cell proliferation in general or at least in certain 
tissues and/or in response to certain signals. Interestingly most of these are 
clustered in 3 subgroups of genes. 
 
To clarify the precise function of these candidate genes it will be 
necessary to perform knockout and/or knockdown the activity of these 
genes. Analysis of homozygous T-DNA insertion mutants of four of the 
previously non-characterized genes that would predict to render the genes 
inactive did not show any phenotypic aberrations under normal growth 
conditions. One plausible explanation for this is redundancy, i.e. that other 
genes in the large bHLH family can take over the function of the non-
functional gene. Our preliminary results from studies of double mutants 
have not resolved this problem. It will therefore be necessary to generate 
triple or higher order mutants or to knockdown the expression of many 
family genes simultaneously to clarify the function of these genes. 
Identification of dimerization partners by biochemical means or via 
interaction screens may be an alternative route, since many bHLH proteins 
are strictly dependent on heterodimerization for function. 
 
The previously characterized bHLH genes within our group of 15 genes 
included  SPT,  ALC,  EGL3 and PIF3. Their potential role in cell 
proliferation has not been emphasized in the literature before. SPT is 
known to be involved in carpel development and has been suggested to 
promote proliferation of certain tissues within the gynoecium (Heisler et al., 
2001). ALC and IND are involved in the development of fruit dehiscence 
and IND has been suggested to play a role in unequal cell divisions in layer 
of cells in the dehiscence zone (Wu et al., 2006). EGL3 participates in 
trichome and root hair initiation and has been suggested to regulate the cell 
division rate in early stages of epidermal specification (Bernhardt et al., 
2003). PIF3 is a regulator of light signaling (Duek and Fankhauser, 2005; 
Monte et al., 2007; Ni et al., 1998), but does not seem to be a strong  
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candidate for a cell cycle regulator in the systems we have looked at (Table 
1). It remains to be explored whether these or any of the other bHLH genes 
described here play important roles in control of cell proliferation in general 
or in specific tissues of the plant. 
 
Materials and Methods 
Alignment, blast and phylogenetic analysis  
The basic helix-loop-helix Zip domain of 14 animal myc genes, 14 animal 
mad genes, and 7 animal max genes were aligned. They are used as quire to 
screen  Arabidopsis gene database using blastn program. Only Arabidopsis 
bHLHZip genes with histidine (H), glutamic acid (E), and arginine (R) at 
the 5, 9, and 13 sites, respectively, in the basic region were considered 
interesting. The amino acid sequence of the bHLHZip domain of bHLH 
H-E-R  Arabidopsis genes were multi-aligned and then used to make NJ 
(neighbor joining) tree with MEGA4. 
Bioinformatic studies 
Published microarray data from different tissues and different cell cycle 
relevant assay were used to identify Arabidopsis genes that have similar 
expression pattern to G1 cyclin, in this case cyclin D3;1 and cyclin D3;3 or 
opposite expression pattern to KRPs, in this case KRP1 or KRP2. 
Suspension culture 
Arabidopsis thaliana ecotype Landsberg erecta cell suspension culture was 
maintained by weekly subculturing in MS media (Murashige and 
Skoog,1962) supplemented with 3% sucrose, 0.5mg/l NAA, 0.05mg/l 
kinetin. Synchronization of cell culture by sucrose starvation-readdition was 
done essentially as described previously (Menges and Murray, 2002) but to 
avoid osmotic stress of cells during sucrose withdrawal the starvation media 
contained 1.8% sorbitol. 
RT-qPCR 
Total RNA was extracted from suspension culture cells using RNeasy mini 
kit (Qiagen Sciences). Samples were DNase-treated before cDNA synthesis 
was performed with oligo (dT) and RevertAid M-MuLV Reverse 
transcriptase from Fermentas. cDNA was used as template in quantitative 
PCR reactions with DyNAmo HS SYBR Green qPCR kit from 
Finnzymes. The comparative Ct method was used for relative quantification 
of expression levels. The expression levels of the genes of interest were 
normalized to the expression level of Arabidopsis thaliana actin 2 (ACT2). 
The primer sequences are provided upon request.  
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T-DNA insertion line analysis and phenotype study 
Seeds of SALK T-DNA insertion lines for At1g63650/EGL3, At1g10120, 
At1g26260, and At3g61950 obtained from the Salk Institute for Biological 
Studies, CA, USA were planted out in green chamber. Leaves of each line 
were used for DNA extraction and seeds from each line were harvested.  
PCR were performed by using two primer pairs, LP+LB and LP + RP. LB 
is a small fragment of sequence in the T-DNA, while LP and RP are the left 
and right flanking sequences of the insertion site, respectively.  DNA 
extracted from wt individuals will produce a single bind with size as 900bp 
by LP+RP primer pair, whereas DNA extracted from homozygous 
insertion individuals will produce a single band with size as 400~700bp by 
LB+LP primer pair. Heterozygous insertion individuals will produce both 
bands. When no homozygous individual were found, which insertion was 
supposed to be lethal. Seeds produced by those identified homozygous 
individuals of 4 At bHLH genes, At1g63650/EGL3, At1g10120, 
At1g26260, and At3g61950 and from SPT and ALC knockout homozygote 
were planted out as before.  Crossings were made between every 2 of the 6 
genotypes when plants were flowering. Seeds of crossed individuals were 
harvested afterwards and panted out again to investigate phenotypes of each 
pair of double gene knockout. Besides known phenotypes of SPT and ALC, 
no other new phenotype was observed. 
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Legends to figures 
 
Figure 1. Phylogenetic tree of B-group bHLH genes in 
Arabidopsis thaliana. The B-group bHLH genes have the signature “H-
E-R”, referring to conserved amino acids in the basic region (see text for 
further explanation). The Arabidopsis bHLH genes were divided into 15 
subgroups and 7 orphans. The bootstrap test of all subgroup clusters are 
above 50 while 9 of them are above 75. 
 
Figure 2. Expression of selected bHLH genes at different 
developmental stages of the root. The graphs are made based on the 
microarray expression data at three indicated development stages in the 
Arabidopsis root (Supplementary Table 3S) (Beemster et al., 2005; Birnbaum 
et al., 2003). In stage 1, the root tip has reached its full diameter (division 
zone); stage 2, where cells begin longitudinal expansion (elongation zone); 
and stage 3, where root hairs were fully elongated (mature region).  
 
Figure 3. Expression of selected bHLH genes after auxin 
treatment. The graphs are based on the microarray expression data in 
Supplementary Table 4S (Vanneste et al., 2005). Arabidopsis wt and slr1 
mutant seedlings were germinated on medium containing 10 mM NPA and 
transferred 3 d after germination under continuous light to 10 mM NAA.  
 
Figure 4. Expression of selected bHLH genes after sucrose-
induced re-entry into the cell cycle in sucrose-starved 
Arabidopsis suspension cell cultures. Sucrose-induced cultures were 
harvested at the indicated time points and analyzed for mRNA expression 
by Q-RT-PCR. The 10 genes were divided into three groups according to 
their expression pattern: CYCD3-like,  KRP2-like, and immediate early 
transient expression. 
 
Supplemental Figure 1S. Multi-alignment of animal Myc/Max/Mad 
network proteins. Amino acid sequences from 14 MAD-family, 14 
MYC-family and 7 MAX-family proteins, representing 10 different animal 
species from human to sea urchin were aligned. Blue color, residues 
conserved in all three families; yellow color, residues conserved in two out 
of the three families; red color, residues uniquely conserved in only one 
family; green color, residues of functional importance in the leucine zipper 
(Zip) domain. The positions of the conserved H-E-R residues in the basic 
region are indicated. 
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Supplementary figure 1S.  
 
 
Sub- 
group 
 
 At-code   Gene name  Shoot 
apex 
  
Flowers 
  
Leaves Siliques/
seeds 
  
developmental
stages in root 
auxin induced early   
lateral  root initiation
Sucrose-
induced cell 
suspension  
1 At3g07340    -       -       D.E      +  -  N.C  + 
 At1g10120    +      +      +      +  D.E  N.C  + 
 At1g26260    +      +      D.E      +  +  +          + (I.E) 
 At5g50915    D.E      N.C      +      +  +  D.E  + 
6    At4g36930 SPATULA +      +      D.E      +  +  N.D          + (I.E) 
    At5g67110 ALCATRAZ +      D.E      N.C      +  +  N.D  + 
9 At1g68810     +      +      +      +  -  N.D  - 
      At3g25710 +      +      +      +  +  -   +
*
10    At1g63650 EGL3 +      D.E      +      +  +  low  - 
14 At4g01460     (-)      D.E      +      D.E  low  low  N.D 
      At3g61950 +      +      +      D.E  +  (-)          + (I.E) 
      At5g46690 -      D.E      +      D.E  D.E  N.D  N.D 
      At1g22490 +      N.C      D.E      -  +  N.D  N.D 
      At5g53210 -      +      +      +  low  N.D  N.D 
orphan At1g09530 PIF3  -      D.E      D.E      D.E  +  -  - 
Table 1. Summary of expression profiles of Arabidopsis B-group bHLH genes. +, coregulated with the G1 cyclins CYCD3;1 and/or CYCD3;3; - , 
coregulated with KRP1 and/or KRP2; I.E, immediate early transient expression; D.E, differentially expressed, but not cell cycle regulated; N.C, no changes in 
expression compared with controls; N.D, not determined; low, low/not expressed; *, based on data from Menges et al (Menges et al., 2003). 
 Shoot apex  Flowers  Leaves  Siliques/seeds 
At-code   1                                        2 3 4 1 2 3 4 1 2 1 4 1 2 3 4 5 6 7 8
At1g10120  1.0717 0.9588 2.0961 1.7352  1.3220  1.4602 1.1196 0.5668 1.1111 0.8486 0.8176 0.1270 1.6642 0.5171 1.0451 1.4853 1.2814 0.6898 0.3677 0.4598 
At1g63650  0,793  3,0211 5,6708 3,3136  1,0238  0,8384 0,7384 1,0113 0,1954 0,1534 0,1361 0.1428 2,284  2,284  0,9484 1,1997 0,7168 0,212  0,2663 0,1996 
At1g26260  0,6335 0,7878 4,0273 2,7796  1,4947  1,0017 0,8104 0,4831 0,5004 0,4406 0,375  0,9461 0,6133 1,5601 1,3961 1,8217 1,5427 0,4035 0,2981 0,3062 
At3g07340  0,1804 0,1241 0,1143 0,0953  0,175  0,6293 0,6579 0,9946 0,6733 1,1263 1,3377 0,1254 1,0212 2,6526 3,0165 0,1331 0,1056 0,095  0,109    0,0962
At5g50915  0,8283 0,2629 0,9177 1,4225  0,4552  0,4563 0,4507 0,5788 3,8783 2,5502 2,4705 0,063  0,6999 2,8982 5,0057 0,0558 0,047  0,0717 0,0987 0,1062 
At3g25710  0,5628 1,014  2,4633 2,8439  0,8801  0,6478 0,551  0,2956 0,4972 0,3687 0,2579 0,1377 0,4976 0,3095 0,3429 0,5735 0,2639 0,2912 0,1679 0,192 
At3g61950  0,5668 0,5315 1,0571 1,0571  1,8921  2,0821 1,5457 1,2234 1,6802 0,6384 0,3891 0,1627 7,0639 0,3386 0,2994 0,2999 0,2692 0,2626 0,3327 0,2454 
At4g01460  1,0046 0,5312 0,7643 0,7744  0,909  1,4824 0,6894 0,4073 2,1138 1,3161 0,6339 0,0983 1,219  0,3146 0,631  2,8151 2,4545 1,8773 0,9464 0,9219 
At1g68810  1,1384 1,305  1,3863 1,554  0,9762  0,9133 0,7613 0,4238 0,8957 0,7036 0,4416 0,1556 0,922  0,3617 0,3276 0,3918 0,3028 0,1353 0,148    0,1224
At1g09530  1,0369 1,1848 1,4059 1,1158  0,9188  0,7861 0,5115 0,9871 0,8816 0,6206 0,5759 2,1526 0,6215 0,3893 0,3656 0,2917 0,2918 0,5268 0,9458 1,6844 
At4g36930  0,6067 0,6576 1,9791 2,1964  1,3804  1,3071 0,9842 0,7212 0,2351 0,1967 0,1717 1,0585 0,4138 1,9714 2,7985 4,1401 4,1595 1,4073 1,037    0,8387
At5g67110  0,2716 0,6525 1,2012 1,59  1,7367  2,2407 2,5021 1,3679 0,049  0,0431 0,0454 0,042  5,354  3,4435 2,5666 0,2429 0,1424 0,0929 0,0655 0,0902 
At5g46690  1,4725 0,7261 0,7345 0,8746  0,5944  1,0747 0,7952 0,2191 1,1678 0,4959 0,416  0,1042 0,2543 0,4007 2,5433 11,325 8,3667 1,6956 0,1546 0,1278 
At1g22490  0,7052 1,4284 4,1548 2,141  0,9481  0,937  1,0155 1,0362 0,6502 0,638  0,6423 0,436  0,8491 0,4421 0,413  0,4707 0,492  0,6249 0,6829 0,7287 
At5g53210  4,7616 4,1265 3,2754 1,6871  0,9842  0,8817 0,7833 0,3383 1,5374 0,5078 0,2745 0,1969 0,1717 0,2915 0,4568 0,762  0,69  0,2609 0,2558 0,24 
CYCD3;1  2.2799 3.2298 3.6452 3.2474  1.9715  1.5385 0.7223 0.2540 0,8622 0,4726 0,2857 0,0209 0.3638 0.2949 0.4817 0.5520 0.1882 0.0497 0.0237 0.0274 
CYCD3;3  1,3125 1,9586 4,1916 4,1646  1,9892  1,5378 1,1293 0,6964 0,2332 0,1312 0,1171 0,0264 0,4362 0,8134 0,7202 0,6696 0,4218 0,115  0,0366 0,0581 
E2Fa    1,4937 2,323  2,9329 2,5195  1,9054  1,2394 1,2029 0,5619 0,7576 0,5258 0,3882 0,1291 0,765  0,7167 0,4911 0,5947 0,5252 0,2646 0,3343 0,1895 
KRP1    0,5114 0,3747 0,272  0,2489  0,3197  0,47  0,5648 1,1312 1,1017 1,1988 1,4734 3,3116 0,4456 1,2251 0,8473 1,2175 0,9268 1,2881 0,7282 1,1438 
 
Supplementary Table 1S. Microarray expression data for selected bHLH genes in different tissues of Arabidopsis thaliana. Data are adapted from the 
AtGenExpress database http://www.weigelworld.org/resources/microarray/AtGenExpress/. CYCD3;1, CYCD3;3, E2Fa and KRP1 were chosen as cell cycle 
regulated reference genes.  
 
 
Tissue      No. Tissue  specification Day
Shoot 1  shoot apex, vegetative + young leaves  7 
Apex 2  shoot apex, vegetative  7 
 3  shoot apex, transition (before bolting)  14 
 4  shoot apex, inflorescence (after bolting)  21 
Flowers 1  flowers stage 9  21+ 
 2  flowers stage 10/11  21+ 
 3  flowers stage 12  21+ 
 4  flowers stage 15  21+ 
Leaves 1  rosette leaf # 12  17 
 2  rosette leaf # 10  17 
 3  rosette leaf # 8  17 
 4  senescing leaves  35 
Siliques/ 1  siliques, w/ seeds stage 3; mid globular to early heart embryos  8 weeks
Seeds 2  siliques, w/ seeds stage 4; early to late heart embryos  8 weeks
 3  siliques, w/ seeds stage 5; late heart to mid torpedo embryos  8 weeks
 4  seeds, stage 6, w/o siliques; mid to late torpedo embryos  8 weeks
 5  seeds, stage 7, w/o siliques; late torpedo to early walking-stick embryos  8 weeks
 6  seeds, stage 8, w/o siliques; walking-stick to early curled cotyledons embryos  8 weeks
 7  seeds, stage 9, w/o siliques; curled cotyledons to early green cotyledons embryos  8 weeks
  8  seeds, stage 10, w/o siliques; green cotyledons embryos  8 weeks
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 2S. Tissue specification of the tissue samples in Supplementary Table 1S. The  
description is adopted from the AtGenExpress database http://www.weigelworld.org/resources/microarray/AtGenExpress/
 
  
 
 
 
 
 
 
At-code  stage 1  stage 2  stage 3 
AT1G63650  273,8567509 149,3743954  14,73567101 
AT1G10120  254,9795286 369,2601116  180,2543203 
AT1G26260  137,4204497 73,96756046  51,96729741 
AT3G07340  98,81518102 316,3702894  278,733134 
AT5G50915  71,53530597 46,65125936  46,66369038 
AT3G25710  69,35495656 22,5059992 42,45998116 
AT3G61950  19,2145778 16,52271164  8,943153806 
AT4G01460  11,06254943 10,57544325  3,388214869 
AT1G68810  103,1609422 120,9390756  212,541196 
AT1G09530  96,43158196 21,92464367  10,92153835 
AT4G36930  370,5121455 152,8481599  86,36289713 
AT5G67110  86,73223161 65,10583691  46,04856132 
AT5G46690  32,85604967 33,10830711  23,11666066 
AT1G22490  68,24089683 54,05950425  25,52175543 
AT5G53210  5,61248608 3,924283374  4,582575695 
CYCD3;3   913,7672351 220,5244884  267,3890237 
CYCD3;1    87,98136166 59,31542801  51,90549104 
E2Fa    174,3965309 106,8951823  64,85869256 
KRP1   12,8066389 25,55895147  34,21110931 
KRP2   58,41746314 122,3078084  179,6696969 
 
Supplementary Table 3S. Microarray expression data for selected bHLH genes at three 
development stages in the Arabidopsis root. At stage 1, the root tip has reached its full 
diameter (division zone); stage 2, where cells begin longitudinal expansion (elongation 
zone); and stage 3, where root hairs were fully elongated (mature region). The data is 
adopted from (Beemster et al., 2005; Birnbaum et al., 2003). 
 
       Arabidopsis wt Col-0  Arabidopsis slr-1 mutant 
At-code  Gene name      0h         2h         6h         0h         2h         6h   
At1g63650 EGL3  7 10  8 9 15  7 
At1g10120     67  150 148 125 203 223 
At1g26260     230 177 1138  250 258 248 
At3g07340     356 385 379 525 543 587 
At5g50915     147 114 166 122 122 145 
At3g25710     2708 2827 1043 840  983  921 
At3g61950     114  42 38 71 48 25 
At4g01460     15 18 10 17 9  9 
At1g09530 PIF3  47 20 22 16 46 25 
At4g34160 CYCD3;1  316 813 2007  607 634 541 
At5g67260 CYCD3;2  774  1154 3034 706  456  761 
 
Supplementary Table 4S. Microarray expression data for selected bHLH genes during 
auxin-induced lateral root initiation. Data adopted from (Vanneste et al., 2005), where 
microarray analysis was performed using Arabidopsis wt Col-0 lateral roots germinated on 
medium containing 10 mM NPA and then transferred 3 d after germination under continuous 
light to 10 mM NAA. The lateral rootless phenotype of the early auxin signaling mutant slr1 
was used as control. 
 
 